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Malaria remains a major global health problem and to date, hundreds of thousands of people 
die as a result of this disease every year. Malaria has been able to adapt and rebound despite 
various efforts made to combat the disease. The decrease in efficacy of many front-line drugs 
against malaria, due to increased resistance, prompts investigation into obtaining effective 
compounds that are able to overcome this resistance. This study investigated the synthesis, 
characterisation and biological evaluation of new quinoline as well as non-quinoline based 
compounds. Selected Rh(I) metal complexes thereof were also studied. The compounds were 
screened for antiplasmodial activity, in addition, their activity against WHCO1 oesophageal 
cancer cells and the parasite, Trichomonas vaginalis (T vaginalis) was also evaluated. 
 
A series of new mono- and multimeric quinoline-containing and ferrocenyl thioureas 
conjugated to polyamine scaffolds were synthesised. In addition to this, new monomeric and 
dimeric salicylaldimine ligands containing a quinoline motif were also prepared. Coordination 
of these ligands with [RhCl(COD)]2, yielded mononuclear and binuclear Rh(I) complexes. 
New ferrocenyl derivatives of some of the afore-mentioned were prepared. All of the 







spectroscopy, IR spectroscopy and mass spectrometry.  
 
The thioureas were evaluated against the NF54 chloroquine-sensitive (CQS) and the Dd2 
chloroquine-resistant (CQR) strains of Plasmodium falciparum (P. falciparum). The quinoline 
compounds showed enhanced activity compared to the ferrocenyl derivatives. The trimeric 
quinoline exhibited the highest activity in the CQS strain (IC50 = 0.09 µM). One of the 
biological targets of quinoline compounds is haemozoin. Studies were carried out in order to 
investigate the compounds’ ability to inhibit synthetic haemozoin (β-haematin) formation. 
The trimeric and tetrameric quinolines were most effective at inhibiting β-haematin formation, 
perhaps due to an increased number of quinoline motifs. The thioureas were also screened 
against the G3 strain of T. vaginalis. This was conducted to gauge the efficacy of these 
compounds against other parasitic diseases as well. The ferrocene-containing thioureas 
exhibited slightly higher parasite growth inhibition compared to the quinolines. The 
quinolines were more cytotoxic when tested against WHCO1 compared to the ferrocenyl 
iv 
 
derivatives. The tetrameric quinoline ligand exhibited the highest cytotoxicity (IC50 = 0.99 
µM). The latter was further tested against KMST-6 human fibroblast and exhibited selectivity 
towards WHCO1 cancer cells. 
 
The monomeric and dimeric salicylaldimine quinolines and their corresponding Rh(I) 
complexes were evaluated against the NF54 CQS and K1 CQR strains of P. falciparum. The 
monomeric systems (particularly the ligands) showed enhanced activity compared to the 
dimeric systems across both strains. The substituent on the salicylaldimine ring had no 
significant effect on antiplasmodial activity. While the monomeric systems showed potency in 
the sensitive strain, these compounds lost their efficacy in the resistant strain. The dimeric 
derivatives exhibited similar activity in each strain, giving RI values close to, or less than 1. 
The metal complexes exhibited similar activity profiles as their ligands. The dimeric ligands 
and complexes exhibited the highest β-haematin inhibition activity suggesting that size or 
lipophilicity plays a role in the inhibition of β-haematin formation. Generally, the metal 
complexes showed better activity against T. vaginalis compared to the ligands. Two dimeric 
complexes exhibited good activity giving IC50 values of 6.1 and 4.8 µM, respectively. 
Compounds containing the 5-Cl substituent showed good promise against this parasite. The 
dimeric derivatives exhibited increased cytotoxicity against the WHCO1 cell-line. The most 
potent being the 3-OMe binuclear Rh(I) complex (IC50 = 3.9 µM). This complex also showed 
selectivity towards WHCO1 cancer cells rather than human fibroblasts.     
 
Ferrocenyl azines containing salicylaldimine motifs and their Rh(I) complexes were screened 
against the NF54 CQS and K1 CQR strains of P. falciparum. Three ferrocenyl quinolines 
were also tested. The ferrocenyl-containing salicylaldimines exhibited weak to moderate 
activity across both parasite strains. The monomeric ferrocenyl quinolines displayed good 
activity in the CQS strain, while the dimeric derivative exhibited low activity, possibly a 
consequence of its lipophilic nature. The ferrocenyl quinoline possessing the salicylaldimine 
moiety demonstrated higher activity than the non-ferrocenyl monomeric salicylaldimines. The 
quinoline-based ferrocenes displayed higher β-haematin inhibition activity compared to the 
non-quinoline compounds. All of the quinoline-based compounds exhibited cytotoxicity 
against the WHCO1 oesophageal cancer cell-line. With the exception of the ferrocenyl 
quinoline possessing the salicylaldimine motif, most of the compounds inhibited less than 
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Malaria is an infectious disease that affects humans and is considered to be the most common 
parasitic disease in the world.
1 
According to the World Health Organisation (WHO), in 2010; 
216 million cases of malaria were reported worldwide and 655 000 cases of malaria-related 
deaths were documented.
2 
This disease is caused by a protozoan of the genus Plasmodium. 
There are five main species of Plasmodium that are recognised to infect human beings i.e. P. 
falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. The latter is a malaria parasite of 
Old World monkeys
 
but has been reported to infect humans in Malaysian Borneo.
3,4
 Amongst 
these species of Plasmodium, the most deadly strain to humans is P. falciparum.
5 
 
Malaria is spread by Anopheles mosquitoes. When an infected mosquito feeds on a human 
host, it injects the parasite in the form of sporozoites, which are asexual, into the bloodstream 
of the human (Figure 1.1).
6
 The sporozoites travel to the liver and divide asexually by a 
process known as schizogony to produce thousands of haploid forms of the parasite, called 
merozoites. These merozoites invade other liver cells and then enter the bloodstream where 
they invade erythrocytes (red blood cells). Once inside, the merozoites enlarge forming a 
uninucleate cell known as a ring trophozoite. The trophozoite’s nucleus divides asexually to 
produce a schizont containing several nuclei. This then divides further to produce 
mononucleated merozoites. Eventually the erythrocyte ruptures and releases toxins into the 
host’s body, which in turn leads to typical symptoms of malaria such as fever and chills. A 
sexual phase begins when some merozoites develop into gametocytes (cells that are able to 
produce both male and female gametes). These gametocytes are not able to produce gametes 
inside of their human hosts but do so once inside the gut of a mosquito. Zygotes develop 
within the intestinal walls of a mosquito and eventually develop into oocysts (a stage of the 
parasite that is produced when male and female gametes combine). A large number of 
sporozoites then develop due to repeated mitotic division occurring within the oocyst. Once 
formed, the sporozoites migrate to the salivary gland of the mosquito to continue the life cycle 
of the parasite.
6 
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Figure 1.1: Life cycle of malaria parasite
6 
 
The spread of malaria is prevented by protection against mosquito bites by means of mosquito 
nets, mosquito repellent creams or insecticides. Preventative medicines are also used when 
visiting areas where malaria is prevalent.
7
 There are many chemotherapeutic options for 
people who contract this disease, however, the management of malaria is impeded by 
increasing drug resistance or in some cases decreased efficacy of some very potent 
antimalarials including chloroquine (1.1, Figure 1.2), quinine, primaquine, amodiaquine, 
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Introduction                                                                                             Chapter 1 
3 
 
Chloroquine (CQ) has been used successfully to treat this disease. It was a highly effective 
and safe drug to use. However, currently chloroquine-resistance is a major issue.
9
 A common 
practice being implemented recently is artemisinin combination therapy (ACT). This involves 
the treatment of an infected individual with artemisinin or a derivative thereof in conjunction 
with another drug of known efficacy, which in turn delays the onset of drug resistance.
10
 
Lumefantrine and artemether (1.4, Figure 1.3) are currently used against multi-drug resistant 











      1.4 
 
Figure 1.3: Artemether, an artemisinin derivative commonly used in combination therapy 
 
 
1.2. Mode of action of quinoline compounds 
 
Compounds containing quinoline moieties have been used extensively for the treatment of 
malaria over many years. Specifically, 4-aminoquinolines have been very successful in the 
treatment of malaria because of their high efficacy, low toxicity, efficiency as well as low cost 
preparation. To date, chloroquine (CQ) has been the most widely used defence against P. 
falciparum, it is cheap and practical for outpatient use. It is also very effective against P.ovale, 
P. vivax as well as P. malariae. Chloroquine is active against the blood stages of the parasite, 
mainly in the trophozoite and early schizont stages of the life-cycle. CQ is a diprotic weak 
base that when unprotonated, passess through the membrane of the infected cell as well as the 
parasite, to accumulate in the acidic digestive vacuole (Figure 1.4).
11-13
 At this stage of the 


















Figure 1.4: Possible mechanism of action of chloroquine  
and quinoline-based antimalarials 
 
It is broadly accepted that many 4-aminoquinolines disturb the process of detoxification of 
free haem, which is generated upon haemoglobin (Hb) degradation.
15
 A series of proteases 
found within the digestive vacuole of the parasite degrade haemoglobin into small peptides 
which are then displaced to the parasite’s cytoplasm. The oxidised by-product of Hb 
degradation is ferriprotoporphyrin-IX (haematin), which is a haem moiety toxic to the parasite 
(Figure 1.4). The parasite therefore converts this compound into a less toxic form by 
biomineralisation of this moiety into haemozoin (malarial pigment). Chloroquine is believed 
to form a complex with the toxic haem and in turn inhibits crystallisation, causing a build-up 
of haematin. Haematin therefore appears to be the target of many 4-aminoquinolines. It has 
been suggested that haem may also be detoxified by two other mechanisms including 
degradation by hydrogen peroxide within the digestive vacuole and also by a glutathione-
dependant degradation which occurs in the cytoplasm of the parasite.
16,17
 However, studies 
conducted by measuring cellular haem fractions as well as Mӧssbauer spectroscopy suggests 
that about 95% of the free haem that is released due to haemoglobin degradation is found in 
haemozoin.
18-20 
Recent evidence provided by Buller et al.
21
 suggests haemozoin may itself be 
the target of quinoline-based drugs. The fastest growing crystal face of β-haematin (synthetic 
haemozoin) appears to be the binding site for quinoline-based drugs. This then leads to 
inhibition of haemozoin crystal growth.
21
 Experimental support for this was provided by de 
Villiers et al., whereby solvated single crystals of β-haematin were grown in the presence of 
antimalarial drugs.
22
 These crystals were almost indistinguishable from haemozoin.  
haematin 
haemozoin 
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A decreased rate in β-haematin formation in the presence of the antimalarial drugs 
chloroquine and quinidine, was attributed to the assumption that drugs are adsorbed to areas 




1.3. Quinolines as potential antimalarial chemotherapeutics 
 
Quinoline compounds have been used extensively to treat malaria for decades. The first 
quinoline compound that was used as an antimalarial was quinine. It consists of an (8S, 9R) 
quinuclidine-methanol group.
23
 Pamaquine was discovered in the 1920’s and is an 8-
aminoquinoline.
 
This particular compound is active against erythrocytic stages of malaria.
24
 
Primaquine, an analogue of pamaquine, is known to be an effective treatment against P. vivax 
liver infections.
25,26
 Chloroquine was envisaged from quinacrine, a 4-aminoacridine, by 
conversion of its core to a chloroquinoline resulted in this very important antimalarial drug. 
 
Due to widespread resistance towards many of these compounds, there have been numerous 
attempts made to prepare drugs possessing superior antimalarial activity and that overcome 
this resistance. Generally, resistance occurs due to spontaneous mutations in the parasite and 
as a result drugs become less effective. Mutations include single-point and multiple mutations. 
For some drugs, a single-point mutation is sufficient to introduce resistance, while in other 
cases multiple mutations are required.
27
 Chloroquine is able to accumulate to a greater extent 
inside of the digestive vacuole of sensitive parasite strains compared to resistant ones.
28-30
 
This is due to mutations in the chloroquine resistance transporter (PfCRT). These mutations 
cause chloroquine to be expelled from the inside of the digestive vacuole.
31 
 
 In order to overcome this resistance, various modifications of chloroquine have been 
explored; however, it is clear that the 4-amino-7-chloroquinoline moiety optimises the 
antimalarial activity of many of these compounds. In most cases, modification of the 
quinoline ring leads to decreased efficacy with the exception of chloroquine N-oxide (1.5, 
Figure 1.5) and 5-azachloroquine (1.6, Figure 1.5). These particular compounds were reported 
to have greater activity in vivo in comparison to chloroquine.
32
      
 
 









1.5                                     1.6 
 
Figure 1.5: Two chloroquine analogues displaying  
superior in vivo activity compared to CQ 
 
In many cases incorporation of electron withdrawing and electron donating groups such as 
NH2, OH, OCH3, H, CH3, NO2 and CF3 onto the aminoquinoline ring has resulted in a 
decrease in antimalarial activity of the parent compound.
33,34 
Modification of the length 
(shortening or lengthening) of the aminoquinoline side chain has also resulted in a favourable 
effect on the antimalarial activity against chloroquine-resistant strains.
35,36  
Bis-aminoquinolines are compounds containing two quinoline moieties linked by various 
organic linkers (aromatic and aliphatic). These quinoline derivatives were initially prepared 
based on the rationale that these bulky compounds may be retained more effectively by 
chloroquine resistant strains of P. falciparum. Many bisquinolines, such as those displayed in 
Figure 1.6 (1.7 and 1.8), exhibit activity against CQ-sensitive and resistant strains of 
Plasmodium. Many of these compounds are also cytotoxic.
37-40   
 
















   
                                  1.7                   1.8 
 
R1 = (CH2)n; trans-l,2-cyclohexyl; (CH2)3CH(CH)3CH2; (CH2)2O(CH2)2; (CH2)2NH(CH2)2. 
R2 = (CH2)n, where n = 0, 2, 4, 6, 8. 
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Many bisquinolines containing piperazine moieties also exhibit antiplasmodial activity. 
Bisquinolines such as piperaquine (1.9, Figure 1.7), hydroxypiperaquine (1.10, Figure 1.7), 
dichloroquinazine (1.11, Figure 1.7), 12,494RP (1.12, Figure 1.7) and 1,4-bis(7-chloro-4-
quinolylamino)piperazine (1.13, Figure 1.7) are believed to act via the same mechanism as 
chloroquine.
41-43
 Initially these drugs were identified as promising drug candidates but their 
activity was not comparable to chloroquine. More recently, these drugs have been re-
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-bis(7-chloroquinolin-4-yl)cyclohexane-1,2-diamine or WR 268,668. This racemic 
mixture was found to be two-hundred times more effective against a CQ-sensitive strain of P. 
falciparum than chloroquine, but only six times more potent against a CQ-resistant strain. 
When this particular compound was used in conjunction with a chloroquine efflux inhibitor 
i.e. desipramine, resistance to WR 268,668 decreased in the resistant strain. This suggests that 
the compound experiences the same mechanism of resistance as chloroquine.
44 
Preparation 
and evaluation of the two enantiomeric forms of this compound showed that the S,S form also 
known as Ro 47-7737 (1.14, Figure 1.8) displays better activity against CQ-resistant parasites 
in comparison to the R,R form or the racemic mixture.
45
 Ro 47-7737 was studied in more 
detail and proved to be potent against P. berghei in vivo and P. vivax ex vivo. This compound 
has been ruled out as a drug candidate however, due to its toxic nature.
46  
 
        
N NH HN N
Cl Cl
       
            1.14 
 
Figure 1.8: Ro 47-7737, a promising molecule suspended due to its toxicity 
 
In order to evaluate the effect of increased bulkiness as well as rigidity on the antiplasmodial 
activity of certain compounds, a series of novel bis-, tris- (containing 3 quinoline moieties) 
and tetraquinolines (containing 4 quinoline moieties) were prepared and evaluated against 
various strains of P. falciparum (1.15 - 1.17, Figure 1.9). Compounds displaying greater 
rigidity than their linear derivatives did not show any significant activity compared to them, 
however, the rigid analogues did not exhibit any appreciable cytotoxicity. Some of the 
trisquinolines did not display any enhanced activity in comparison to their parent bisquinoline 
derivatives, some of the tetraquinolines however, were non-cytotoxic and displayed potent 
activity against CQ-resistant strains of P. falciparum.
47 
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Quinoline compounds still remain one of the most important classes of compounds for 
malaria treatment. Not much research has been done with regards to compounds containing 
multiple quinoline units. As is observed for many bisquinolines, multimeric quinoline systems 




























        1.17 
 
 
R1 = CH2-piperazine-CH2; phenyl; CH2-NH-CH2; (CH2)n (where n = 2, 3, 5, 7, 10). 
 
 
Figure 1.9: Various tris- and tetraquinolines synthesised for biological evaluation 
 
 
1.4. Metal complexes as antimalarials 
 
The success of metal-containing compounds such as cisplatin and its analogues in cancer 
treatment has generated interest into the use of metal complexes in the field of medicinal 
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for life, such as iron used to treat anaemia or they contain toxic elements such as platinum, 
used to treat various cancers.
48
 Much emphasis has been placed on the use of inorganic 
compounds as part of cancer chemotherapy due to the success of many platinum-containing 
compounds. Based on this rationale, there have been examples of metal-containing 
compounds being prepared as potential antimalarial agents. Great success has been achieved 
by the modification of chloroquine by means of incorporating metal-containing segments.
49 
This section highlights quinoline-containing metal complexes and their antiplasmodial 
activity, with the focus on ferrocene-containing and some transition metal-quinolines.   
1.4.1. Transition metal quinoline complexes 
Transition metals have often been used to enhance the activity of existing drugs. In many 
cases this has led to compounds with promising activities, but there have also been cases 
where metal complexes have not shown superior activity. Metal complexes of primaquine and 
amodiaquine have been prepared, but these complexes did not show increased activity 
compared to the parent organic compounds. Some of the compounds synthesised included 
Cr(III), Fe(III), Cu(II), Rh(III), Pd(II) and Au(III) quinoline complexes.
50
 It was later 
proposed that metal complexes of chloroquine may result in enhanced activity. The first 
organometallic complex of chloroquine was reported by Sanchez-Delgado et al.
51
 
[RhCl(COD)(CQ)] (COD = 1,5-cyclooctadiene) (1.18, Figure 1.10) was evaluated in vitro 
against Plasmodium berghei and its activity was comparable to that of chloroquine 
diphosphate (CQDP). The compound was also tested in vivo and was found to decrease 
parasitemia by 73%.
51
 In the same study, [RuCl2(CQ)]2 (1.19, Figure 1.10) was also 
synthesised and was found to be 5 times more active than CQDP. This compound was also 
tested against two CQ-resistant strains of P. falciparum and was 2-5 times more active than 
the parent compound.
51









































Figure 1.10: The first metal complexes of CQ 
 
Based on the promising activity of the rhodium and ruthenium complexes of chloroquine, 





-arene)(CQ)] (arene = p-cymene or benzene) compounds were active in vitro 
against four CQ-sensitive and three CQ-resistant strains of P. falciparum. Specifically, these 
compounds exhibited enhanced activity against resistant strains. It is believed that these 
compounds rapidly hydrolyse in aqueous media forming ruthenium(II) aqua compounds (1.20 
– 1.23, Figure 1.11)  which are believed to be the active species.
52
   
 
Coordination of chloroquine to [Au(PPh3)]
+
 resulted in the active complex, 
[Au(PPh3)(CQ)]PF6 (1.24, Figure 1.12).
53
 This complex was evaluated against the blood stage 
of two CQ-resistant strains of P. falciparum (FcB1 and FcB2) and displayed activity in the 
low nanomolar range. This particular compound also displayed in vitro and in vivo activity 
against P. berghei.
53
 Similar Au(I) complexes (1.24, Figure 1.12) of the general formula 




) were also prepared and 
evaluated against several P. falciparum strains.
54
 The nature of the anion did not appear to 
affect the activity of the complexes, although these complexes presented lower activity in 
comparison to the corresponding triphenylphosphine derivative previously mentioned. Au(III) 
complexes [AuCl2(CQ)2]Cl (1.25, Figure 1.12) and [AuCl(CQ)(SR)(Et2O)]Cl (where SR = 1-
thio-β-D-tetraacetateglucose) were found to be moderately active, however, no structure-
activity correlations were discernible for these complexes.
54 



















































Figure 1.11: Ru(II) arene complexes of chloroquine with promising activity  






      
 
     1.24      1.25 
 
X = PPh3, Y = PF6
-
; X = PPh3, Y = NO3
-
, X = PMe3, Y = PF6
-
; X = PEt3, Y = PF6
- 
 
Figure 1.12: Examples of gold complexes possessing antimalarial activity 
 
 
1.20                                                                         1.21 
1.22                                                                        1.23 





























Iridium-chloroquine complexes i.e. [IrCl(COD)(CQ)] (1.26, Figure 1.13) and [Ir2Cl6(CQ)] 
(1.27, Figure 1.13) were evaluated in vitro against P. berghei.
55
 Complex 1.26 showed 
activity comparable to CQDP, while complex 1.27 showed slightly enhanced activity 
compared to CQDP.
55
 Platinum-containing chloroquine, trans-[PtCl2(CQ)2] (1.28, Figure 
1.13), has been tested and found to exhibit good antiplasmodial activity.
56 
 
Organometallic rhenium half-sandwich quinolines were evaluated against two strains of P. 
falciparum (3D7 and W2).
57
 The complexes that were evaluated included two 
cyrhetrenylimine (1.29, Figure 1.14) and two cyrhetrenylamine (1.30, Figure 1.14) 
complexes. In addition to this, organic derivatives were also evaluated for comparison. In 
vitro, the cyrhetrenylimine complexes displayed enhanced activity in comparison to the 
corresponding amines against the 3D7 strain. The organic derivatives appeared to exhibit 
better activity than some of the complexes. The low activity of these compounds may be a 








         1.26                                                1.27 
 
                  
     









Figure 1.13: Proposed structures of iridium and platinum quinoline complexes. 
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     1.29                   1.30 
 
R = H or R = CH2OH 
 
Figure 1.14: Cyclopentadienyl rhenium quinoline complexes evaluated  
in vitro for antiplasmodial activity. 
 
Cymantrene and cyrhetrene quinoline compounds (1.31 and 1.32, Figure 1.15) were evaluated 
against CQ-sensitive and CQ-resistant strains of P. falciparum for antiplasmodial activity. 
The cymantrene complex possessing an amine linker (1.31) exhibited good activity against 
the CQ-sensitive strain but no activity against the resistant strain. The cymantrene and 























    
                       1.31                                                                   1.32 
 
M = Mn or Re 
 
 
Figure 1.15: Cymantrene and cyrhetrene quinolines 
 
 
Tricarbonylchromium arene quinoline complexes were also tested against CQ-sensitive and 
resistant strains of Plasmodium falciparum. The two complexes, (1.33 and 1.34, Figure 1.16) 
were screened, showing high in vitro activity against both strains of P. falciparum. Complex 
1.33 was active against the CQ-resistant parasite strain and was two times more active than a 
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   1.33                            1.34 
Figure 1.16: Chromium complexes of a 4-amino-7-chloroquinoline derivative. 
 
Ruthenium p-cymene quinoline complexes with bidentate coordination have been studied 
against the D10 (CQ-sensitive) and Dd2 (CQ-resistant) strains of P. falciparum. Compounds 
1.35 and 1.36 (Figure 1.17) were less active than their corresponding ligands, while complex 
1.37 was reasonably active.
60
 New silicon-containing quinoline ligands and their 
corresponding Ru(II), Rh(I) and Rh(III) complexes (1.38 – 1.40, Figure 1.18) were prepared 
and tested against NF54 (CQ-sensitive) and Dd2 (CQ-resistant) P. falciparum.
61
 In most cases 
the complexes showed better activity compared to the ligands. Generally the compounds were 
less active in the CQ-resistant strain than in the sensitive strain. This suggests that the 
compounds may experience cross-resistance similar to that of chloroquine.
61












   
      
1.37 
 
Figure 1.17: Ru(II) p-cymene quinoline complexes evaluated against 
the D10 and Dd2 strains of P. falciparum. 





























                    1.38    1.39                    1.40 
 




Figure 1.18: Organosilicon Ru(II), Rh(I) and Rh(III) quinolines 
 
 
A series of ruthenocene-chloroquine complexes (1.41 and 1.42, Figure 1.19) were also 
prepared and evaluated against CQ-resistant (K1) and CQ-sensitive (D10) strains of P. 
falciparum.
62
 All compounds exhibited good efficacy against both parasitic strains. Activity 
exhibited against the CQ-resistant strain suggests that the metallocene aids in overcoming any 
resistance experienced by the chloroquine motif. The activity of the ruthenocene compounds 




    
 
                                    
                                   
                                  
 
1.41      1.42                
 
Figure 1.19: Examples of ruthenocene 4-amino-7-chloroquinolines exhibiting 
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1.4.2. Ferrocene-quinoline compounds as antimalarials 
Ferrocene (Fc) is an organometallic sandwich compound that was first prepared in 1951. This 
particular compound (and its derivatives) is used as a fuel additive, in catalysis and more 
recently, due to its stability in aqueous and aerobic media, lipophilicity and low toxicity, has 
been used in medicinal chemistry.  
 
Incorporation of ferrocene as part of the chemical structures of active antimalarial drugs such 
as artemisinin (1.43, Figure 1.20),
63,64
 atovaquone (1.44, Figure 1.20),
65
 mefloquine (1.45, 
Figure 1.20) and quinine (1.46, Figure 1.20),
66
 did not significantly improve the antimalarial 
activity of the parent compounds. In most cases the parent organic compounds displayed 
better activity in comparison to the ferrocenyl derivatives.  
 
 

































Figure 1.20: Ferrocene derivatives of established antimalarial agents. 
 
 
In the case when ferrocene is covalently linked to a 7-chloroquinoline moiety, an important 
and potent antimalarial agent was produced, ferroquine (FQ) (1.47, Figure 1.21).
67
 This 
1.43                                                1.44 
    1.45                                1.46 
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particular compound displays 22-times greater antimalarial activity than chloroquine against 
CQ resistant strains of P. falciparum when studied in vitro. In vivo this compound displayed 
potent activity in mice infected with P. yoeli, P. berghei and P. vinkei vinkei.
67,68
 Due to its 
ability to overcome CQ resistance, ferroquine has undergone phase IIb clinical trials and is 
being developed by Sanofi-aventis.
69 
This particular compound is extremely active against CQ 
sensitive and resistant strains of P. falciparum, suggesting that FQ may possess a distinct 
mechanism of action to that of CQ or there is an absence of interaction of this compound with 
resistance mechanisms.
64 
It was found that ferroquine targets the digestive vacuole of the 




pharmacodynamic data supports the use of ferroquine as an antimalarial, however, further 









                                     1.47 
 
Figure 1.21: Ferroquine, a potent antimalarial. 
 
Many structural derivatives of ferroquine have been prepared and tested to assess whether 
certain modifications may affect the activity of this particular compound. Modification of the 
basic tertiary amino group adjacent to the ferrocenyl moiety (1.48, Figure 1.22) by 
introduction of various alkyl substituents such as H, C2H5, CH3 and FcCH2, resulted in 
comparable activity to FQ and good activity against CQ resistant strains (Dd2 and W2). 
Contradictory to this, it was found that incorporation of a second ferrocenyl moiety onto the 
terminal nitrogen atom decreased the efficacy of the compounds.
74
 Introduction of secondary 
amines as the basic amino group does not alter the activity in comparison to the parent 
compound, but does exhibit better activity than chloroquine against the Dd2 CQ sensitive 
strain.
75
 Hydroxyferroquines or ferroquine derivatives possessing hydroxyl moieties on the 
terminal nitrogen atoms (1.49, Figure 1.22) have been shown to exhibit lower cytotoxicity in 













comparison to ferroquine. In addition to this, these compounds display much better in vitro 













                                       1.48                                                                   1.49 
 
R1 = R2 = C2H5 or R1 = C2H5 and R2 = CH3; R1 = H and R2 = CH3 or C2H5 or 
t
Bu; R3 = H, CH3, C2H5 
 
Figure 1.22: Ferrocene derivatives that display comparable antimalarial activity to FQ 
 
 
Incorporation of thiosemicarbazones (TSCs) onto the side chain of ferroquine has also been 
investigated. Thiosemicarbazones are another class of compounds that possess antimalarial 
activity. TSCs possessing the 2-acetylpyridine moiety have exhibited good antimalarial 
activity in P. berghei in mice.
77-79
 Thiosemicarbazones are chelating ligands that are able to 
produce reactive oxygen species. This is believed to be the mode of action responsible for 
their potent activity.
80
 In order to investigate the effect of combining thiosemicarbazones and 
ferroquine, a chimeric ligand approach was employed to investigate the effect on the 
antimalarial activity. The chimeras (1.50, Figure 1.23) were found to be active against four 
strains of P. falciparum. The presence of the aminoquinoline motif appears to be the major 




                                                                            
 
        1.50 
 
X = Cl or Br; Y = Cl or H 
 
Figure 1.23: Thiosemicarbazone ferrocenyl conjugates 
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Many other ferrocene-containing conjugates have been prepared and their antimalarial activity 
tested. Association of chloroquine with a ferrocenecarboxylic acid via an electrostatic 
interaction (1.51, Figure 1.24) resulted in this compound displaying low activity against CQ-
sensitive and CQ-resistant strains in vitro. It is believed that the low activity is as a result of 
an antagonistic effect between the chloroquine and the carboxylic acid derivative.
82
 
Condensation of a ferrocenylmethyl moiety onto the nitrogen atom of the quinoline ring of 
chloroquine afforded a quaternary ammonium salt (1.52, Figure 1.24). This particular 
compound was inactive against the CQ-sensitive (HB3) and the CQ-resistant (Dd2) strains of 
P. falciparum.
83
           
 
                                       
 
 
                      
                      
 
                   1.51    1.52              
 
Figure 1.24: Charged ferrocenyl complexes evaluated for their antimalarial activity 
  
 
Ferrocenic dual molecules (1.53 and 1.54, Figure 1.25) consisting of a ferroquine analogue 
conjugated with either a glutathione reductase inhibitor or a glutathione depletor by means of 
an amide bond were evaluated for their antimalarial activity against NF54 (CQ-sensitive) and 
K1 (CQ-resistant) strains of P. falciparum. A slight decrease in the antimalarial activity of the 
dual molecules was observed in comparison to the corresponding ferroquine analogues. The 
decrease in activity may be due to cleavage of the amide bond as well as the side chain once 




































                                       
                                    1.53               1.54 
 







Figure 1.25: Ferroquine conjugates of glutathione reductase 
inhibitors and glutathione depletors 
 
 
Another series of hybrid molecules that show promise are the trioxaferroquines. These 
compounds are antimalarial drugs containing 1,2,4-trioxane moieties covalently bound to an 
organometallic ferrocene derivative. The rationale behind the preparation of these compounds 
stems from two very potent antimalarials, namely artemisinin (1,2,4-trioxane) and 
ferroquine.
85 
The preparation of these compounds was inspired and supported by the success 
of trioxaquine PA1103/SAR116242.
86
 The antimalarial activity of several trioxaferroquines 
(1.55, Figure 1.26) and trioxaferrocenes (1.56, Figure 1.26) were evaluated against two CQ-
resistant strains of P. falciparum (FcB1 and FcM29). The trioxaferroquines display good 
activity against both strains of the parasite. The corresponding trioxaferrocenes, however, did 
not exhibit any note-worthy activity. This further supports the importance of the 4-
aminoquinoline moiety for antimalarial activity. In vivo studies also support the use of these 
compounds as antimalarial drugs due to the ability of one of the complexes to clear 
parasitemia in mice infected with P. vinkei petteri.
85 








1.55      1.56 
 
Figure 1.26: An example of a trioxaferroquine and trioxaferrocene 
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Ferrocene-containing triazacyclononane quinoline conjugates were also prepared and their 
activity tested against HB3 (CQ-sensitive) and Dd2 (CQ-resistant) P. falciparum. Compound 
1.57 (Figure 1.27) showed potent activity against the Dd2 strain, but was less active against 
the sensitive strain.
87










   1.57 
 
Figure 1.27: Triazacyclononane bisquinoline ferrocene conjugate active 
against CQ resistant P. falciparum. 
 
Ferrocene compounds incorporating a 7-chloroquinoline and a 1,2,3,5-(diisopropylidene-α-D-
glucofuranose moiety (1.58, Figure 1.28) were prepared and tested against the D10, Dd2 and 
K1 strains of P. falciparum. Two of the compounds showed consistently high in vitro activity 
against the two resistant strains (Dd2 and K1), higher than chloroquine.
88
 Ferrocene-
containing carbohydrate derivatives of chloroquine (1.59, Figure 1.28) and mefloquine (1.60, 
Figure 1.28) were evaluated against the D10 and Dd2 P. falciparum strains. Incorporation of 
















































                         1.58      1.59    1.60 
 
Figure 1.28: Diisopropylidene-α-D-glucofuranose and carbohydrate ferrocene quinolines 
 
Ferrocenaphane analogues of ferroquine (1.61, Figure 1.29) have recently been prepared and 
tested against various strains of P. falciparum. The compounds were active against both 
choroquine-sensitive and chloroquine-resistant strains. These compounds were able to 
overcome resistance and this phenomenon was mainly attributed to the lipophilicity of the 
compounds, intramolecular hydrogen bonding and their compact size.
90 




                       1.61 
 
 
Figure 1.29: Ferrocenaphane 7-chloroquinolines that may overcome CQ resistance 
 
The derivatisation of ferroquine, its analogues and other organometallic compounds has been 
a major contributor towards the quest for new organometallic compounds displaying 
antimalarial activity. The success of many of these compounds supports the development of 
various other organometallic molecules in order to evaluate their antimalarial activity in the 
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hope to obtain compounds possessing similar or more potent activity as well as those that 
possess distinct biological mechanisms to chloroquine. 
  
1.5. Polyamines: potential drug delivery systems 
 
Polyamines are compounds that play an important role in all living systems. They are 
generally defined as compounds containing two or more amine moieties. These compounds 
are naturally occurring and are found in mammalian cells. Putrescine (1.62, Figure 1.30), 
spermidine (1.63, Figure 1.30) and spermine (1.64, Figure 1.30) are found in most eukaryotes. 
These compounds are mainly responsible for maintaining cell viability.
91
 Studies reveal that 
these systems are able to transport cytotoxic drugs into tumour cells.
92 
Cells import 
polyamines by means of a polyamine transporter (PAT) in order to sustain cell growth. The 
transporter is able to tolerate modified polyamines, therefore drug incorporated polyamines 















Figure 1.30: Naturally occurring polyamines involved in 
cell proliferation and differentiation. 
 
Although polyamine research has been aimed mainly towards the discovery of selective drugs 
targeting human tumour cells, these compounds have also been found to exhibit selective 
uptake by Plasmodium infected erythrocytes.
 
The erythrocytes were analysed and it appeared 
as though polyamine levels increased by more than 10 fold.
94,95 
It has also been shown that a  
bis(benzyl) polyamine analogue, MDL27695, inhibits growth in CQ-sensitive and resistant 
strains of P. falciparum.
96
 Polyamine amides (Figure 1.31) of N-methylanthranilic acid were 
synthesised in order to exploit the PAT system of parasites. These compounds are analogues 
           1.62                                                               1.63 
    
 
    1.64 
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of spermidine, putrescine (1.65) and spermine (1.66). Intracellular uptake was monitored 
using fluorescent microscopy. The spermine derivative showed measurable accumulation.
97 














1.65                    1.66 
 
Figure 1.31: Polyamine amides of putrescine and spermine 
 
A series of 1,3,5-triazine-substituted polyamines (1.67, Figure 1.32) have been screened 
against CQ-sensitive (NF54) and CQ-resistant (K1) strains of P. falciparum. The compounds 
were generally more active against the resistant strains. Incorporation of multiple triazine 
moieties resulted in enhanced activity.
98 
In another study, tetrameric 
ferrocenylthiosemicarbazones conjugated to a polyamine backbone were evaluated against the 
W2 resistant strain of P. falciparum. Increased efficacy of the conjugated systems was 




                                                             
 
 
                                                         
 
                          1.67 
 
 
Figure 1.32: An example of a triazine polyamine that inhibits 
growth of P. falciparum in vitro. 
Polyamines are desirable systems because they could be used as drug delivery agents in a 
similar manner to dendrimers. Dendrimers (1.68, Figure 1.33) are multivalent, tree-like, three 
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extensively in polymer and material science; however, there is a growing interest in the use of 




Dendrimers have mainly been used in the delivery of cancer chemotherapeutic drugs.
101
 Drug 
delivery can essentially be carried out by two distinct mechanisms: (i) by utilising host-guest 
chemistry, where the drug is introduced as the guest and released due to changes in pH, 
temperature or diffusion, or (ii) by degradation of a drug-dendrimer conjugate (where the drug 
is covalently linked to the dendrimer) in vivo. The first mechanism is less desirable because 
controlling the amount of drug loaded onto the dendrimer as part of a host-guest system can 
be problematic. The second mechanism would be favoured because dendrimers have a large 
number of surface groups that can be functionalised with drug molecules which leads to the 
formation of pro-drugs.
100
 An example of a dendrimer-quinoline system can be seen with the 
PEGylated (PEG = polyethylene glycol) peptide dendrimeric carrier of chloroquine (Figure 
1.34). The results revealed that loading of the drug onto the dendrimer reduced the haemolytic 
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Very few studies have been conducted where polyamines were used as carriers in order to 
afford potential antimalarial agents. This study looked at making use of various mono- and 
polyamines in order afford new imino- and amino-containing compounds with potential 
antiplasmodial activity. The rationale for this study was supported by the use of polymers (or 
multimeric structures) as drug delivery systems.
103
 It must be noted that the compounds 
prepared in this study are not polymers or macromolecules, but the preparation of multimeric 
and multinuclear systems was influenced by the use of macromolecular systems as 
therapeutics. This project involved the design, synthetic preparation and biological evaluation 
of various mono- and multimeric organic and organometallic compounds. These compounds 
were prepared for their potential as antiplasmodial agents. In addition to this, their activity 
against other diseases including trichomoniasis and oesophageal cancer was also investigated. 
Preliminary mechanistic studies were performed in order to elucidate the possible mode of 
action of these compounds against Plasmodium falciparum.  
Figure 1.34: A pictorial representation of chloroquine loaded onto a PEG-lysine G5 dendrimer
101
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Many biological studies have been conducted on monomeric quinoline or mononuclear metal 
complexes of various quinolines. There is much scope for the development of multimeric 
systems towards the discovery of new compounds that may potentially possess antiplasmodial 
activity. The overall aims of the project were as follows: 
1) To prepare various mono- and multimeric quinoline-containing compounds conjugated 
to various amine and polyamine scaffolds (Figure 1.35). 
2) To prepare compounds containing one or more metal moiety by also making use of 
polyamine scaffolds. 
3)  To evaluate these compounds for biological activity in order to compare the activity of 
monomeric and multimeric systems. 

















Figure 1.35: Polyamines used in this study. 
 
1.6.2. Specific objectives 
 
1) To prepare a series of mono- and multimeric quinoline and ferrocenyl compounds 
conjugated to amine and polyamine scaffolds (Figure 1.36). These compounds possess 
thiourea moieties which are also active antimalarial pharmacophores. 
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Figure 1.36: General structures of some thiourea compounds prepared in this study. 
 
2) To prepare a series of mono- and binuclear Rh(I) quinoline salicylaldimine complexes 
and their corresponding ligands (Figure 1.37) in order to gain insight to any structure-
activity relationships. Rh(I) was been chosen because very few studies have been 
conducted using this metal in malaria therapy. It also possesses square-planar 








    
R = electron withdrawing or donating groups 
 
Figure 1.37: Mononuclear Rh(I) salicylaldimine complexes investigated in this study. 
 
3) To prepare mono- and multinuclear ferrocene compounds (Figure 1.38) containing 
imino and amino moieties. Since ferroquine is one of the most promising 
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organometallic compounds for malaria therapy it was considered worthwhile to 













Figure 1.38: Some ferrocenyl derivatives investigated in this study. 
 
4) To test these compounds against the CQ-sensitive (NF54) and CQ-resistant (Dd2 or 
K1) strains of P. falciparum. To evaluate the activity of these compounds against 
Trichomonas vaginalis, a parasite responsible for the sexually transmitted infection, 
trichomoniasis. To investigate the cytotoxicity of the compounds against WHCO1 
oesophageal cancer cells. To use physicochemical methods to evaluate the extent to 
which these compounds are able to inhibit synthetic haemozoin (β-haematin) 
formation using an NP-40 detergent assay. 
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Synthesis, characterisation and 




Thiourea-containing compounds are attractive for the design of new antiplasmodial agents. 
Thiosemicarbazones are a class of thioureas that possess a wide range of biological properties 
including antimalarial activity.
1-5 
Many thiosemicarbazones display activity against 
protozoans by inhibiting various cysteine proteases as well as other targets.
5
 Recent studies 
have shown that a series of quinoline-containing thioureas (Figure 2.1a) exhibited activity in 
both chloroquine-sensitive and resistant strains of Plasmodium falciparum (P. falciparum) in 
vitro. Ferrocene-containing compounds have also been found to possess biological activity 




     
     
             
 
 
         
 a        b   
 
R1 = alkyl, aryl; 
R2 = H, alkyl 
 
Figure 2.1: (a) Monomeric quinoline thioureas showing activity against sensitive and 
resistant strains of P. falciparum and (b) ferroquine a ferrocene-containing analogue of 
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In addition to this, thiosemicarbazones (TSCs) containing ferrocenyl moieties have proven to 
be active against parasites as well as certain tumours.
7,8 
More recently ferrocenyl 
thiosemicarbazones conjugated to a poly(propyleneimine) (PPI) dendrimer were evaluated in 
vitro and displayed moderate antiplasmodial activity against the W2 chloroquine-resistant 
strain of P. falciparum.
9 




incorporation of the ferrocenyl moiety alters 
the lipophilic nature of molecules and therefore may enhance the activity of certain 
compounds due to increased uptake of the compounds into the digestive vacuole of the 
parasite. Ferroquine (Figure 2.1b) is an excellent example of a ferrocenyl-containing molecule 





Since very little research has been geared towards investigating the biological activity 
(specifically antiplasmodial activity) of systems containing multiple biologically active 
motifs, this study investigated the synthesis, characterisation and biological evaluation of 
mono- and multimeric quinoline and ferrocene thiourea compounds. An increased number of 
biologically active moieties may result in enhanced activity. These moieties were incorporated 
onto polyamine systems in the hope of enhancing the transport of these motifs across 
membranes and in addition to this aid in the accumulation of these compounds inside of the 
digestive vacuole of the parasite due to pH trapping. The in vitro antiparasitic and antitumour 
activity as well as β-haematin inhibition activity of these compounds is described.  
 
2.2. Synthesis and characterisation of mono- and multimeric quinoline  




Four new 4-amino-7-chloroquinoline thioureas were synthesised using template procedures. 
4,7-Dichloroquinoline was reacted with an excess of 1,3-diaminopropane via a nucleophillic 
aromatic substitution (SNAr) reaction to afford N’-(7-chloroquinolin-4-yl)-propane-1,3-
diamine (2.1, Figure 2.2). The chlorine atom at position 4 (numbering shown in Figure 2.2) of 
the quinoline ring is the favoured leaving group which is a consequence of the position of the 
quinoline nitrogen. The quinoline nitrogen is an electron sink which is able to accept a lone 
pair of electrons in order to allow attack at C-4 by the nucleophilic nitrogen (Figure 2.2). 
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N’-(7-Chloroquinolin-4-yl)-propane-1,3-diamine (2.1) was modified to form [3-(7-chloro-
quinolin-4-ylamino)-propyl]-dithiocarbamic acid methyl ester (2.2) by means of a modified 
one-pot synthesis previously described by Katti et al.
11
 N-(7-Chloroquinolin-4-yl)-propane-
1,3-diamine (2.1) was reacted with carbon disulfide in the presence of KOH in isopropanol, 
followed by methylation with iodomethane at 0°C. Compounds 2.3 – 2.6 were obtained by 
subjecting 2.2 to nucleophillic substitution by various amines such as n-propylamine, 1,3-
diaminopropane, tris(2-aminoethyl)amine and N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-
butanediamine (DAB-Am-4), respectively (Scheme 2.1). Compounds 2.3 – 2.6 were obtained 





























Figure 2.2: Mechanism of nucleophillic aromatic substitution (SNAr) to afford 2.1. 
   




























































































Scheme 2.1: Synthesis of quinolines 2.1 – 2.6. Reagents and conditions: (a) neat; (b) KOH  
(1 eq.), NH2NH2
.
H2O (1 eq.), CS2 (1 eq.), CH3I (1 eq.) 0 – 5 °C; (c) n-propylamine,  













C), heteronuclear single quantum coherence (HSQC) and correlation 
spectroscopy (COSY) nuclear magnetic resonance (NMR) spectroscopy, infrared (IR) 
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NMR Spectroscopy  
 
Analysis of the 
1
H NMR spectra of compounds 2.1 – 2.6 confirmed that the proposed 
compounds were obtained. The 
1
H NMR spectrum of 2.1 was recorded using CD3OD and was 
in agreement with the proposed structure. The integration of all of the proton resonances in 
the spectrum of 2.1 was consistent with the mono-substituted amine. The 
1
H NMR spectra of 
2.2 – 2.6 were recorded in DMSO-d6. The spectrum of 2.2 supported formation of the 
thioester moiety due to the presence of a singlet at 2.46 ppm, which was assigned to the CH3 
group of the ester moiety. The absence of this particular signal in the spectra of 2.3 – 2.6 
confirmed displacement of the -SCH3 group of compound 2.2 in each case.  
 
The spectrum of 2.3 displayed signals for the protons of the propyl chain at 0.86, 1.49 and 
3.30 ppm for the -CH3, -CH2CH2CH3 and -NHCH2- groups, respectively. Signals for the 
protons of the propyl chain of compound 2.4 were observed at 1.73 and 3.30 ppm for  
-CH2CH2CH2- and -NHCH2-, respectively. Signals for the ethyl moiety of the trimeric 
compound 2.5, resonated at 2.66 and 3.44 ppm. Signals were significantly broader in the 
spectrum of compound 2.6, in comparison to the spectra of the mono-, di- and trimeric 
counterparts. This may be attributed to the multimeric nature (containing four quinoline 
moieties) of this compound.  Signals for the protons of the butyl core were observed at 1.32 
and 2.35 ppm. Multiplets for the protons of the propyl groups resonated at 1.59, 2.35 and 
between 3.21 and 3.50 ppm (overlap of signals observed) for -CH2CH2CH2-, -CH2CH2N- and 




H NMR spectrum of 2.6 is shown in Figure 2.3. For compounds 2.3 – 2.6, signals for the 
newly formed NH group were assigned at approximately 7.19 ppm. The signal for H3 
(numbering shown in Figure 2.2) of the quinoline moiety occurred as a doublet at 
approximately 6.4 ppm for these compounds. Proton H8 was assigned to a doublet at 
approximately 7.8 ppm in all cases. A doublet with a coupling constant of approximately 2 Hz 
was observed for the latter, due to coupling of H8 to H6. The signal for H6 appeared as a 
doublet of doublets in each spectrum, thus confirming long-range coupling within the 
aromatic system. The integration observed in each spectrum was consistent with the proposed 
structures. 
 








H NMR spectrum of the tetrameric thiourea 2.6 in DMSO-d6 
 




H} NMR spectra further confirmed the structures of these compounds. 
Resonances for the carbon atoms of the quinoline rings appeared in the region of 98 and 152 
ppm. The thiocarbonyl signals for 2.3 - 2.6 were observed at approximately 182 ppm. In the 
case of 2.3, signals affiliated with the aliphatic carbon atoms were found between 11.10 and 
45.10 ppm. One signal was observed for carbon atoms C5 and C6 in the spectra of 2.3, 2.5 
and 2.6. This was confirmed by a 2D HSQC experiment. Two cross-peaks were observed for 
this signal, confirming the same resonance for these two atoms. In the case of 2.4, two distinct 
resonances were observed for C5 (123.67 ppm) and C6 (123.88 ppm). Signals attributed to the 
aliphatic carbon atoms were observed at similar resonances compared to 2.3 and occur 
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structures and compared favourably with the monomeric and dimeric analogues. Signals for 
the aliphatic carbon atoms of 2.5 resonated between 27.30 and 55.98 ppm, while these 




Infrared spectroscopy is another useful tool used to identify functional groups that are present 
in various compounds. The infrared spectra of these compounds were recorded in the solid 
state and prepared as KBr pellets. The spectra of compounds 2.1 – 2.6 displayed absorption 
bands for the quinoline C=N between 1611 and 1613 cm
-1
. Absorption bands for the 
thiocarbonyl (C=S) vibrations of 2.3 - 2.6 were observed between 1136 and 1138 cm
-1
. This 
particular band in 2.2 appeared at a slightly higher frequency, 1141 cm
-1
, compared to the rest 
of the compounds. This may be attributed to the presence of the adjacent electron donating 
-SCH3 group, resulting in shortening of the C=S bond and therefore causing a slight increase 
in the wavenumber of this band. 
 
ESI mass spectrometry  
 
The new compounds 2.3 – 2.6 were submitted for ESI-MS analysis to further confirm the 
proposed structures. The samples were analysed in the positive mode. For compound 2.3, a 
peak at m/z 337.1248 (100%) was observed and corresponds to the protonated form of the 
monomeric quinoline molecule. For 2.4, a peak at m/z 315.0951 (100%) was assigned to 
[M+2H]
2+
. Peaks at 513 (60%) corresponding to [M+2Na]
2+
 and 1429 (70%) corresponding to 
[M+H]
+
 were observed in the spectra of 2.5 and 2.6, respectively. Sodium adducts are 
commonly observed when using this technique. In the mass spectra of 2.5 and 2.6 successive 
loss of the quinoline thiourea moieties were observed giving rise to fragmentation peaks. 
Figure 2.4 shows the mass spectrum of 2.6 as an example.  
 
Based on the characterisation data outlined above, it was concluded that a series of mono- and 
multimeric quinoline thioureas were successfully synthesised using template procedures. 
NMR spectroscopy, IR spectroscopy and ESI-MS confirmed the integrity of these 
compounds. 





Figure 2.4: ESI mass spectrum of 2.6 obtained in the positive mode – highlighted peaks 
correspond to masses of the tetrameric
 
(blue); trimeric (yellow) and dimeric (orange) 
fragments. 
 
2.3. Synthesis and characterisation of mono- and multimeric ferrocene  
thioureas 2.7 – 2.12  
 
2.3.1.  Synthesis 
 
Three ferrocenylimine thiourea compounds were prepared by the procedures outlined in 
Scheme 2.2. Methyl hydrazinecarbodithioate (2.7) was prepared in a similar manner to 
compound 2.1 using the method described by Klayman et al.
1 
Hydrazine hydrate was treated 
with carbon disulphide in i-PrOH in the presence of KOH. Methylation with iodomethane 
afforded 2.7 in 32% yield. Ethane-1,2-dithiosemicarbazide (2.8) was prepared in order to 
afford a dimeric ferrocene derivative. This method also involved the preparation of the 
915 
m/z 
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dithiosemicarbazide from 1,2-ethanediamine via a diacid precursor. The diacid that formed in 
situ was then treated with excess hydrazine hydrate which displaced the carboxylic acid 
moiety by nucleophillic addition to the thiocarbonyl forming the desired dithiosemicarbazide. 
Subsequent reaction of 2.7 with ferrocenecarboxaldehyde in i-PrOH gave rise to thioester 
2.9.
12
 The monomeric (2.10) and trimeric (2.12) ferrocene-thioureas were prepared by 
refluxing 2.9 with n-propylamine and tris(2-amino)ethyl amine in EtOH, respectively. The 
dimeric ferrocene-thiourea 2.11 was prepared by modification of the method outlined by 
Wiles et al.
13
 whereby ethane-1,2-dithiosemicarbazide (2.8)
14 
and ferrocenecarboxaldehyde 
were reacted at room temperature in water to afford the desired product. The compounds were 






































































Scheme 2.2: Synthesis of ferrocenyl thioureas 2.9 – 2.12. Reagents and conditions: (a) KOH 
(1 eq.), CS2 (1 eq.), CH3I (1 eq.) 0 – 5 °C; (b) ferrocenecarboxaldehyde, i-PrOH, reflux;  
(c) n-propylamine, EtOH, reflux; (d) tris(2-amino)ethyl amine, EtOH, reflux; (e) NaOH, CS2, 
NH2NH2
.
H2O; (f) ferrocenecarboxaldehyde, H2O, r.t. 
 









H NMR spectra obtained for compounds 2.9 – 2.12 were consistent with the proposed 
structures. Schiff-base condensation of 2.7 and ferrocenecarboxaldehyde was confirmed by 
the appearance of a singlet at 8.12 ppm attributed to the imine proton. A singlet for the CH3 
protons of the thioester moiety was observed at 2.50 ppm. Signals for the imine protons 
resonated between 7.89 and 7.90 ppm for 2.10 – 2.12. These shifts were found upfield in 
comparison to the same signal observed for compound 2.9. Signals for the -CH3, 
CH3CH2CH2- and -NHCH2CH2- protons of compound 2.10 were assigned at 0.86, 1.59 and 
3.49 ppm, respectively. The CH2 protons of the spacer for 2.11 (Figure 2.5) appeared as a 
singlet at 3.78 ppm, while two multiplets were assigned to the ethyl protons of 2.12 at 2.83 
and 3.71 ppm. Singlets for the hydrazinic protons resonated between 11.11 and 11.29 ppm. 
Signals for the newly formed secondary amine were observed between 8.12 and 8.36 ppm. 
Signals for the protons of the unsubstituted cyclopentadienyl (Cp) ring of the ferrocenyl 
moieties were observed as singlets between 4.17 - 4.21 ppm for the mono-, di- and trimeric 
derivatives. These signals were shifted upfield compared to the same signal in the spectrum of 




H} NMR spectroscopy was also used to further characterise these compounds. Signals 
for the thione carbon atoms (C=S) were assigned at approximately 177 ppm for compounds 
2.10 – 2.12. The C=N resonances were observed at 143.45, 143.96 and 143.70 ppm for the 
mono-, di- and trimeric ferrocenyl derivatives, respectively. Resonances for the carbon atoms 
of the unsubstituted Cp rings were assigned at 69.40, 69.43 and 69.44 ppm for 2.10 - 2.12, 
respectively. Signals for the carbon atoms of the substituted Cp rings resonated at 
approximately 70.5 ppm for those closest to the imine moiety and at 68 ppm for those furthest 
from the imine moiety.  
IR spectroscopy 
Absorption bands attributed to the imine bond were observed at 1604, 1611 and 1606 cm
-1
 for 
2.10, 2.11 and 2.12, respectively. These bands were found at a higher frequency compared to 
thioester 2.9 (1597 cm
-1
). Absorption bands for the N-H vibrations were observed between 
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3437 and 3129 cm
-1
. Absorption bands for the asymmetric ferrocene ring vibrations were also 
observed between 1103 and 1106 cm
-1
 for these compounds.  
ESI mass spectrometry  
Compounds 2.10 – 2.12 were analysed using ESI mass spectrometry. Base peaks at m/z 
330.0724 and 601.0582 corresponding to the protonated molecular ion, [M+H]
+
, were 
observed for 2.10 and 2.11, respectively. A peak at m/z 957.1362 (70%) corresponding to 
[M]
+




H NMR spectrum of the dimeric ferrocene derivative 2.11 in DMSO-d6 
 
The NMR spectoscopic, IR spectroscopic and mass spectrometry data described above was in 
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2.4. Biological and physicochemical evaluation 
Once the synthesised compounds were characterised, their biological activity was 
investigated. Specifically, the compounds were screened in vitro against two strains of P. 
falciparum, namely the NF54 chloroquine-sensitive (CQS) strain and the Dd2 chloroquine-
resistant (CQR) strain for antiplasmodial activity. The ability of the compounds to inhibit  
β-haematin (synthetic haemozoin) formation was also evaluated. In addition to this, the in 
vitro antitumour activity of the compounds was also investigated against WHCO1 
oesophageal cancer. Lastly, the compounds were also screened against the G3 strain of the  
T. vaginalis parasite, which is responsible for the sexually transmitted disease trichomoniasis.    
2.4.1. Prediction of the lipophilicity of compounds 2.3 – 2.6 and 2.10 – 2.12 
 
In order to gain some insight into the relationship between the lipophilicity of these 
compounds and their activity, the lipophilicity of the quinoline compounds at pH 7.4 and pH 
4.8 were estimated using Marvinsketch V5.9.4. Due to the fact that this program cannot 
predict lipophilicity of metal complexes, the lipophilicity of the ferrocenyl compounds could 
not be evaluated in the same manner and therefore an alternative method was employed in 
order to estimate their logP.  
 
To estimate the logP of the ferrocenyl-containing compounds 2.10 – 2.12, modification of the 
fragmental approach proposed by Rekker et al
15
 and Lanez et al
16-18
 were used to predict the 
logP of the Fc compounds. The Rekker method is a calculation based on the decomposition of 
a molecule into substructures that possess theoretical hydrophobicity values. This approach 
was adapted to use theoretical values obtained from Marvinsketch as well as the experimental 
logP value of ferrocene (Fc) which is 2.66. In this case, the logP of the Fc-H fragment 
(ferrocene less one hydrogen atom) is required. The logP value of this fragment (f(Fc-H)) is 
2.456 based on literature.
16
 Two different logP methods found in the Marvinsketch V5.9.4 
program (weighted – method 1 and Klop – method 2) were applied in order to predict the logP 
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The logP of the Fc compounds were predicted using the following equation: 
 
LogP(Fc derivative) = LogP(benzene derivative) – f(benzene fragment) + f(fc-H)   
 
Where: LogP(benzyl derivative) was calculated using Marvinsketch  
  f(benzyl fragment) was obtained from Marvinsketch 



























































                 F7    F8     F9 
 
Figure 2.6: Reference ferrocene compounds F1 – F9 that were used to 
validate the adapted method 
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Initial correlation (before 
correction): 
 Y = 0.8238x + 0.9425  
 R
2
 = 0.9676 
Calculations were carried out for all compounds and their predicted values compared to 
experimental values. Experimental values for F1 - F9 were taken from literature.
16-18
 XY 
scatter plots (Figure 2.7 and 2.8) were generated in order to assess the correlation between the 
experimental values and the estimated ones. An example of the calculation of the logP of F1 
using the weighted method is shown below:  
 










      Fc derivative (F1)   benzene derivative 
 
LogP(Fc derivative) = LogP(benzene derivative) – f(benzene fragment) + f(fc-H)   
    = 2.45 – (0.33x5+0.02) + 2.456 
    = 3.24 
Experimental value: 2.64.  
 







                  
 
Figure 2.7: Correlation between estimated and experimental logP values 
using the weighted method 
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Initial correlation (before 
correction):  
Y = 0.8028x + 1.0092 
R
2
 = 0.9722 
The XY scatter plot (Figure 2.7) resulted in good correlation (R
2
 > 0.9), however, the slope 
was less than 1 and the intercept not equal to zero. A correction was then applied to the 
values. The same procedure was carried out on F1 – F9 using the Klop method (method 2). 
The results are shown in Table 2.1 and 2.2. 
 
Table 2.1 
LogP values obtained for compounds F1 – F9 using the weighted method 
compound experimental estimated corrected estimate 
F1 2.64 3.24 2.79 
F2 4.10 4.44 4.24 
F3 4.59 4.26 4.03 
F4 5.04 5.06 4.99 
F5 4.68 4.77 4.65 
F6 6.47 6.51 6.76 
F7 4.89 5.10 5.05 
F8 6.70 6.42 6.65 
F9 6.60 6.34 6.55 
 RMSD 0.290 0.229 
 
        





Figure 2.8: Correlation between estimated and experimental logP values  











experimental  logP 




LogP values obtained for compounds F1 – F9 using Klop method 
compound experimental estimated corrected estimate 
F1 2.64 3.22 2.75 
F2 4.1 4.54 4.40 
F3 4.59 4.34 4.15 
F4 5.04 4.92 4.87 
F5 4.68 4.62 4.41 
F6 6.47 6.24 6.52 
F7 4.89 5.08 5.07 
F8 6.7 6.47 6.80 
F9 6.6 6.35 6.14 
 RMSD 0.301 0.269 
 
The corrected values were in close agreement with the experimental values using both 
methods. This therefore supported the use of this particular method to estimate the logP 
values of the Fc-containing compounds. Since the weighted method (Method 1) gave the 
smallest root mean square deviation (RMSD) after correction, this method was applied to 
estimate the logP of the ferrocenyl thioureas 2.10 – 2.12. The estimated logP and selected 
logD values of compounds 2.3 – 2.6 and 2.10 – 2.12 are presented in Table 2.3. 
 
Estimation of LogP of Fc thioureas (2.10 – 2.11) 
 
                                   
                              
     2.10 
 
 
Initial prediction: 2.77 – (0.33x5+0.17) + 2.456 = 3.41   
Corrected value: (3.41 – 0.9425) / 0.8238 = 2.99    
 












   
         2.11 
 
Initial prediction: 3.61 – 2(1.82) + 2(2.456) = 4.88 
Corrected value: (4.88 – 0.9425) / 0.8238 = 4.78 






Initial prediction: 5.34 – 3(1.82) + 3(2.456) = 7.25 
Corrected value: (7.25 – 0.9425) / 0.8238 = 7.66 
 
Table 2.3 

















compound logP logD7.4 logD4.8 
2.3 2.95 2.71 1.63 
2.4 4.03 3.54 1.40 
2.5 5.88 5.02 -0.22 




2.11 4.78 nd nd 
2.12 7.66 nd nd 
CQ 4.63
h
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2.4.2. Antiparasitic activity against P. falciparum. 
 
Compounds 2.3 – 2.6 and 2.10 – 2.12 were evaluated for their antiplasmodial activity in vitro 
against the NF54 CQS and Dd2 CQR strains of P. falciparum. A dose-response experiment 
was performed on the compounds to determine the IC50 value, the concentration of the 
compound inhibiting 50% of parasite growth. The activity of these compounds were 
compared to the reference drug, chloroquine. The lower the IC50 value, the more active the 
compound is. The results are presented in Table 2.4.  
 
Table 2.4 
In vitro antiplasmodial activity of thioureas 2.3 – 2.6 and 2.10 – 2.12 against NF54 and Dd2 




 ± SE NF54
b







2.3 0.16 ± 0.03 0.26 ± 0.01 1.6 
2.4 0.34 ± 0.03 0.23 ± 0.01 0.7 
2.5 0.09 ± 0.01 0.52 ± 0.06 5.8 
2.6 0.20 ± 0.01 0.51 ± 0.03 2.5 
2.10 15.79 ± 1.28 16.22 ± 1.59 1.0 
2.11 1.15 ± 0.07 31.88 ± 5.89 27.7 
2.12 71.71 ± 9.93 5.63 ± 0.19 0.1 
CQ 0.025 ± 0.01 0.14 ± 0.01 7 




IC50 represents the micromolar equivalents of test compounds required to inhibit parasite growth by 50%. 
b
 NF54 chloroquine-sensitive strain of P. falciparum. 
c
 Dd2 chloroquine-resistant strain of P. falciparum 
d






Antiplasmodial activity against the NF54 CQ-sensitive strain of P. falciparum 
 
Overall, the quinoline-containing compounds (2.3 – 2.6) showed better activity than the 
ferrocenyl compounds (2.10 - 2.12). This suggests that the quinoline moiety has a greater 
influence on antiplasmodial activity compared to the ferrocenyl motif. This is consistent with 
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other potent 4-amino-7-chloroquinolines that have been used successfully to combat malaria. 
The trimeric quinoline, 2.5, exhibited the best activity in the CQ sensitive strain, while the 
trimeric ferrocenyl compound (2.12), showed the lowest activity. Comparing the activity of 
quinolines 2.3, 2.4 and 2.5, the enhanced activity of the last may be due to the incorporation 
of a basic tertiary amino group, which is not present in 2.3 and 2.4. This may aid in 
accumulation of 2.5 in the digestive vacuole of the parasite as a result of pH trapping. The 
slightly lower activity of 2.6, which also contains basic tertiary amino groups, can probably be 
attributed to its highly lipophilic nature.  
 
Compound 2.5 exhibited the best activity which suggests sufficient accumulation of this 
compound inside of the digestive vacuole. This appears to be a consequence of the logD7.4 and 
logP values (Table 2.3). Compounds 2.3 and 2.6 exhibited similar activity in the sensitive 
strain, but these compounds were less active than 2.5. This suggests that these compounds 
accumulate less than 2.5 based on their lower logD7.4 values. Compound 2.4 has a higher 
logD7.4 value compared to 2.3 and 2.6, but appears to accumulate less based on the larger IC50 
value. The mono- and trimeric ferrocenyl thioureas (2.10 and 2.12) exhibited the lowest 
activity of all the compounds at the tested concentration, while the dimeric ferrocenyl thiourea 
(2.11) displayed moderate activity in this strain. This compound has a logP value comparable 
to chloroquine. The low activity of 2.12 in this strain may be a combination of its highly 
lipophilic nature and the lack of the active quinoline moiety. The high lipophilicity may 
hinder its transport because it may be trapped in the lipid membrane and not accumulate 
sufficiently inside of the digestive vacuole.
21 
The ferrocenyl precursor (2.9), was also 
screened, but was found to be inactive at the tested concentration. This particular compound is 
less lipophilic (logP = 3.72) than compound 2.11. This suggests functionalisation with the 
various amines, in this case, leads to enhanced activity, but these compounds were less active 
than the quinoline thioureas. 
 
Antiplasmodial activity against the Dd2 CQ-resistant strain of P. falciparum  
 
Compounds 2.3, 2.4 and 2.10 exhibited similar activities in both the sensitive and resistant 
strains of P. falciparum, while 2.5 and 2.6 showed slightly lower activity in the Dd2 strain 
compared to the NF54 strain. Compound 2.10 demonstrated consistent activity across both 
strains. The activity of compound 2.11 decreased significantly in the Dd2 strain compared to 
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the NF54 which was confirmed by the large resistance index (RI) of 27.7. The RI is valuable 
for the analysis of potential drugs. RI values are defined as the quotient of the IC50 value 
obtained in the resistant strain and the IC50 value obtained in the sensitive strain. Smaller RI 
values (1 or < 1) indicate that the parasite is equally or more active in the resistant strain 
compared to the sensitive strain. Figure 2.9 shows the RI values for compounds 2.3 – 2.6 and 
2.10 – 2.12, chloroquine and ferroquine. The activity of 2.12 increased significantly in the 
resistant strain, as this particular compound gave a RI of 0.1. In most cases, with the exception 
of 2.11, the compounds showed a lower RI value compared to CQ. In this strain, lipophilicity 
appears to have a negligible effect on the activity of these compounds. Compounds 2.3 and 
2.4 exhibited comparable activity, while compounds 2.5 and 2.6 showed similar activity in 
this strain of the parasite. 
 
       
 
Figure 2.9: Resistance index values (RI) for compounds 2.3 – 2.6,  
2.10 – 2.12, CQ and FQ 
 
Since the activity of quinoline compounds 2.5 and 2.6 decreased in the resistant strain, this 
suggests that these compounds may encounter the same problems that CQ experiences. It is 
suggested that CQ accumulation is less in chloroquine-resistant strains compared to sensitive 
strains. This is associated with mutations in a gene encoding for the P. falciparum 

























 The mutation allows for some of the protonated form of CQ to be 
expelled from the digestive vacuole. Essentially, only the uncharged form of chloroquine is 
able to permeate membranes. Once it reaches the digestive vacuole, it is able to form  
mono- or di-protonated forms which results in accumulation in the digestive vacuole,
24,25
 
since these forms are not membrane permeable. This is not the case in CQ-resistant strains as 
CQ can be expelled. Perhaps due to the structural similarities between chloroquine and the 
quinoline thioureas discussed here, the thioureas may experience a similar fate in the resistant 
strain.           
2.4.3. β-Haematin inhibition studies 
 
The mode of action of chloroquine is believed to be inhibition of haemozoin crystal growth. 
Once chloroquine reaches the digestive vacuole, it binds to haematin (a toxic product of 
haemoglobin degradation) and prevents conversion into haemozoin. A build-up of free 
haematin results in damage to the parasite. Many 4-amino-7-chloroquinolines are believed to 
inhibit haemozoin crystal growth. In some cases, haemozoin itself is believed to be the target 
of antimalarials.
26,27
 Since the quinoline derivatives prepared in this study showed promising 
antiplasmodial activity against the NF54 strain of P. falciparum, their ability to inhibit haem 
aggregation was evaluated in order to obtain some idea of their possible mode of action. The 
β-haematin (synthetic haemozoin) inhibition activity of the ferrocenyl compounds, including a 
tetrameric derivative (2.13, Figure 2.10) was also studied. Compound 2.13 showed activity 
against the W2 CQ-resistant strain of P. falciparum in a previous study.
9
 Figure 2.11 depicts 
the data obtained from the β-haematin inhibition assay. The compounds were studied using a 
Nonidet P-40 (NP-40) detergent mediated assay.
28 
Evidence suggests that haemozoin 
formation is not a spontaneous process. Research has shown that haem crystallisation occurs 
in the presence of neutral lipids found inside of the digestive vacuole of the parasite.
29,30
 The 
neutral detergent, NP-40, was therefore used to mimic lipids and thus mediates β-haematin 
formation in the assay.  The assay was performed in a 96-well plate and each compound tested 
in quadruplicate. Haematin was incubated with an increasing concentration of the drug in the 
presence of the detergent. The amount of synthetic haemozoin formed was then quantified 
using the colorimetric pyridine ferrochrome method published by Egan et al.
31
 Pyridine is 
able to complex to free haematin, but not to β-haematin. This allowed for the amount of 
synthetic haemozoin formed, to be measured. Amodiaquine and chloroquine diphosphate 
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were used as controls in order to validate the data obtained. The IC50 values obtained for these 



















Figure 2.10: A tetrameric ferrocene thiourea (2.13) also 
evaluated for its β-haematin inhibition activity 
 
 
The quinoline compounds inhibited β-haematin formation better than the ferrocenyl thioureas, 
specifically compound 2.6 (IC50 < 4.5 µM). This may be attributed to an increased number of 
quinoline moieties that are able to interact with haem thus inhibiting crystallisation.
32
 
Compounds 2.4 and 2.5 also appeared effective at inhibiting haem aggregation giving IC50 
values of 4.5 and 6.5 μM, respectively. Compounds 2.12 and 2.13 inhibited β-haematin 
formation more modestly, giving IC50 values of 31 and 15 μM, respectively. With the 
exception of 2.10 and 2.11, the compounds inhibited β-haematin formation to a greater extent 
compared to CQ. There appears to be a trend between the size of these molecules and their 
ability to inhibit haem aggregation. The larger, tetrameric molecules were able to inhibit  
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2.11). No clear correlation is discernable between β-haematin inhibition activity and the in 
vitro antiplasmodial activity (Figure 2.12). This is probably due to differences in 
accumulation of these compounds inside of the parasite. Since the  
β-haematin inhibition study was conducted in a cell-free medium, other factors including 
lipophilicity and pH trapping could affect the uptake and accumulation of these compounds in 
parasites and therefore no correlation was observed.  
 
            
Compound 
 
Figure 2.11: Graph depicting the IC50 values for compounds 2.3 - 2.6 





















Figure 2.12: Plots of β-haematin inhibition activity vs antiplasmodial activity in the  
a) CQ sensitive strain (NF54) and b) CQ resistant strain (Dd2) for selected compounds. 
 
2.4.4. In vitro cytotoxicity studies  
The in vitro activity of compounds 2.3 – 2.6 and 2.10 – 2.11 were evaluated in the WHCO1 
oesophageal cancer cell-line. Oesophageal cancer is the eighth most common cancer globally. 
The occurrence of oesophageal cancer is highest in Southern Africa. Southern Europe and 





logIC50 β-haematin (nM) 
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Many quinoline and ferrocene-containing compounds have been studied as potential 
anticancer agents.
34,35
 Some ferrocene-containing compounds have been found to be highly 
effective against certain cancers.
35
 The compounds were evaluated for their activity using a 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
36
 The results 
obtained from this assay are shown in Table 2.5. The IC50 value of cisplatin against this  
cell-line is also given in the table. 
 
Table 2.5 
IC50 values obtained for 2.3 – 2.6 and 2.10 – 2.12 against WHCO1 cancer cells.
a
 









2.3 43.8 36.2 - 52.9 273 168 
2.4 38.4 30.5 - 48.2 113 167 
2.5 6.2 5.2 - 7.5 69.0 11.9 
2.6 0.99 0.9 - 1.1 4.95 1.94 
2.10 55.7 31.8 - 97.8 3.53 3.44 
2.11 inactive - - - 
2.12 inactive - - - 
Cisplatin 13.0
d
 - - - 
a
 Values were determined from a dose response curve (assayed with MTT), IC50 represents the micromolar 










With the exception of 2.11 and 2.12, all the quinoline compounds (2.3 - 2.6) and 2.10 
appeared to exhibit some form of activity against this particular cell-line. In particular, 
compounds 2.5 and 2.6 showed good activity, with IC50 values in the low micromolar range. 
In the case of the ferrocenyl thioureas, 2.10 displayed moderate activity (IC50 = 55.7 μM) 
against this cell-line. The quinoline compounds were more active than the ferrocenyl 
thioureas. Compound 2.6 exhibited very promising activity, giving an IC50 of about 1 μM. It 
appears in the case of the quinoline derivatives that the larger molecules (2.5 and 2.6) 
displayed enhanced activity compared to their mono- and dimeric counterparts. There also 
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appeared to be size-dependent activity for this class of compounds. This phenomenon is also 
observed for certain dendritic compounds whereby cytotoxicity is often generation-dependant, 
with higher generation dendrimers showing the best activity.
38-40 
Studies carried out on natural 
polyamines show that these systems are able to transport cytotoxic drugs into tumour cells.
41 
In this case, synthetic polyamines were under investigation, it has been shown that the 
polyamine transporter is able to tolerate modified polyamines thus the compound can be taken 
up by the cell.
42
 This factor, in combination with the ability of these quinolines to interact 
with DNA, possibly by intercalation, may be a reason for the enhanced activity.
43
 The activity 
of the compounds was also compared to cisplatin, a potent metal-containing anticancer agent, 
compounds 2.5 and 2.6 exhibited better activity than this drug in this particular cell-line.  
 
The selectivity index (SI) is useful in order to gauge the selectivity towards a particular cell 
type. SI values concerning the WHCO1 cell-line and the two antiplasmodial strains (NF54 
and Dd2) were calculated and are given in Table 2.5. The SI values were calculated by 
dividing the IC50 value obtained in the cancer cell-line by the IC50 value obtained in the 
respective P. falciparum strain. A large value suggests selectivity towards malaria parasites 
rather than cancer cells, i.e. the compounds are better antiplasmodial agents than they are 
antitumoural. Generally, the compounds showed similar selectivity, regardless of the 
antiplasmodial strain. Compounds 2.3 – 2.5 were more selective towards P. falciparum than 
WHCO1 cells. SI values in the range of 11.9 – 273 were observed for these compounds. 
Compounds 2.3 and 2.4 both gave SI values greater than 100. Compounds 2.6 and 2.10 
exhibited lower SI values, which indicate similar antiplasmodial activity and cytotoxicity. 
This suggests that in these cases, antiplasmodial activity may be a consequence of their 
cytotoxicity.       
 
The most cytotoxic compound, 2.6, was further screened against normal KMST-6 human 
fibroblast, along with cisplatin, in order to ascertain the degree of toxicity of the compound 
(Table 2.6). This particular compound was more cytotoxic towards WHCO1 oesophageal 
cancer cells than the KMST-6 fibroblast. This is evidenced by the large SI value (93). In this 
case, the SI value was calculated by dividing the IC50 value obtained in normal tissue by the 
IC50 value obtained against cancer cells. A large value indicates that the compound decreases 
cell viability in WHCO1 cells to a larger degree compared to normal tissue. Cisplatin was also 
screened against the KMST-6 cell-line. Both compound 2.6 and cisplatin exhibited similar 
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toxicity against the KMST-6 cell-line, however, when the activity of cisplatin was compared 
across both the KMST-6 and WHCO1 cell-lines, cisplatin gave a lower SI value (7.30) 
compared to compound 2.6. This suggests that whereas cisplatin’s toxic nature may result in 
relatively poor selectivity against cancer cells, compound 2.6 is much more selective and 
worthy of further investigation. 
 
Table 2.6 
 IC50 values against KMST-6 human fibroblast and WHCO1 cancer cells. 
compound IC50 (μM) ± SD  KMST-6 IC50 (μM)  WHCO1 selectivity index
a
 
2.6 92 ± 4 0.99 93.0 
cisplatin 96 ± 0.4 13.0 7.30 
   a 
IC50KMST-6/IC50WHCO1 
 
2.4.5. Antiparasitic activity against T. vaginalis 
Trichomonas vaginalis (T. vaginalis) is a protozoan responsible for the sexually transmitted 
disease trichomoniasis. The current FDA-approved treatment, metronidazole (M), Figure 
2.13, experiences resistance in some patients.
44,45
 Unfortunately, in many countries, there is 
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This therefore supports research towards alternative therapies that are equipotent and are able 
to overcome resistance experienced by metronidazole. There has recently been an interest in 
obtaining suitable alternative therapies for this infection.
45 
More recently metal-based 
compounds have shown promise as potential candidates against trichomoniasis.
46-48
 The 
application of metal complexes as potential antiparasitics against  
T. vaginalis has been sparsely explored. 
 
 
A preliminary study to evaluate the activity of the afore-mentioned compounds (2.3 – 2.6 and 
2.10 – 2.13) against this particular parasite was conducted. The compounds were screened 
against the G3 strain of T. vaginalis at a drug concentration of 10 μM. Figure 2.14 shows the 
data obtained from this preliminary screen. The graph depicts the percentage parasite growth 
inhibition for the screened compounds along with the data obtained for thioester 2.9 and 
metronidazole. 
 
Studying the quinoline compounds, the monomeric thiourea 2.3 showed the lowest percentage 
growth inhibition, while the tetrameric compound 2.6, showed the highest inhibition in this 
series, followed by 2.4 and then compound 2.5. A similar trend was observed for the 
ferrocenyl thioureas. The tetrameric compound 2.13 showed the highest percentage inhibition, 
followed by the dimeric and then the trimeric derivative. The monomeric ferrocene 
derivatives 2.9 (thioester) and 2.10 displayed the lowest inhibition in this series. The thioester 
showed slightly lower percent growth inhibition compared to the amine-functionalised 
derivative 2.10.  
 
Trends in percent parasite inhibition for compound 2.3 – 2.6 and 2.9 – 2.13: 
 
mono    <       trimeric      <       dimeric      <      tetrameric 
 



































2.3     2.4    2.5     2.6               2.9    2.10  2.11   2.12   2.13             M
                                                              
 
Figure 2.14: Percent growth inhibition for compounds 2.3 – 2.6 
and 2.9 – 2.13 against T. vaginalis. 
 
Overall, the tetrameric compounds (2.6 and 2.13) showed the highest percent inhibition in 
each series. On average the ferrocenyl compounds inhibited parasite growth slightly better 
compared to the quinoline compounds. The lipophilic nature of the ferrocene moiety may be a 
factor contributing to the slightly enhanced activity of the organometallic derivatives. 
Although many of these compounds were able to inhibit more than 50% of parasite growth, 




A series of mono- and multimeric quinoline (2.1 – 2.6) and ferrocene-containing (2.9 – 2.12) 
thioureas were prepared. The quinoline compounds were synthesised by displacement of  
the –SCH3 group of the quinoline-containing precursor by various amines. Two of the 
ferrocenyl compounds (2.10 and 2.12) were prepared using similar methodology, while the 
dimeric ferrocene thiourea was obtained via a Schiff-base condensation reaction between 
Compound 
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H}, HSQC and COSY NMR spectroscopy, infrared spectroscopy 
and ESI mass spectrometry. 
 
The synthesised compounds were evaluated for their biological activity in vitro. The 
compounds were screened against two strains of P. falciparum, the NF54 CQ-sensitive and 
Dd2 CQ-resistant strains of P. falciparum. The quinoline thioureas displayed good activity 
against the sensitive strain, while the ferrocene-containing compounds were less active. The 
quinoline compounds displayed lower resistance index values compared to chloroquine but 
only the dimeric derivative exhibited a RI value less than 1. All of the quinoline compounds 
were able to inhibit β-haematin formation, with the tetrameric derivative (2.6) displaying the 
best activity. No correlation between the β-haematin inhibition activity and the antiplasmodial 
activity was observed. The quinoline compounds also showed moderate to good activity 
against WHCO1 oesophageal cancer cells. The tetrameric quinoline thiourea (2.6) was found 
to be the most active compound in this cell-line. This compound was also found to be more 
active in cancer cells compared to normal cells. In the case of the T. vaginalis parasite growth 
inhibition assay, the ferrocenyl compounds showed slightly enhanced activity compared to the 
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Synthesis, characterisation and biological evaluation 




One of the first organometallic complexes that was screened against malarial parasites was 
[RhCl(COD)CQ] (Figure 3.1a). The in vitro activity of this compound against Plasmodium 
berghei (P. berghei) was promising.
1
 A ratio of 0.96 for the IC50 value of chloroquine 
diphosphate (CQDP)/IC50 of the complex indicates very little difference between the activity 
of CQ and the rhodium complex against P. berghei. In vivo, this complex reduced parasitemia 
to a greater extent to that of CQ. Based on this, other metal-based antimalarials were prepared 
and tested for activity.
2,3
 A binuclear ruthenium chloroquine complex [RuCl2(CQ)]2 (Figure 
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More recently, ruthenium arene half sandwich complexes have received attention for their 
biological activity.
4-6
 In one instance, ruthenium p-cymene complexes have been prepared and 
tested for their activity against various plasmodial strains.
7
 In these cases, the ruthenium 
moiety is not bonded to the quinoline nitrogen (which plays a role in antimalarial activity), but 
is coordinated to the ligand in a bidentate manner in the lateral side chain. One of the 
complexes, a salicylaldimine quinoline complex, shown in Figure 3.2, exhibited promising 











Figure 3.2: Ruthenium p-cymene quinoline complex that showed promising 
activity against malaria parasites. 
 
Based on the promising activity of [RhCl(COD)CQ] and since the antimalarial activity of 
only a few Rh(I) complexes have been reported,
1,8,9
 there is scope to investigate the activity of 
new Rh(I) compounds as potential antiplasmodial agents. Rh(I) complexes have also been 
shown  to possess biological activity including anticancer
10
 and anti-trypanosomal activity.
11
 





where COT = 1,3-1,5-cyclooctatetraene and L = pentamidine (Figure 3.3), were screened 
against Trypanosoma brucei brucei. This particular protozoan is the cause of sleeping 
sickness. The corresponding Ir(I) complexes were also prepared and evaluated, but the Rh(I) 
compounds showed enhanced activity compared to the Ir(I) compounds. Generally, the 
rhodium complexes showed activity 4-times greater than the iridium compounds.
11 
 


















Figure 3.3: Binuclear Rh(I) complex possessing activity against 
the parasite Trypanosoma brucei brucei. 
Very little work has been done to investigate the effect of multinuclearity on antimalarial 
activity. In the case of [RuCl2(CQ)]2 (Figure 3.1b), the increased number of metal centres and 
quinoline moieties appeared to have a favourable effect on antiplasmodial activity. In this 
chapter, the preparation, characterisation and biological properties of mononuclear and 
binuclear Rh(I) salicylaldiminato quinoline complexes and their corresponding ligands were 
investigated.     
3.2. Synthesis and characterisation of mono- and dimeric salicylaldimine quinoline 
ligands 3.1 – 3.7 
3.2.1. Synthesis  
A series of monomeric and dimeric salicylaldimine quinoline ligands were prepared using 
standard Schiff-base chemistry. Salicylaldehyde and two substituted salicylaldehydes were 
condensed with N’-(7-chloroquinolin-4-yl)-propane-1,3-diamine (2.1) and N-(7-
chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) to afford mono- and dimeric 
salicylaldimines, respectively (Scheme 3.1). N-(7-Chloroquinolin-4-yl)-tris(2-
aminoethyl)amine was prepared by a nucleophilic aromatic substitution (SNAr) reaction of 
4,7-dichloroquinoline and an excess of tris(2-amino)ethylamine (11 mol equivalents) under an 
argon atmosphere to yield a monofunctionalised product after the work up process. The 
amines were reacted with the appropriate aldehydes giving rise to the desired ligands. In the 
case of the monomeric ligands, N’-(7-chloroquinolin-4-yl)-propane-1,3-diamine (2.1) was 
reacted with 5-chlorosalicylaldehyde, o-vanillin and salicylaldehyde in a 1:1 stoichiometric 
ratio in diethyl ether to afford the desired monosalicylaldimine ligands (3.2 – 3.4). N-(7-
Chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) was reacted with the same aldehydes in 
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ethanol in a 1:2 stoichiometric ratio to afford the desired dimeric salicylaldimines (3.5 – 3.7). 
The preparation of these ligands is outlined in Scheme 3.1.  
In the case of the monomeric salicylaldimine ligands (3.2 – 3.4), the compounds precipitated 
from solution. The dimeric salicylaldimine ligands (3.5 – 3.7) were soluble in ethanol and 
were therefore precipitated with diethyl ether. All compounds were isolated by filtration. The 
ligands were obtained as yellow powders in moderate to good yields (40 - 83%). The 
monomeric salicylaldimine ligands exhibited slightly enhanced solubility in common organic 
solvents such as dichloromethane and acetone compared to the dimeric systems. All the 
ligands were readily soluble in alcohols and dimethyl sulfoxide. The compounds were 
insoluble in diethyl ether, hexane and pentane.      














































R = 5-Cl (3.2 and 3.5); 3-OMe (3.3 and 3.6); H (3.4 and 3.7) 
Scheme 3.1: Synthesis of quinoline ligands 2.1 and 3.1 - 3.7. Reagents and conditions:  
(a) 1,3-propanediamine (5 eq.), neat 5 h; (b) aldehyde (1 eq.), diethyl ether, 16 h, r.t;  
(c) tris(2-aminoethyl)amine (11 eq.), neat, 24 h, 90°C; (d) aldehyde (2 eq.), EtOH, 16 h, r.t.          
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3.2.2. Characterisation  






H}, HSQC and COSY NMR spectroscopy, IR 





H NMR spectra of 3.2 – 3.7 were recorded in CDCl3 and were consistent with the 
structures of the proposed ligands. The 
1







H} NMR resonances are given in Table 3.1 (numbering of the quinoline 
ring is shown in Scheme 3.1). Schiff-base condensation was confirmed by the appearance of a 
signal for the imine resonances between 8.30 and 8.38 ppm for 3.2 – 3.4 and between 7.99 
and 8.29 ppm for 3.5 – 3.7. The imine signal was observed upfield in the 5-Cl derivatives 
compared to the 3-OMe and unsubstituted salicylaldimine compounds. The same signal in the 









H} NMR resonances for ligands 3.2 – 3.7. 
compound HC=N NH H2 H8 HC=N C2 C8 
3.2 8.30 5.07 8.52 7.94 164.65 151.98 128.88 
3.3 8.35 5.12 8.50 7.92 165.86 152.04 128.82 
3.4 8.38 5.10 8.52 7.94 165.83 152.03 129.01 
3.5 7.99 5.96 8.37 7.84 165.58 151.39 127.15 
3.6 8.16 - 8.30 8.06 166.71 154.26 125.79 
3.7 8.29 7.33 8.09 8.04 166.78 154.73 129.58 
 






H NMR spectrum of 3.2 in CDCl3. 
 
The NH signals in the spectra of the monomeric derivatives (3.2 – 3.4) were more shielded 
compared to those observed in the dimeric salicylaldimine compounds. In the case of 3.6, the 
NH signal was not observed. The deshielding could possibly be explained by the occurrence 
of intramolecular hydrogen bonding in the dimeric derivatives. The NH proton is able to 
hydrogen bond with the nitrogen atom of the tertiary amine (Figure 3.5), forming a  
5-membered ring. This could possibly be a reason for the difference in this signal position 
between the monomeric and dimeric derivatives. Resonances for H2 were observed between 
8.50 and 8.52 for 3.2 – 3.4 and 8.09 and 8.37 for 3.5 – 3.7. Signals for H8 appeared as 
doublets at approximately 8 ppm for these ligands. This splitting pattern is attributed to long 







































H} NMR spectroscopy was used to further confirm that the desired compounds were 
obtained. The spectra of 3.2 – 3.4 were recorded in CDCl3, while the spectra of 3.5 – 3.7 were 
recorded in DMSO-d6 (due to lower solubility in CDCl3). Resonances for the CH2 carbon 
atoms of the aliphatic chains were assigned between 29.96 and 57.40 ppm for 3.2 – 3.4 and 
between 41.28 and 56.62 ppm for 3.5 – 3.7. Signals for the imine carbon atoms were observed 
between 164.65 and 166.78 ppm for these ligands. Signals for C8 appeared between 125.79 
and 129.01 ppm.  Signals for C2 appeared between 151.39 and 154.73 ppm. Analysis of the 




The infrared spectra of these ligands were recorded in the solid state as KBr pellets. Upon 
condensation of the respective precursors, two absorption bands were observed for the two 
C=N stretching frequencies. Bands for the newly formed C=N bond was observed at a higher 
frequency compared to the C=N of the quinoline ring. An absorption band for the Schiff-base 
C=N stretching frequency appeared between 1631 and 1648 cm
-1
, while the absorption band 
for the quinoline C=N stretching frequency appeared between 1609 and 1615 cm
-1
. 
Absorption bands for the NH stretching frequencies were observed in the range of  
3238 – 3424 cm
-1
















The molecular weights of these compounds were confirmed using ESI or EI mass 
spectrometry (Table 3.2). Compounds 3.2 – 3.5 were analysed using ESI-MS in the positive 
mode, while 3.6 and 3.7 were analysed using EI-MS. The mass spectra of 3.2, 3.3 and 3.5 
showed peaks corresponding to the protonated molecular ion, [M+H]
+
. The spectra of 3.4, 3.6 
and 3.7 exhibited peaks corresponding to [M]
+
. This data further confirmed synthesis of the 
desired ligands.   
 
Table 3.2  
Mass spectrometry data obtained for ligands 3.2 – 3.7. 





















Upon synthesis and characterisation of the ligands, the next step was to prepare their 
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3.3. Synthesis and characterisation of mono- and binuclear Rh(I) salicylaldimine 
quinoline complexes 3.9 – 3.14 
 
3.3.1. Synthesis  
The afore-mentioned ligands 3.2 – 3.7 were subsequently reacted with [RhCl(COD)]2 (3.8)
12 
to afford the desired mono- and binuclear Rh(I) salicylaldimine quinoline complexes  










                                                            
R = 5-Cl (3.9, 3.12); 3-OMe (3.10, 3.13); H (3.11, 3.14) 
Scheme 3.2: Synthesis of Rh(I) salicylaldimine complexes 3.9 – 3.14. Reagents and 
conditions: (a) Ligand (1 eq.), excess NaH, [RhCl(COD)]2 (1 eq.), DCM, 3 – 6 h,  r.t.  
(b) Ligand (2 eq.), excess NaH, [RhCl(COD)]2 (1 eq.), DCM, 3 – 6 h,  r.t.    
 
A dilute solution of the ligand in DCM was prepared. To this, excess NaH was added. During 
initial attempts, Et3N was used as the base instead, but the base proved difficult to remove 
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excess base using water. The role of the base is to deprotonate the OH group of the 
salicylaldimine moiety to facilitate coordination at this particular site upon addition of the 
metal precursor. Mononuclear complexes 3.9 – 3.11 were obtained by reaction of the ligand 
and the metal precursor in a 2:1 stoichiometric ratio, while binuclear complexes 3.12 – 3.14 
were obtained using a 1:1 ligand to metal precursor ratio. The complexes were obtained as 
yellow powders in moderate to good yields (52 – 79%).  
 
3.3.2. Characterisation 






H NMR spectra for complexes 3.9 – 3.14 were recorded in CDCl3. Analysis of the 
spectra suggested that the desired compounds were obtained. The 
1
H NMR spectrum of 
complex 3.11 and its corresponding ligand (3.4) is shown in Figure 3.6.    
 
Coordination of the metal to the ligand was confirmed by an upfield shift of the signal for the 
imine proton compared to the free ligand (Table 3.3). The upfield shift is due to shielding as a 
result of the formation of the Rh-N bond. The resonance for the phenolic proton was absent in 
the spectra of the complexes. Both the shifting of the imine proton signal and the loss of the 
signal for the phenolic proton suggests coordination in a bidentate manner by the imine 
nitrogen and the phenolic oxygen. In complexes 3.9 – 3.14 four distinct resonances for the 
protons of the COD moiety were observed. The CH2 protons of the COD moiety exhibited 
chemical non-equivalence. The exo and endo methylene resonances of the COD moiety 
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Figure 3.7: Structure indicating the exo and endo methylene protons 
A non-uniform magnetic field is commonly observed in π systems.
13,14
  When electrons in π 
systems encounter an applied field, a magnetic field that causes non-uniformity is induced. 
This in turn influences the chemical shifts of surrounding nuclei by either causing a shielding 
or deshielding effect, depending on the position of the nuclei in this field. Figure 3.8 shows 
the various shielded and deshielded regions associated with alkenes. The shielded area (blue) 
is observed above and below the plane of the double bond, whereas the deshielded region 
(pink) occurs in the plane of this bond. This may explain why the signal for the exo methylene 
protons (situated in the shielded region) appeared upfield compared to the endo methylene 
signal. The olefinic hydrogen atoms were more deshielded compared to the methylene protons 
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Signals for the olefinic protons of the COD moiety appeared at approximately 3.6 and 4.5 
ppm for the complexes. Two multiplets were observed for these protons in the complexes, 
while these protons appeared as one multiplet in the spectrum of the [RhCl(COD)]2 precursor. 
This is attributed to the trans effect induced by the N,O ligand. The signal further downfield 
was assigned to the proton trans to the imine nitrogen, while the signal found more upfield 
was attributed to the proton trans to the phenolic oxygen. This phenomenon is consistent with 
other N,O-Rh(I) complexes.
15-19
 This further confirmed coordination to the imine nitrogen and 




H} NMR spectroscopy was also used to characterise these complexes. Coordination was 
confirmed by the appearance of signals for the aliphatic carbon atoms of the COD moiety at 
approximately 28.8 ppm for the mononuclear complexes 3.9 – 3.11 and 28.9 ppm for the 
binuclear complexes 3.12 – 3.14. The second COD resonances were observed at 
approximately 31.7 ppm for these complexes. The olefinic carbon atoms appeared as two 
signals. These signals are doublets (see Table 3.2) due to carbon-rhodium coupling as a result 
of the 100% natural abundance of 
103
Rh and its nuclear spin of ½. The signals for these carbon 
atoms were assigned at approximately 71 and 86 ppm, respectively. A resonance at 71 ppm 
was assigned to the carbon atoms found trans to O, while the signal at 86 ppm accounts for 




C spin-spin coupling constants for C trans to O 
were approximately 14 Hz, while the coupling constant for C trans to N was approximately 12 
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HC=CHCOD (m, JC-Rh Hz); 
HC=CHCOD (m, JC-Rh Hz) 
3.9 7.87 (8.30) 1.84; 2.34 3.66; 4.54 
71.66 (d, 14.09); 
86.04(d, 11.86) 
3.10 7.95 (8.35) 1.85; 2.35 3.68; 4.66 
71.21 (d, 14.12); 
85.49 (d, 11.78) 
3.11 7.94 (8.38) 1.84; 2.34 3.66; 4.54 
71.29 (d, 14.08); 
85.70 (d, 11.96) 
3.12 7.71 (7.99) 1.84; 2.37 3.51; 4.52 
71.48 (d, 14.03); 
86.08 (d, 11.53) 
3.13 7.75 (8.16) 1.83; 2.36 3.51; 4.64 
71.04 (d,14.18); 
85.47 (d, 11.68) 
3.14 7.76 (8.29) 1.82; 2.36 3.51; 4.53 
71.13 (d, 13.69); 





Infrared spectroscopy was used to further confirm formation of the Rh(I) complexes 3.9 – 
3.14. The most obvious difference between the spectra of the ligands and the complexes was 
that in the spectra of the ligands, two absorption bands were observed for the two different 
C=N environments. In the case of the complexes, one absorption band was observed. Upon 
coordination, the absorption band that was initially at a higher frequency (~ 1630 cm
-1
) in the 
ligands, shifted towards lower frequency (similar to that of the C=Nquinoline). This was 
expected upon coordination to the imine nitrogen. The nitrogen atom donates electrons to the 
rhodium centre, resulting in the elongation of the C=N bond which causes a shift of this band 
to lower wavenumbers. The spectra suggest that both C=N absorption bands appeared at a 
similar frequency and therefore only one distinguishable absorption band was observed in the 
spectra of the complexes. The spectra shown in Figure 3.9 highlight the region where 
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absorption bands for the C=N frequencies appear for compounds 3.7 and 3.14. Absorption 
bands for the C=N stretching frequencies of the complexes appeared between 1604 and 1613 
cm
-1
. Absorption bands for the N-H frequencies were observed between 3362 and 3439 cm
-1
. 
The NH absorption bands appeared to remain constant upon coordination. 
 
     
Figure 3.9: Infrared spectra of ligand 3.7 (orange) and complex 3.14 (blue) 
obtained in the solid state. 
Mass Spectrometry  
Mass spectrometry was also used to characterise these complexes (See Table 3.4). Both ESI 
(recorded in the positive mode) and EI mass spectrometry (for complexes 3.9 - 3.11) was used 
to analyse these compounds. In all cases the molecular ion peak or a peak for the molecule’s 
protonated form was observed in the spectra of the complexes. Complexes 3.9, 3.10 and 3.11 
were analysed using EI mass spectrometry. The spectra of the mononuclear complexes 
showed peaks corresponding to [M]
+
 at m/z 582.7133, 578.7728 and 548.6803, respectively. 
Complexes 3.12, 3.13 and 3.14 were analysed using ESI mass spectrometry. The spectra of 
3.13 and 3.14 exhibited peaks at 996.2199 and 936.2004 corresponding to [M+H]
+
. A peak in 
the spectrum of 3.12 at 1004.1231 was assigned to the protonated molecular ion, [M+H]
+
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Table 3.4  
Mass spectrometry data obtained for complexes 3.9 – 3.14. 





















The above-mentioned characterisation data clearly supports preparation of the desired 
rhodium(I) quinoline complexes. Based on satisfactory correlation of the characterisation data 
and the proposed structures, the biological activity of these compounds were studied and the 
data are described in the next section.  
 
3.4. Biological and physicochemical evaluation 
 
3.4.1. Antiparasitic activity against P. falciparum 
 
The in vitro antiplasmodial activity of ligands 3.2 – 3.7 and complexes 3.9 – 3.14 were 
evaluated against chloroquine-sensitive (NF54) and chloroquine-resistant (K1) strains of 
Plasmodium falciparum. Chloroquine (CQ) and ferroquine (FQ) were used as reference drugs. 








In vitro antiplasmodial activity and resistance indices of compounds 3.2 – 3.7, 3.9 – 3.14, CQ 
and FQ against the NF54 CQ-sensitive and the K1 CQ-resistant strains of P. falciparum.  
compound IC50
a
 ± SE NF54
b
 (μM) IC50 ± SE K1
c
 (μM) resistance index
d
 
3.2 0.052 ± 0.001 0.72 ± 0.089 13.7 
3.3 0.055 ± 0.001 0.65 ± 0.083 11.8 
3.4 0.072 ± 0.006 0.68 ± 0.017 9.4 
3.5 4.9 ± 0.28 2.3 ± 0.26 0.4 
3.6 4.9 ± 0.37 1.8 ± 0.18 0.4 
3.7 7.0 ± 0.48 4.5 ± 0.78 0.6 
3.9 0.098 ± 0.009 0.87 ± 0.055 8.8 
3.10 0.16 ± 0.020 1.3 ± 0.19 7.7 
3.11 0.091 ± 0.009 1.8 ± 0.061 19.6 
3.12 7.9 ± 0.37 2.9 ± 0.35 0.4 
3.13 4.8 ± 0.075 2.2 ± 0.12 0.4 
3.14 4.0 ± 0.12 1.5 ± 0.14 0.4 
CQ 0.025 ± 0.005 0.30 ± 0.038 11.8 




IC50 represents the micromolar equivalents required to inhibit parasite growth by 50% 
b
 NF54 chloroquine-sensitive strain of P. falciparum; n = number of data sets averaged, n = 3  
c
 K1 chloroquine-resistant strain of P. falciparum 
d
 Resistance index (RI) = IC50K1/IC50NF54 
e
 Literature IC50 value against K1
20 
 
Antiplasmodial activity against the NF54 CQ-sensitive strain of P. falciparum  
 
The monomeric salicylaldimine ligands (3.2 – 3.4) showed good activity against the NF54 
strain of P. falciparum. Compounds that exhibit IC50 values lower than 1 µM would be 
considered as potential antimalarial candidates. The monomeric ligands exhibited IC50 values 
less than 1 µM. The 5-Cl (3.2) and 3-OMe (3.3) derivatives exhibited similar IC50 values, 
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while the IC50 value obtained for the unsubstituted derivative (3.4) was slightly higher. The 
activity observed for these compounds are comparable to the activity of chloroquine (IC50 = 
0.025 µM) and ferroquine (IC50 = 0.033 µM) against the same strain. The dimeric 
salicylaldimine ligands (3.5 – 3.7) were far less active than their monomeric counterparts. The 
monomeric ligands were at least 90-times more active than the dimeric compounds. A similar 
trend in activity was observed for the dimeric compounds as the monomeric systems. The  
5-Cl (3.5) and 3-OMe (3.6) derivatives exhibited similar activity and showed slightly 
enhanced activity compared to the unsubstituted analogue (3.7). This suggests that the 
substituents play a minor role in activity in this case. 
 
Corresponding rhodium COD complexes were prepared in order to establish whether 
incorporation of the metal moiety is beneficial towards antiplasmodial activity since this 
would alter the lipophilic properties of the compounds. Table 3.6 shows the ratio between the 
IC50 value obtained for the complex and the IC50 value obtained for the ligand.       
 
Table 3.6 
Ratio of the activity between ligands (3.2 – 3.7) and complexes (3.9 – 3.14) against NF54  
CQ-sensitive P. falciparum.   
complex (ligand) IC50 ratio
a
 
3.9 (3.2) 1.9 
3.10 (3.3) 3 
3.11 (3.4) 1.3 
3.12 (3.5) 1.6 
3.13 (3.6) 1.0 





A value close to 1 suggests that the ligand and the complex exhibit similar activity. A value 
greater than 1 suggests that complexation lowers activity. A value less than 1 indicates that 
complexation enhances the activity of the compound. Comparing the activity of the 
monomeric ligands (3.2 – 3.4) and mononuclear complexes (3.9 – 3.11), it was found that the 
compounds exhibited ratios between 1.3 and 3. Complex 3.10 (R = H) and complex 3.9 (R = 
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5-Cl) appeared to be less active than their corresponding ligands (ratios of 3.0 and 1.9, 
respectively. The unsubstituted complex 3.11 showed similar activity to its ligand as a ratio of 
approximately 1.3 was obtained. Although most of the complexes were less active than their 
ligands, the compounds exhibited high activity giving IC50 values much lower than 1 µM. 
With respect to the binuclear complexes, complex 3.13 (R = 3-OMe)  and its ligand (3.6) 
exhibited similar activity giving an IC50 ratio of approximately 1, suggesting that 
complexation has little to no effect on activity in this case. The 5-Cl derivative, complex 3.12, 
was observed to be slightly less active compared to its free ligand (ratio  = 1.6), while 
complex 3.14, the unsubstituted derivative, was approximately 1.8 times more active than its 
corresponding ligand (IC50 ratio = 0.6). The latter appeared to be the only case where 
incorporation of the metal had a favourable effect on activity against this P. falciparum strain. 
 
The mononuclear complex possessing the 3-OMe moiety (3.9) exhibited lower activity (IC50 
= 0.16 µM) compared to the 5-Cl (IC50 = 0.098 µM) and unsubstituted (IC50 = 0.091 µM) 
derivatives. In the binuclear complexes, it was found that the compound with the 5-Cl group 
(3.12) was least active, followed by the 3-OMe derivative (3.13). The unsubstituted 
compound, 3.14, was the most active binuclear complex.  
 
The CQ-Rh(I) COD complex mentioned in Figure 3.1a was tested previously by Sànchez-
Delgado et al. against Plasmodium Berghei and exhibited similar activity (IC50 = 73 nM) to 
CQ.
1
 Although the values obtained for these complexes cannot directly be compared to that of 
the CQ derivative mentioned (since different strains of Plasmodium were used), the 
mononuclear complexes (3.9 – 3.11) showed similar activity to this complex (IC50 values 
between 91 and 160 nM). The quinoline moiety appears to be the driving force behind the 
activity of these compounds since the free ligands also exhibited good activity.        
 
Antiplasmodial activity against the K1 CQ-resistant strain of P. falciparum  
 
Similar trends in activity were observed for this strain. The monomeric ligands (3.2 – 3.4) 
were the most active. The dimeric ligands, mononuclear complexes and binuclear complexes 
exhibited activity in the same range (1.3 – 2.9 µM). All the tested compounds were found to 
be less active than chloroquine and ferroquine in this strain. 
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The monomeric ligands (3.2 – 3.4) were the most active compounds exhibiting IC50 values 
 less than 1 µM. These values are comparable to one another (IC50 values between 0.65 and 
0.72 µM). The substituent has a negligible effect on activity. The mononuclear complexes  
(3.9 – 3.11) were slightly less active than their ligands (IC50 ratios shown in Table 3.7). In this 
strain, the 5-Cl complex (3.9) exhibited similar activity to its free ligand (IC50 ratio = 1.2), 
while the rest of the mononuclear complexes were less active than their ligands. The dimeric 
ligands (3.5 – 3.7) showed moderate to weak activity against this strain. The 3-OMe 
derivative (3.6) exhibited better activity than the 5-Cl and the unsubstituted salicylaldimine 
derivative. Two of the binuclear complexes (3.12 and 3.13) exhibited comparable activity to 
their free ligands based on their IC50 ratio (1.3 and 1.2, respectively). Once again the 
unsubstituted derivative (3.14) showed improved activity upon complexation (IC50 ratio = 
0.3).           
 
Table 3.7  
Ratio of the activity between ligands (3.2 – 3.7) and complexes (3.9 – 3.14) against K1  
CQ-resistant P. falciparum.   
complex (ligand) IC50 ratio
a
 
3.9 (3.2) 1.2 
3.10 (3.3) 1.9 
3.11 (3.4) 2.6 
3.12 (3.5) 1.3 
3.13 (3.6) 1.2 




      
Overall, the monomeric ligands and mononuclear complexes showed decreased activity in the 
resistant strain compared to the sensitive strain. Figure 3.10 gives the resistance indices for the 
compounds. Ligands 3.2 – 3.4 and complexes 3.9 – 3.11, which contain one salicylaldimine 
moiety, exhibited larger RI values compared to the dimeric salicylaldimine compounds  
3.5 – 3.7 and 3.12 – 3.14. Ligands 3.2 – 3.4 and their corresponding complexes (3.9 – 3.11) 
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displayed similar antiplasmodial behaviour to CQ. In the sensitive strain, the compounds 
















Figure 3.10: Resistance indices for compounds 3.2 – 3.7 and 3.9 – 3.14 
 
The monomeric ligands and complexes demonstrated similar activity profiles to that of 
chloroquine because these compounds showed very good activity against the sensitive strain, 
but were less active in the resistant strain. This was not observed for the dimeric derivatives. 
The dimeric compounds showed similar or enhanced activity in the resistant strain compared 
to the sensitive strain. Ferroquine appeared to follow a similar activity profile to the dimeric 
compounds. In the case of ferroquine it is believed that this compound’s activity in the 
resistant strain is due to its lipophilic character and in addition to this, an intramolecular 
hydrogen bond (Figure 3.11) between the tertiary amino group and the secondary amino 
group aids in the formation of a folded conformation, which results in an enhancement of its 
transport through membranes.
21,22

















Figure 3.11: Intra-molecular bonding observed in ferroquine. 
     
As suggested in section 3.2.2 of this chapter, the dimeric systems may also possess  
intramolecular hydrogen bonding based on the shift of the NH signal. If the intramolecular  
H-bonding aids in the transport of these molecules across membranes, perhaps this is a reason 
for the similar activities observed for these compounds in the resistant and the sensitive 
strains. This was not observed for the monomeric derivatives. The lower activity of the 
dimeric compounds, however, compared to the monomeric compounds may be a consequence 
of their highly lipophilic nature. 
 
To more closely compare the activity of these compounds to the susceptibility and resistance 
of chloroquine, a plot of the IC50 values obtained from this study is shown in Figure 3.12. CQ 
susceptibility is defined as values less than 0.1 μg/ml (194.1 nM), while values greater than 1 
μg/ml (1941 nM) define resistance.
23,24
 The plot includes these margins for a better 
comparison. All the monomeric salicylaldimine compounds 3.2 – 3.4 lie within the margin 
defining CQ resistance. Their activity and in vitro behaviour is therefore comparable to 
chloroquine. Ferroquine, the most active compound, exhibited similar behaviour in vitro 
across both strains. The dimeric compounds 3.5 – 3.7 were far less active compared to the 
monomeric compounds. This may be a consequence of their size or lipophilicity. Lipophilicity 
plays a role in the transport of the drug across membranes into the digestive vacuole of the 
parasite. If the compound is too lipophilic, this may hinder its transport. The predicted logP 











Figure 3.12: Scatter plot depicting the correlation between the NF54 CQ-sensitive strain and 
the K1 CQ-resistant strain. The margins (shown in blue) represent CQ susceptibility 
 (194.1 nM) and CQ resistance (1941 nM), respectively. 
 
Table 3.8 
Predicted logP values of compounds 3.2 – 3.7 
compound logP
a
 logD4.7 logD7.4 
3.2 4.32 2.11 4.02 
3.3 3.56 1.07 3.30 
3.4 3.71 1.05 3.43 
3.5 6.33 1.92 5.47 
3.6 4.81 0.23 4.01 
3.7 5.12 0.34 4.31 
1,5-cyclooctadiene 2.83 2.83 2.83 
a
logP and logD values predicted using MarvinSketch V5.9.4 
 
Generally, the monomeric ligands (3.2 – 3.4) exhibited lower logP values compared to their 
dimeric counterparts (3.5 – 3.7). Comparing the lipophilicity to the activity (given as logIC50) 
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against the sensitive strain (Figure 3.13), the monomeric compounds were more active 
compared to the dimeric salicylaldimines. As can be seen in Figure 3.13, compounds that 
have logP values between 3.5 and 4.3 appear to exhibit good antiplasmodial activity.  
          
 
Figure 3.13: Plot of logP vs the logIC50 obtained for the NF54 CQS strain of P. falciparum. 
 
The logP value of the 1,5-cyclooctadiene moiety was predicted to be 2.83 (Table 3.8). The 
addition of the cyclooctadiene moiety to the ligands would therefore result in an overall 
increase in the lipophilicity of the complexes compared to the free ligands. This may be a 
reason for the slight decrease in the activity of the complexes compared to the ligands in some 
cases. Of course many other factors, including vacuolar accumulation play a role in the 
activity of these compounds.  
 
3.4.2. β-Haematin inhibition studies 
 
Inhibition of haemozoin formation remains an important target for the development of 
potential antimalarials. Since other successful quinoline compounds, including chloroquine, 
are believed to inhibit haemozoin formation, it was expected that the prepared compounds 
would act by means of a similar mechanism.
25
 The NP-40 detergent mediated assay was used 
to establish if these compounds inhibit β-haematin (synthetic haemozoin) formation.
26
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Both the ligands (3.2 – 3.7) and the complexes (3.9 – 3.14) were screened and Figure 3.14 
shows dose-response curves obtained for compounds 3.3 and 3.10. This figure depicts the 
relationship between the absorbance of a haem-pyridine complex with an increasing drug 
concentration. At higher drug concentrations, the absorbance was higher, due to the presence 
of the haem-pyridine complex,
27
 hence, inhibition of β-haematin formation occurred at higher 














Figure 3.14: Dose-response curves obtained for ligand 3.3 and its complex 3.10  
using the NP-40 detergent mediated assay 
 
The monomeric ligands 3.2 – 3.4 were found to exhibit the lowest β-haematin inhibition 
activity of all the tested compounds in this series. The data are presented in Figure 3.15. The 
monomeric salicylaldimine ligands showed comparable activity with slight differences. The 
5-Cl derivative (3.2) displayed slightly higher activity (IC50 = 64 µM) compared to the 
methoxy (IC50 = 74 µM) derivative (3.3), while the unsubstituted salicylaldimine (IC50 = 84 
µM) was the least active ligand (3.4). The monomeric ligands exhibited similar β-haematin 
inhibition activity as chloroquine. The dimeric ligands (3.5 – 3.7) were found to be 
approximately twice as active compared to their monomeric counterparts. The R group 
appeared to have little to no significant effect on β-haematin inhibition activity unlike with the 
monomeric ligands. The IC50 values for these compounds were observed in the range of 33 
and 35 µM. The higher activity suggests that these compounds inhibit β-haematin 
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Figure 3.15: IC50 values (µM) obtained from β-haematin inhibition studies for the 
salicylaldimine quinoline compounds (3.2 – 3.7 and 3.9 - 3.14). Same coloured pairs represent 
ligand and its corresponding metal complex. 
 
The mononuclear complexes 3.9 – 3.11 exhibited enhanced activity compared to their 
corresponding ligands. The methoxy derivative (3.10) showed the lowest activity of the series 
(IC50 = 50 µM), while the 5-Cl (3.9) and unsubstituted (3.11) derivatives exhibited 
comparable activity (IC50 = 33 and 37 µM, respectively). The binuclear complexes 3.12 – 
3.14, exhibited similar activity to their ligand counterparts. IC50 values were observed 
between 24 and 32 µM. In this case, the unsubstituted salicylaldimine complex 3.14 exhibited 
the highest activity. The mononuclear complexes (with the exception of 3.10) possessed 
similar activity to the binuclear complexes.  
 
Overall, it appears that incorporation of the metal fragment onto these systems results in 
enhancement of the β-haematin inhibition activity of the free ligands. This may be a 
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complexes possess a square planar geometry about the metal centre, which introduces a planar 
system about the salicylaldimine moiety, which may be a reason for the increased activity. 
This may favour interactions between haem and the compounds. 
 
 
Figure 3.16: Relationship between the molecular weight of the  
tested compounds and logIC50. 
 
On closer inspection of the activity of these compounds, it was observed that compounds with 
similar molecular weights behave similarly. A plot comparing logIC50 and molecular weight 
is shown in Figure 3.16. The monomeric ligands (3.2 – 3.4) have molecular weights in the 
range of 339 – 373 g.mol
-1
. These compounds were the least active and gave logIC50 values of 
approximately 1.9. Compounds 3.5 – 3.11, which are the dimeric salicylaldimine ligands and 
mononuclear complexes, have molecular weights in the range of 515 and 583 g.mol
-1
. These 
compounds gave logIC50 values of approximately 1.5. Compounds 3.13 and 3.14 were the 
most active and have large molecular weights. Based on this, there appears to be some 
relationship between the size of the compound and its ability to inhibit β-haematin formation. 
This is consistent with data obtained for the compounds described in chapter 2. An 
explanation for this may be that lipophilicity influences β-haematin inhibition activity. The 
monomeric ligands are less lipophilic than the dimeric ligands and were therefore less 
effective at inhibiting β-haematin formation. The mononuclear complexes are more lipophilic 
MW: 339 – 373 gmol-1 (blue) 
MW: 515 – 583 gmol-1 (green) 
MW: 936 – 1003 gmol-1 (red) 
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than their corresponding ligands due to incorporation of the lipophilic COD moiety. As a 
result, the mononuclear complexes showed improved β-haematin inhibition compared to its 
ligands. The dimeric ligands, mononuclear complexes and binuclear complexes exhibited 
comparable β-haematin inhibition activity. It may be that the increased lipophilicity is a 
reason for this enhanced activity. No simple correlation between β-haematin inhibition and 
antiplasmodial activity was observed. For instance, the monomeric ligands (3.2 – 3.4) were 
the most active compounds in both the NF54 CQ-sensitive and K1 CQ-resistant strains, but 
these compounds were the least effective β-haematin inhibitors. In addition to this, the least 
active compounds (dimeric salicylaldimines) in vitro displayed the best β-haematin inhibition. 
 
It would be expected that antiplasmodial activity be related to the compound’s ability to 
inhibit haemozoin formation, however, the ability of the drug to be transported into the 
digestive vacuole and accumulate therein is an important factor that governs the extent of 
antiplasmodial activity.       
 
3.4.3. In vitro cytotoxicity studies 
The compounds described in this chapter were also screened against the WHCO1 oesophageal 
cancer cell-line. Ideally, the compounds should exhibit selectivity towards malaria parasites. 
If no selectivity is observed, the antiplasmodial activity may be a consequence of the 
cytotoxicity of these compounds. Many traditional quinoline-containing antimalarials, 
including chloroquine, have also been investigated as antitumour agents against human breast 
cancer cells.
29
 The results pertinent to this study are depicted in Table 3.9.  
The tested compounds showed moderate cytotoxicity against this cell-line. The compounds 
did however exhibit greater activity compared to cisplatin against this cell-line (IC50 =  
13.0 µM).
30
 The dimeric salicylaldimine compounds 3.5, 3.7 and 3.13 exhibited the highest 
cytotoxicity. With the exception of the monomeric 3-OMe salicylaldimine ligand (3.3) and its 
corresponding dimeric derivative (3.6), the monomeric salicylaldimine compounds exhibited 
slightly lower cytotoxicity compared to the dimeric derivatives (Figure 3.17). 
 
 




IC50 values obtained for compounds 3.2 – 3.7 and 3.9 – 3.14 against WHCO1 cancer cells.  









3.2 8.5 7.5 - 9.2 163 11.8 
3.3 8.8 7.8 - 9.9 160 13.5 
3.4 8.4 7.2 - 9.6 116 12.3 
3.5 5.9 5.2 - 6.8 1.20 2.63 
3.6 11.1 9.7 - 12.8 2.25 6.31 
3.7 4.7 4.3 - 5.2 0.674 1.04 
3.9 8.7 7.9 - 9.7 89.2 10.1 
3.10 11.3 9.5 - 13.6 68.7 8.97 
3.11 9.8 8.8 - 10.9 107 5.45 
3.12 7.8 6.3 - 9.5 0.975 2.63 
3.13 3.9 3.4 - 4.4 0.802 1.76 
3.14 7.6 7.2 – 8.0 1.91 4.96 
Cisplatin 13.0
c
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Figure 3.17: Graph comparing the cytotoxicity between  
monomeric and dimeric salicylaldimines. 
 
The dimeric derivatives are considered to be polyamines because they contain more than one 
amino group. Studies carried out on polyamine systems reveal that these compounds are 
capable of transporting cytotoxic drugs into tumour cells.
31
 Tumour cells are able to import 
polyamines by means of a polyamine transporter (PAT) in order to sustain their growth. The 
transporter is able to tolerate modified polyamines, therefore drug-incorporated polyamines 
may be able to penetrate the tumour cells via the PAT.
32
 This may be a reason for the 
enhanced activity of some of the dimeric salicylaldimine compounds.  
 
A similar trend in anticancer activity was observed for the quinoline derivatives discussed in 
chapter 2. Similarly, there are examples of other systems where activity appears to be a  
size-dependent phenomenon. Dendritic ruthenium arene compounds have been shown to 
display a similar effect. The multimeric systems show enhanced activity compared to 
monomeric systems.
33,34
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The monomeric ligands 3.2 – 3.4, displayed comparable cytotoxicity. The substituent did not 
appear to affect activity significantly in this case. The dimeric ligands 3.5 (where R = 5-Cl) 
and 3.7 (where R = H) exhibited enhanced activity compared to the dimeric ligand where R = 
3–OMe. The unsubstituted dimeric salicylaldimine ligand 3.7 showed the highest activity in 
the series. The mononuclear rhodium complexes exhibited a similar trend in activity 
compared to the dimeric ligands. Complex 3.9 (R = 5-Cl) and complex 3.11 (R = H) showed 
slightly increased activity compared to the methoxy-containing derivative (3.10). The 
binuclear rhodium complexes showed an opposing trend in anticancer activity compared to 
the mononuclear analogues. The 5-Cl substituted (3.12) and unsubstituted salicylaldimine 
(3.14) exhibited lower activity compared to the methoxy-containing derivative (3.13). 
Complex 3.13 was the most active compound of the series.       
 
Comparing activity of the ligands and the metal complexes, the complexes generally exhibited 
slightly lower cytotoxicity compared to the free ligands. The only case where this was not 
observed is with ligand 3.6 and its corresponding rhodium complex 3.13.  
 
Selectivity indices (SI) were calculated for these compounds for both the chloroquine-
sensitive strain (NF54) and the chloroquine-resistant strain (K1) of P. falciparum. Figure 3.18 
compares the selectivity indices for the tested compounds (numerical values are shown in 
Table 3.9).     
 
Firstly, against the NF54 strain of P. falciparum, the monomeric ligands (3.2 – 3.4) showed 
high selectivity towards malaria parasites giving rise to SI values greater than 100 (shown in 
blue). The mononuclear complexes (3.9 – 3.11) also exhibited high selectivity towards this 
strain, although the SI values were somewhat lower compared to the free ligands (SI: 69 – 
107). This is a consequence of the slightly lower activity of the complexes against the NF54 
strain of P. falciparum compared to the ligands. The dimeric ligands and complexes displayed 
similar SI values giving values in the range of 0.7 and 2.2. Compared to the SI values of the 
monomeric compounds, these compounds exhibited much lower SI values. These values are 
also close to 1 which suggests that the antimalarial activity (NF54 strain) is comparable to the 
activity against the WHCO1 cell-line suggesting little to no selectivity. This insinuates that 
cytotoxicity may be an explanation for the antimalarial activity of the dimeric compounds. 
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                                                                     Compound 
 
Figure 3.18: Selectivity indices obtained for the monomeric and dimeric salicylaldimines 
 
 
When looking at the SI values obtained for the K1 strain, a large difference is observed for the 
monomeric salicylaldimine ligands and mononuclear complexes compared to the NF54 strain. 
In some cases a 10-fold decrease in selectivity was observed for these compounds when 
comparing the two strains. This is due to the lower activity of these compounds in the 
resistant strain compared to the sensitive strain. The SI values obtained for the dimeric 
salicylaldimine ligands and complexes are consistent with those obtained for the sensitive 
strain. This suggests that these dimeric compounds may act by means of a cytotoxic 
mechanism.  
 
Further testing of the most cytotoxic compound 3.13, was conducted against normal healthy 
human fibroblast KMST-6. This was done in order to provide further insight into whether 
these compounds act against all cell types or perhaps these compounds may be potential 
anticancer agents. The data obtained from this study is given in Table 3.10. The selectivity 













> 100 > 100 > 100 
> 100 




IC50 values against KMST-6 human fibroblast and WHCO1 cancer cells. 
compound IC50 (μM) ± SD  KMST-6 IC50 (μM)  WHCO1 selectivity index
a
 
3.13 92 ± 4 3.9 23.6 
cisplatin 96 ± 0.4 13.0 7.30 
   a 
IC50KMST-6/IC50WHCO1 
 
As can be seen by the IC50 values obtained for 3.13 against the two cell-lines, the complex 
exhibited higher activity in the WHCO1 cancer cell-line compared to the normal fibroblast. A 
selectivity index of 23.6 was determined for this compound, indicating selectivity towards 
cancer cells. Comparing the SI value to that of cisplatin, the complex exhibited higher 
selectivity than cisplatin towards WHCO1 cancer cells. This suggests that complex 3.13 may 
not be toxic towards all cell types and its activity should be investigated against various other 
cell-lines. 
 
3.4.4. Antiparasitic activity against T. vaginalis 
The salicylaldimine ligands (3.2 – 3.7) and their complexes (3.9 – 3.14) described in this 
chapter were screened for potential activity against the G3 strain of T. vaginalis. The data are 
presented in Figure 3.19. All the compounds were screened at a concentration of 50 µM.         
 
At the tested concentration, more than half of the tested compounds exhibited less than 50% 
parasite inhibition. The dimeric 3-OMe ligand (3.6) displayed the lowest activity giving a 
percentage inhibition of about 10%. With respect to the monomeric ligands (3.2 – 3.4), the  
3-OMe substituted (3.3) and unsubstituted (3.4) ligands exhibited comparable activity (49% 
inhibition observed). The 5-Cl derivative (3.2) showed slightly lower activity in this series. 
Contrary to this, the 5-Cl derivative of the dimeric ligands (3.5 – 3.7), mononuclear 
complexes (3.9 – 3.11) and binuclear complexes (3.12 – 3.14) exhibited the best activity in 
each series of compounds. The 5-Cl binuclear complex (3.12) exhibited the best activity 
overall, comparable to metronidazole at the tested concentration (100% inhibition). Slightly 
less active was the 3-OMe binuclear complex (3.13). 
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It is noteworthy that the compounds containing the 5-Cl derivative (with the exception of 3.2) 
showed enhanced activity compared to the compounds where R = 3-OMe and R = H. 
Metronidazole is a 5-nitroimidazole compound, its activity appears to be dependent on the 
presence of the electron-withdrawing NO2 group.
35
 Perhaps in this case the electron 
withdrawing 5-Cl moiety imparts a similar biological effect as the 5-NO2 group for 
metronidazole. It has been suggested that free radical production may be a possible mode of 
action for this drug.
35
 The chlorido substituent has previously been shown to enhance the 
antiparasitic activity of some metal–containing compounds towards trichomoniasis. For 
example, palladium(II) thiosemicarbazones (Figure 3.20a) containing this group showed 
considerable parasite inhibition against the T1 strain of T. vaginalis.
36
 In a separate study, 
ruthenium–arene  thiosemicarbazone complexes possessing a chlorido moiety on the aryl ring 
(Figure 3.20b) exhibited promising activity against the G3 strain of T. vaginalis. It was also 
observed that the binuclear complexes 3.12 – 3.14) displayed enhanced activity compared to 
their corresponding free ligands (3.5 – 3.7). 
 
One of the possible reasons why the compounds containing the 5-Cl group displayed good 
activity may be a consequence of their lipophilicity. As shown in Table 3.8, the 5-Cl ligands 
are more lipophilic compared to the rest of the ligands in each case. In addition to this, 
incorporation of cyclooctadiene moieties further increases the lipophilic character of the 
complexes. As a result, the binuclear complexes (3.12 – 3.14) exhibited moderate to high 
parasite inhibition. This would also account for the enhanced activity of the binuclear 
complexes compared to their ligands. This phenomenon was also evident for some 
compounds described in chapter 2. The more lipophilic ferrocene-containing compounds 



























Figure 3.19: Percentage parasite inhibition of salicylaldimine ligands  
and their corresponding Rh(I) complexes. 
 
 
Lipophilicity has been shown to be an important factor that influences antiparasitic activity. 
For example, 2-pyridyl pyrimidines tested for their antiplasmodial and antileishmanial activity 
have shown a correlation between increased lipophilicity and good activity.
38
 In another 
study, some lipophilic tetracyclines showed enhanced parasite growth inhibition over non-
lipophilic derivatives against various strains of T. vaginalis.
39
 In many cases, it is believed 
that the uptake of these compounds is dependent on the lipophilicity. Increased lipophilicity 
aids in the transport of the compounds across various cell membranes and in turn, results in 




































PTA      
    a                                                                  b 
PTA = phosphatriazaadamantane 
 
Figure 3.20: (a) Palladium(II) thiosemicarbazone complex and (b) ruthenium-arene  
complex showing promising activity against T. vaginalis. 
 
Compounds 3.9, 3.12 and 3.13 exhibited parasite inhibition greater than 80%. These 
compounds were further evaluated in order to obtain IC50 values for a better comparison of 
their activity to metronidazole. The IC50 values determined from this study are shown in Table 
3.11. Complex 3.12 exhibited the highest activity giving an IC50 value of 4.8 µM. 
Comparatively, this compound was found to be less active than metronidazole (IC50 = 0.72 
µM) despite both of these compounds showing 100% parasite growth inhibition at 50 µM. 
Metronidazole is therefore more effective than 3.12 because a lower concentration of the drug 
can be used to obtain high parasite growth inhibition. Complex 3.13 displayed similar activity 
to 3.12 as an IC50 value of 6.1 µM was observed for this compound. The percent growth 
inhibition observed for this compound was approximately 97%. The 5-Cl mononuclear 
complex (3.9) exhibited activity 2-fold lower than 3.13 (IC50 = 12 µM). 
 
Despite the fact that the tested compounds were found not to possess activity comparable to 
metronidazole, some valuable insight has been obtained from this study. Firstly, it is further 
emphasised that the chlorido substituent plays an important role in antiparasitic activity, 
including activity against T.vaginalis. This further supports the preparation of compounds 
possessing this particular moiety. Furthermore it was also observed that the lipophilicity of the 
compound is also important. In this case, increased lipophilicity, due to the multimeric nature 
of the compounds, appeared to affect parasite growth inhibition favourably. In addition to this, 
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due to their enhanced parasite growth inhibition properties compared to their corresponding 
ligands.   
 
Table 3.11 
IC50 values obtained for selected compounds against the G3 strain of T. vaginalis in vitro. 
compound structure IC50(µM)
a


















































IC50 represents the micromolar equivalents of test compounds required to inhibit parasite growth by 50%. 
b 










A small series of mono- (3.2 – 3.4) and bis-imine (3.5 – 3.7) quinoline ligands based upon 
different salicylaldehydes were prepared using template procedures. The ligands contained 
either electron withdrawing groups (5-Cl derivatives), electron donating substituents (3-OMe 
derivatives) or these ligands were unsubstituted salicylaldimine derivatives. The 
salicylaldimine ligands were afforded in various yields (40 – 83%). Once the ligands were 
successfully obtained, their corresponding neutral Rh(I) 1,5-cyclooctadiene complexes (3.9 – 
3.14) were prepared (yields: 52 – 79%). The ligands and the complexes were characterised 
using standard spectroscopic and analytical techniques including NMR and IR spectroscopy, 
ESI or EI mass spectrometry. The characterisation data suggested coordination of the metal to 
the ligand in a bidentate manner to the imine nitrogen and the phenolic oxygen and not at the 
quinoline nitrogen.   
 
The ligands and their complexes were screened for their antiplasmodial activity in vitro 
against two strains of P. falciparum. Against the chloroquine-sensitive strain (NF54), the 
monomeric ligands (3.2 – 3.4) and the mononuclear complexes (3.9 – 3.11) exhibited 
enhanced activity compared to their dimeric counterparts (3.5 – 3.7 and 3.12 – 3.14). In the 
resistant strain (K1), the monomeric ligands and complexes experienced a loss of activity as 
was evident by the large RI values, suggesting that these complexes possess a similar activity 
profile to that of chloroquine. The dimeric derivatives maintain the same activity in the 
resistant strain compared to the sensitive strain. In some cases, there was a slight enhancement 
in activity.       
 
The compounds were evaluated for their ability to inhibit β-haematin formation in order to 
elucidate a possible mechanism of action for these compounds. There appeared to be a 
relationship between the size of the molecules and their ability to inhibit β-haematin 
formation. The monomeric ligands (3.2 – 3.4) were less efficient at inhibiting β-haematin 
formation but exhibited similar activity to CQ.  Their corresponding rhodium complexes  
(3.9 – 3.11) appeared to inhibit β-haematin formation to a larger extent. The dimeric 
salicylaldimine ligands (3.5 – 3.7) and complexes (3.12 – 3.14) also showed enhanced activity 
compared to the monomeric ligands. This may be a consequence of increased lipophilicity of 
the larger molecules.  
Salicylaldimine quinolines                                                                       Chapter 3 
108 
 
The compounds were also screened for their cytotoxicity against WHCO1 oesophageal cancer 
cells in order to evaluate their activity. In most cases, the dimeric derivatives (3.5 – 3.7 and 
3.12 – 3.14) showed increased cytotoxicity compared to their monomeric counterparts. The 
most cytotoxic complex was the 3-OMe binuclear Rh(I) complex (3.13). Generally, with the 
exception of the latter complex, the metal complexes were slightly less cytotoxic than their 
corresponding ligands. Comparing the antiplasmodial activity to the cytotoxicity, the 
monomeric compounds showed selectivity towards malaria parasites. The dimeric compounds 
appeared to show similar activity towards malaria parasites and cancer cells. This suggests 
that cytotoxicity may be a reason for the antiplasmodial activity as well.    
 
The antiparasitic activity of the compounds against the G3 strain of T. vaginalis was also 
evaluated. It was observed that the binuclear Rh(I) complexes (3.12 – 3.14) exhibited 
enhanced activity compared to the monomeric counterparts as well as their corresponding 
ligands. The 5-Cl bis-salicylaldimine Rh(I) complex (3.12) showed the highest activity 
against the parasite. Increased lipophilicity appears to promote enhanced activity. In addition 
to this, it was also observed that compounds possessing the 5-Cl moiety exhibited promising 
antiparasitic activity. 
 
Overall, the prepared compounds, specifically the monomeric derivatives, showed some 
potential as antimalarial agents. One major downfall is that the monomeric compounds 
showed decreased activity in the CQ-resistant strain of P. falciparum compared to the 
sensitive strain. The next step would be to attempt to enhance the activity of these compounds 
in the resistant strain. This could possibly be done by altering the lipophilic properties of the 
compounds by incorporating ferrocene as part of these systems. This may help overcome 
cross-resistance experienced by these compounds in a similar way that ferroquine is able to 
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Synthesis, characterisation and biological evaluation of 




As mentioned previously, malarial parasites rapidly develop resistance towards many 
antimalarials, treatment of this disease remains problematic. Ferroquine (Figure 4.1) has the 
ability to overcome resistance experienced by chloroquine and is therefore an important 
model for the development of other compounds that are equipotent and that are able to 
overcome resistance. Ferroquine has recently completed phase IIb clinical trials.
1
 Its mode of 
action is not fully understood, but it is believed that this compound is also able to hinder 
haemozoin formation like chloroquine due to the presence of the 4-aminoquinoline moeity.
2 
Ferroquine is also able to accumulate more efficiently inside of the digestive vacuole of the 
parasite compared to chloroquine.
3 
Once inside of the digestive vacuole, ferroquine inhibits 
haemozoin formation strongly and is also able to generate reactive oxygen species (ROS). The 















Figure 4.1: Ferroquine, a potent antimalarial that has completed Phase IIb clinical trials
Fc moiety results in the compound overcoming PfCRT resistance possibly by means of ROS generation  
Weak bases aid in vacuolar accumulation 
4-aminoquinoline necessary for haemozoin crystal growth inhibition  
Electron withdrawing group for correct charge distribution and haemozoin crystal growth inhibition  




Non-quinoline based ferrocenes have also been investigated as antiplasmodial agents. For 
example, ferrocenyl chalcones were evaluated against the K1 strain of P. falciparum. The 
compounds exhibited activity in the low micromolar range. The derivative containing a  
4-nitro-phenyl group (Figure 4.2) showed the highest activity. The ferrocenyl motif appeared 










Figure 4.2: Ferrocenyl chalcone exhibiting antiplasmodial activity 
 against the K1 strain of P. falciparum 
 
 
More recently, ferrocenyl azines and various metal complexes thereof (Figure 4.3) were 
synthesised and evaluated for their antiplasmodial activity. Neutral as well as anionic 
salicylaldimine ruthenium(II), rhodium(III) and iridium(III) complexes were tested in order to 
establish potential activity.
7,8
 The neutral compounds (Figure 4.3a) exhibited moderate 
activity against the NF54 chloroquine-sensitive strain of P. falciparum, giving values in the 
low micromolar range. The metal complexes displayed enhanced activity compared to the 
salicylaldimine ligand.
7
 In a separate study, water-soluble anionic versions (Figure 4.3b) were 
evaluated, but these compounds were less active than their neutral analogues.
8
 It appears that 
the enhanced water-solubility diminishes activity, possibly due to insufficient uptake of the 
compounds by the parasite. A way to remedy this would be to enhance their lipophilicity, 
which may in turn result in increased activity. In addition to this, incorporation of a metal with 
square-planar geometry may enhance interactions with haematin/haemozoin, which may 

























   a       b 
 
M = Ru(II); Rh(III); Ir(III) 
L = p-cymene; Cp* 
 
Figure 4.3: Ferrocenyl azines that showed moderate to weak antiplasmodial activity 
 
In addition to antiparasitic activity; various metallocenes, including ferrocene-containing 
compounds, have also exhibited a wide range of biological properties.
9
 This includes 
antitumour properties.
9
 Many ferrocene-based compounds have attracted interest due to their 
chemical stability and non-toxic nature, making them suitable for biological use. Ferrocene 
itself is also easily functionalised in order to afford diverse variations. All of these factors 
need to be considered when developing new therapies. In this chapter, ferrocenyl moieties 
have been incorporated as part of various systems in the hope to afford biologically active 
compounds.   
 
4.2. Synthesis and characterisation of ferrocenyl salicylaldimines 4.5 – 4.7,  
quinolines 4.9 – 4.11 and some Rh(I) complexes 4.12 – 4.14 
 
4.2.1. Synthesis  
 
Since the monomeric salicylaldimine systems mentioned in chapter 3 showed promising 
antiplasmodial activity in the NF54 CQ-sensitive strain of P. falciparum, it was decided to 
attempt to improve on the activity of these compounds in the resistant strain (since these 
compounds showed loss of activity in the resistant strain compared to the sensitive strain). 
This was proposed by incorporating ferrocenyl moieties as part of these systems. This would 
hopefully result in improved activity in the resistant strain, as can be seen with the activity of 
ferroquine compared to chloroquine. The initial idea to prepare salicylaldimine ferrocenyl 
quinolines involved the method outlined in Scheme 4.1. This procedure involved the 
preparation of ferrocenyl-containing salicylaldimines 4.5 (R = 5-Cl), 4.6 (R = 3-OMe) and 4.7 




(R = H), followed by quaternisation of the tertiary amine using iodomethane to form the 
desired quaternary ammonium salts. The salts could then be reacted with  
N’-(7-chloroquinolin-4-yl)-propane-1,3-diamine (2.1) in the hope to afford the desired 
quinoline-containing ferrocenyl salicylaldimines. Compounds 4.5 – 4.7 were prepared by 
means of Schiff-base condensation reactions between the (dimethylamino)methyl 
ferrocenecarboxaldehyde (4.1) and various salicylaldehyde hydrazones (4.2 (R = 5-Cl), 4.3  
(R = 3-OMe), 4.4 (R = H)).  
 
Compound 4.1 was prepared by means of ortho-lithiation of (dimethylamino)methyl ferrocene 
using n-butyllithium in hexanes to afford the lithiated species in situ (Scheme 4.1). The 
dimethylamino group is ortho-directing and thus the ortho-metalated product was obtained.
10
 
The lithium derivative was then reacted with N,N-dimethylformamide giving, after the work-
up procedure, the desired 1,2-disubstituted product 4.1. Formation of the 1,2-disubstituted 
derivative is mainly attributed to the added stability of the lithiated intermediate. The 
dimethylamino group is able to stabilise the alkali metal. Aldehyde 4.1 was then reacted with 
either 5-chlorosalicylaldehyde hydrazone (4.2), 3-methoxysalicylaldehyde hydrazone (4.3) or 
salicylaldehyde hydrazone (4.4) in diethyl ether to afford salicylaldimine ferrocenes 4.5 – 4.7. 
The hydrazones were prepared by modification of literature procedures.
11,12 
The hydrazones 
were condensed with 4.1 in a 1:1 stoichiometric ratio. After purification by means of silica gel 
chromatography, ferrocenyl salicylaldimines 4.5 – 4.7 were obtained as red oils in moderate 
to good yields (66 – 88%). These ligands were soluble in common solvents including diethyl 
















































































R = 5-Cl (4.2, 4.5); 3-OMe (4.3, 4.6); H (4.4, 4.7) 
 
 
Scheme 4.1: Synthesis of ferrocenyl derivatives 4.1 and 4.5 – 4.7. Reagents and conditions: 
(a) (dimethylamino)methyl ferrocene (1 eq.), n-BuLi (1.45 eq.), Et2O, 16 h, r.t. (b) DMF  
(1.25 eq), 4 h, r.t. (c) appropriate salicylaldehyde hydrazone (1 eq.), Et2O, 16 h, r.t. (d) MeI 









Quaternisation of the tertiary amine of 4.5 was carried out using iodomethane and the 
resulting ammonium salt was reacted with N’-(7-chloroquinolin-4-yl)-propane-1,3-diamine 
(2.1) in acetonitrile under reflux conditions in the presence of K2CO3. The ferrocenyl 
precursor appeared unstable upon heating at elevated temperatures. The reaction was also 
attempted at ambient temperature for a prolonged time period, but starting material was 
recovered. It was then decided that since the substituent on the aryl ring of the salicylaldimine 
quinoline compounds discussed in chapter 3 did not have a significant influence on 
antiplasmodial activity, the ferrocenyl and salicylaldimine moieties could then be incorporated 
differently onto the quinoline component (Scheme 4.2). N’-(7-Chloroquinolin-4-yl)-propane-
1,3-diamine (2.1) was reacted with the ferrocenyl salicylaldehyde 4.8
13
 via a Schiff-base 
condensation reaction (Scheme 4.2) to afford the salicylaldimine ferrocenyl quinoline 4.9 in 
good yield. In addition to this, a non-salicylaldimine containing mono-ferrocenyl quinoline 
(4.10) and a bis-ferrocenyl quinoline (4.11) were also prepared (Scheme 4.2) in order to probe 
the importance of the salicylaldimine motif for biological activity (see later sections). 
Compound 4.9 was specifically prepared in order to compare the effect of having a 
salicylaldimine, quinoline and ferrocene moiety present in the same compound to compare its 
activity to those compounds mentioned in chapter 3 (3.2 – 3.4) and compound 4.10. 
Compounds 4.10 and 4.11 were prepared by means of Schiff-base condensation reactions 
between ferrocenecarboxaldehyde and N’-(7-chloroquinolin-4-yl)-propane-1,3-diamine (2.1) 
in the case of 4.10 or N-(7-chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) in the case of 
4.11.  
 
The corresponding rhodium(I) cyclooctadiene complexes of ferrocenyl salicylaldimine 
ligands 4.5 – 4.7 were also prepared (Scheme 4.3) in order to evaluate the effect of the metal 
on biological activity compared to the ligands. Rh(I) was chosen due to its square-planar 
geometry. This may aid in interactions with haem. Complexes 4.12 – 4.14 were prepared by 
firstly deprotonation of the phenolic proton using excess NaH in dichloromethane, followed 
by addition of 0.5 eq of [RhCl(COD)]2 (3.8).
14
 The complexes were obtained as orange-red 
powders in excellent yields (94 – 98%). The complexes were soluble in organic solvents such 
as dichloromethane, chloroform and dimethyl sulfoxide. 
       

































































Scheme 4.2: Synthesis of ferrocenyl quinolines 4.9 – 4.11. Reagents and conditions: (a) 
Compound 2.1 (1 eq.), ferrocenecarboxaldehyde (1.1 eq.), Et2O, 16 h, r.t. (b) Compound 2.1 
(1 eq.), ferrocenyl aldehyde 4.8 (1 eq.), DCM/MeOH, 16 h, r.t. (c) Compound 3.1 (1 eq.), 
ferrocenecarboxaldehyde (2 eq.), EtOH, 16 h, r.t. 
 
   
 
 
R = 5-Cl (4.5, 4.12); 3-OMe (4.6, 4.13); H (4.7, 4.14) 
 
Scheme 4.3: Synthesis of ferrocenyl salicylaldimine Rh(I) complexes. Reagents and 
conditions: (a) Salicylaldimine ligand (1 eq.), NaH (excess), DCM, 1.5 h, r.t.  










4.5 -  4.7 4.12 -  4.14
a, b












H} NMR spectroscopy, infrared spectroscopy and high resolution (HR) ESI mass 






H NMR spectra of these compounds were recorded in CDCl3 and the spectra were 
consistent with the proposed structures. Selected 
1
H NMR resonances for compounds  
4.5 – 4.7 and 4.9 – 4.11 are given in Table 4.1. The details are discussed in the subsequent 





H NMR resonances for 4.5 – 4.7 and 4.9 – 4.14  










4.5 8.66 8.59 11.88 3.29 (d, 13.01) 3.73 (12.92) 4.18 
4.6 8.66 8.67 12.18 3.32 (d, 12.61) 3.74 (13.01) 4.19 
4.7 8.66 8.67 11.89 3.30 (d, 12.97) 3.72 (12.96) 4.18 
compound H2 H3 H8 HC=N NH Cpunsub 
4.9 8.54 6.43 7.93 8.35 5.10 4.16 
4.10 8.50 6.36 7.93 8.18 6.76 4.18 
4.11 8.48 6.33 7.89 8.10 6.66 4.31 




4.12 7.98 7.58 1.95; 2.46 3.98; 4.60 4.20 
4.13 8.00 7.68 1.95; 2.47 3.98; 4.70 4.20 
4.14 8.01 7.67 1.95; 2.48 3.98; 4.62 4.21 
 
 




The spectra of precursors 4.1 – 4.4 compared favourably with literature.
10-12
 In the case of 
precursor 4.1, the structure of the product was confirmed by the appearance of a signal at 
10.03 ppm, which is indicative of the proton of the aldehyde moiety. This particular signal 
was absent in the spectra of (dimethylamino)methyl ferrocene. Successful synthesis of 
hydrazones 4.2 – 4.4 was confirmed by the appearance of signals for the imine protons in the 
range of 7.77 and 7.86 ppm. Further to this, broad singlets at about 5.5 ppm confirmed that the 
mono-condensed products were obtained. These signals were assigned to the protons of the 
NH2 group. The method outlined for the synthesis of compounds 4.5 – 4.7 results in the 
formation of racemic mixtures. The chirality of ligands 4.5 – 4.7 was evident in their 
1
H NMR 
spectra. The CH2 protons adjacent to the dimethylamino group (assigned as H2) are 
diastereotopic, thus two signals were observed for these protons. In an achiral environment, 
these protons would be observed as one singlet, but since the metallocene exhibits planar 
chirality due to the fact that the ferrocene is 1,2-disubstituted, the protons are non-equivalent. 
The environments above and below the substituted cyclopentadienyl ring are different. This 
resulted in one of the methylene protons (e.g. H2a) to be closer to the Fe centre compared to 
the other (e.g. H2b). This chemical non-equivalence causes the protons to couple to each 
other. This therefore resulted in the appearance of two doublets with coupling constants of 
about 13 Hz in each case.  
 
Schiff-base condensation for 4.5 – 4.7 was confirmed by the appearance of two imine proton 
signals in each spectrum. A singlet for the proton of the newly formed imine bond was 
observed at 8.66 ppm for ligands. The imine signal adjacent to the salicylaldimine moiety 
appeared in the region between 8.59 and 8.67 ppm for 4.5 – 4.7, while signals for the 
hydroxyl protons of these ligands were observed between 11.88 and 12.18 ppm. Three signals 
were observed for the protons of the substituted Cp ring in the range of 4.5 and 4.9 ppm. 
Singlets for the unsubstitued Cp ring were assigned at ca. 4.18 ppm. For compounds 4.9 – 
4.11, Schiff-base condensation was confirmed by the appearance of a singlet at 8.35, 8.18 and 
8.10 in the spectra of 4.9, 4.10 and 4.11, respectively, for the imine proton. The integration 
was in agreement with the proposed compounds. The 
1




















H NMR spectrum of compound 4.9 in CDCl3 
 
Signals for the aromatic protons of the quinoline motif appeared in the expected region for 4.9 
– 4.11. A doublet was observed for each H2 proton (numbering of the quinoline ring shown in 
Scheme 4.2) of the quinoline ring and occurred in the region of 8.48 and 8.54 ppm, while the 
signal for H3 was observed between 6.33 and 6.43 ppm. A broad signal was assigned to the 
NH proton in each case. For compound 4.9, this particular signal was more shielded than the 
same signal in the spectra of 4.10 and 4.11. In the case of 4.9, this signal resonated at 5.10 
ppm, while in the case of 4.10 and 4.11 it was seen at 6.66 and 6.76 ppm, respectively. Signals 
for the protons of the unsubstituted Cp ring were observed between 4.16 and 4.31 ppm. A 













































4.9 and 4.10, two triplets were observed in each spectrum for the Hα,α’ and Hβ,β’ protons of the 




H NMR spectra of compounds 4.12 – 4.14 were in agreement with the proposed 
complexes. The 
1
H NMR spectrum of complex 4.13 can be seen in Figure 4.5. Firstly, the 
broad singlet attributed to the phenolic proton in the spectra of the ligands were absent from 
the spectra of the complexes. This suggested coordination to the metal via the phenolic 
oxygen. An upfield shift was observed for the signals of both imine protons in the spectra of 
the complexes. A shift of about 1 ppm was observed for the imine proton adjacent to the 
salicylaldimine moiety. This confirmed bidentate coordination to the phenolic oxygen and 
salicylaldimine nitrogen. As a result, the imine proton resonance adjacent to the ferrocenyl 
motif shifted upfield by about 0.6 ppm. In addition to this, complexation was further 
confirmed by the presence of signals for the cyclooctadiene (COD) moiety in the expected 
region. Four signals were observed due to the trans influence of the nitrogen and oxygen 
donor atoms of the ligand. The CODexo protons were seen as a multiplet at 1.95 ppm, while 
the CODendo signals were observed at approximately 2.47 ppm. Two multiplets for the olefinic 
protons were assigned at 3.98 and ca. 4.6 ppm. This compared favourably with the spectra of 
the complexes discussed in chapter 3 and similar complexes found in literature.
15-19
 The signal 
for the unsubstituted Cp ring remained constant upon coordination, it was observed at 






H} NMR spectra of ligands 4.5 – 4.7 and 4.9 – 4.14 further supported formation of 
the desired compounds. The expected number of signals was observed in each spectrum. 




H} NMR data. The imine carbon signals of the salicylaldimine 
moiety of ligands 4.5 – 4.7 were observed in the region between 162.99 and 163.91 ppm. This 
signal was particularly deshielded in the case of the 5-chloro derivative (163.91 ppm) (4.5) 
compared to the unsubstituted derivative (4.7), which was attributed to the electron 
withdrawing ability of the substituent. The carbon signals of the imine adjacent to the 
ferrocenyl moiety resonated between 161.23 and 162.60 ppm. The CH2 carbon signals were 
seen at approximately 57.1 ppm, while the carbon atoms of the unsubstituted Cp ring 
resonated around 70 ppm. For ligands 4.9 – 4.11, the imine carbon atom signals were 
observed in the range of 162.00 and 165.37 ppm. The signals of the quinoline ring were 
consistent in all three spectra. Signals for the carbon atoms C2, C3 and C8, resonated at 




approximately 152, 99 and 128 ppm, respectively. These data are also consistent with data 














































H} NMR resonances for 4.5 – 4.7 and 4.9 – 4.14  
compound HC=N (Fe) HC=N CH2 NCH3 Cpunsub 
4.5 161.23 163.91 57.18 44.96 70.12 
4.6 162.54 163.22 57.11 44.87 70.09 
4.7 162.60 162.99 57.18 45.01 70.06 
compound HC=N C2 C3 C8 Cpunsub 
4.9 165.37 151.97 99.11 128.81 69.32 
4.10 162.00 152.17 98.57 128.63 69.16 
4.11 162.04 151.95 99.01 128.31 69.05 
compound HC=N (Fe) HC=N 
HC=CHCOD (m, JC-Rh Hz); 
HC=CHCOD (m, JC-Rh Hz) 
Cpunsub 
4.12 157.65 152.06 73.38 (d, 13.36); 85.43 (d, 12.12) 70.03 
4.13 157.55 152.99 72.77 – 73.35 (m); 84.86 (10.71) 70.00 
4.14 157.57 153.12 72.86 (d, 13.46); 85.02 (d, 12.12) 69.99 
 
 
Complexation of ligands 4.5 – 4.7 was confirmed by the appearance of signals for the COD 
moiety in the expected regions. In the case of compounds 4.12 and 4.14, two doublets were 
observed for the olefinic carbon atoms at about 73 ppm (for olefinic carbon atom trans to 
oxygen) and 85 ppm (for olefinic carbon atoms trans to nitrogen). In the case of compound 
4.13, a doublet at 85 ppm was assigned to the olefinic carbon atoms trans to nitrogen, while a 
multiplet was observed in the region of 72.77 – 73.35 ppm for the olefinic carbon atoms trans 
to oxygen. The aliphatic carbon atoms of the COD moiety appeared at 29 and 31 ppm for 












Infrared spectroscopy further confirmed that the desired ligands and complexes were 
obtained. Characteristic bands for the azine (-C=N-N=C-) motif of 4.5 – 4.7 were observed in 
the range of 1616 and 1618 cm
-1
. In each case, one strong absorption band appeared for both 
C=N bonds, this suggests an overlap of the two frequencies. Absorption bands for the C=C 
aromatic moieties were observed between 1587 and 1582 cm
-1
. In the case of complexes 4.12 
– 4.14, these bands shifted to lower wavenumber, due to the metal withdrawing electron 
density away from the nitrogen of the azine moiety. This in turn causes elongation of the C=N 
bond, and therefore a shift was observed. Figure 4.6 shows the IR spectra of ligand 4.7 and its 
corresponding complex 4.14. In the case of the complexes, bands for the azine moiety were 
observed around 1600 cm
-1
. Absorption bands for the C=C stretching frequencies also shifted 
to lower wavenumbers compared to the ligands. These absorption bands appeared between 
1574 and 1576 cm
-1
. Schiff-base condensation to afford 4.9 – 4.11 was confirmed by the 
appearance of absorption bands at 1611, 1638 and 1639 cm
-1
 for the C=N stretching 
frequencies, respectively. Absorption bands for the C=N stretching frequencies of the 
quinoline ring of 4.10 and 4.11 appeared at 1613 and 1611 cm
-1
, respectively. This particular 
absorption band for 4.9 overlaps with the Schiff-base C=N stretching frequency and therefore 




High resolution ESI mass spectrometry was used to confirm the molecular weights of the 
synthesised compounds. Analysis of the mass spectra of ligands 4.5 – 4.7 and 4.9 – 4.11, 
confirmed that the desired compounds were obtained. With the exception of 4.9, the spectra of 
the ligands showed base peaks for the protonated molecular ion ([M+H]
+
). In the case of 4.9, a 
base peak corresponding to [M+2H]
2+
 was observed. Peaks corresponding to [M+H]
+
 were 
observed in the spectra of complexes 4.12 – 4.14. In all cases, the assignments were in close 
agreement with the calculated values.  
 





              Wavenumber (cm-1) 
 
Figure 4.6: IR spectra of ligand 4.7 (green) and corresponding  
complex 4.14 (purple) obtained in the solid state. 
 
The afore-mentioned characterisation data clearly supports preparation of the proposed 
ferrocenyl quinolines, salicylaldimines and rhodium(I) complexes. Based on satisfactory 
correlation of this data and the proposed structures, the biological activities of these 
compounds were investigated and the data are described in the next section. 
 
4.3. Biological and physicochemical evaluation 
 
4.3.1. Antiparasitic activity against P. falciparum 
 
Many quinoline-based compounds are effective antimalarials, but resistance remains a major 
issue. As discussed previously, ferrocenyl compounds such as ferroquine are able to 
counteract this resistance. Chapter 1 highlighted various examples of ferrocene-containing 
derivatives that exhibited promising antiplasmodial activity. The compounds discussed in this 
chapter (quinoline and non-quinoline) were therefore screened for activity against two strains 




i.e. the NF54 CQS and K1 CQR strains of P. falciparum. It was expected that the non-
quinoline compounds would not experience the same fate as many quinoline-containing 
compounds regarding resistance. The results obtained from a preliminary screen are presented 
in Table 4.3. The values of CQ and FQ are also given. 
   
Table 4.3 
In vitro antiplasmodial activity and resistance indices of compounds 4.5 – 4.7, 4.9 – 4.14, CQ 
and FQ against the NF54 CQ-sensitive and the K1 CQ-resistant strains of P. falciparum. 
compound IC50
a
 ± SE NF54
b










4.5 32 ± 2 14 ± 2 0.44 4.04 
4.6 101 ± 36 13 ± 2 0.13 3.12 
4.7 11 ± 5 50 ± 36 4.50 3.31 
4.9 nd
f
 0.82 ± 0.28 nd 6.97 
4.10 0.083 ± 0.01 (n = 2) 0.59 ± 0.03 (n = 2) 7.11 4.51 
4.11 0.72 ± 0.04 0.65 ± 0.04 (n = 2) 0.90 7.36 
4.12 18 ± 7 3.9 ± 0.04 0.22 nd 
4.13 9.6 ± 2.5 8.1 ± 1.9 0.85 nd 
4.14 7.9 ± 4.2 11 ± 3 1.41 nd 









IC50 represents the micromolar equivalents required to inhibit parasite growth by 50% 
b
NF54 chloroquine-sensitive strain of P. falciparum; n = number of data sets averaged, n = 3,  
c
K1 chloroquine-resistant strain of P. falciparum; n = number of data sets averaged,  n = 3, 
d
Resistance index (RI) = IC50K1/IC50NF54 
e
logP predicted using the method described in chapter 2 
f







Antiplasmodial activity against the NF54 CQ-sensitive strain of P. falciparum 
 
The data obtained from this screen are preliminary findings. Compound 4.10, a quinoline–
containing derivative, was found to be the most active, exhibiting an IC50 value of 0.083 µM. 
Compound 4.11 displayed slightly lower activity but still exhibited an IC50 value less than  




1 µM. One of the reasons for its lower activity may be a consequence of its high lipophilicity. 
A predicted logP of 7.36 was observed for this compound. Compounds that are too lipophilic 
may experience difficulty accumulating inside of the digestive vacuole of the parasite because 
they might interact more with various cell membranes and therefore may not be transported 
effectively. Surprisingly, the remaining quinoline derivative, 4.9 was not active at the tested 
concentration (1000 ng/ml). This was an unexpected result and further tests are required in 
order to quantify its activity.  
 
The activity of the afore-mentioned quinolines was also compared to the activity of ligands 
3.2 – 3.7 discussed in chapter 3. Monomeric salicylaldimine ligands 3.2 – 3.4 exhibited potent 
activity (0.052 – 0.072 µM) in this strain, in the same range as CQ and FQ. Compound 4.10 
also displayed similar activity to these compounds which suggests that the salicylaldimine 
motif does not contribute significantly towards the activity of 3.2 – 3.4. Compound 4.11 also 
showed a significant increase in activity compared to dimeric salicylaldimines 3.5 – 3.7. This 
suggests that substitution of the salicylaldimine moiety by ferrocene, results in enhanced 
activity in this case.  
 
The ferrocenyl azine ligands 4.5 – 4.7 exhibited variable activity ranging from 11 to 
101 µM. The complexes (4.12 – 4.14) exhibited activity in the low micromolar range and 
were more active than their respective ligands. In each case, the unsubstituted salicylaldimine 
derivative was the most active. These compounds, however, did not exhibit comparable 
activity to 4.10. The lower activity was mainly attributed to these compounds not possessing a 
bioactive quinoline moiety. The activity of 4.5 – 4.7 and 4.12 – 4.14 were also compared to 
the activity of similar ferrocenyl azines depicted in Table 4.4. The IC50 values were taken 
from literature.
7,8
 One series of compounds were neutral (4.15 and 4.17 – 4.19), while the 
other was a series of water-soluble, anionic compounds (4.16 and 4.20 – 4.21). When the 
activities of compounds 4.5 – 4.7 were compared to the activity of 4.15 and 4.16 in this 
particular strain, compounds 4.5 and 4.15 were found to exhibit similar antiplasmodial 
activity. Compound 4.6 was least active, while 4.7 exhibited the highest activity. Complexes 










Antiplasmodial activity of similar ferrocenyl azine derivatives (4.15 – 4.22) against  
the NF54 CQS strain.
7,8
  
compound structure IC50 (µM) 
4.15: R = H 
 











4.15:  33 
 
4.16:  55 
 
 
4.17: R = H, M = Ru(II), L = p-cymene 
4.18: R = H, M = Rh(III), L = Cp* 
4.19: R = H, M = Ir(III), L = Cp* 
4.20: R = 5-SO3
-
, M = Ru(II), L = p-cymene 
4.21: R = 5-SO3
-











4.17:  3.9 
4.18:  5.8 
4.19:  6.0                                 
4.20:  47 
4.21:  57 
     
Complexes 4.12 – 4.14 and 4.17 – 4.19 all displayed enhanced activity compared to the water-
soluble derivatives 4.20 and 4.21. From this data it was evident that lipophilicity plays an 
important role on the activity of these compounds. The water-soluble derivatives 4.20 and 
4.21, are probably not able to accumulate sufficiently inside of the digestive vacuole of the 
parasite due to their hydrophilicity and were therefore less active. A correct balance between 
hydrophilicity and lipophilicity is required in order for compounds to be transported 
effectively into the parasite. Incorporation of the (dimethylamino)methyl group as part of 
these systems did not appear to have a significant effect on activity. The substituents on the 
salicylaldimine ring also did not appear to affect activity favourably. The unsubstituted 
derivative showed the best activity in each family. All of the non-quinoline based compounds 
that were tested did not exhibit activity comparable to CQ or FQ in this strain and none 
exhibited IC50 values lower than 1 µM. 
 
Antiplasmodial activity against the K1 CQ-resistant strain of P. falciparum 
 
In order to obtain information about the behaviour of these compounds in CQR strains, all the 
compounds were screened against the K1 strain of P. falciparum. The data are given in Table 
4.4. Overall, compounds 4.9 – 4.11 exhibited good activity against this strain of P. 




falciparum, giving values less than 1 µM (0.82, 0.59 and 0.65 µM, respectively). This is 
similar to data obtained for ligands 3.2 – 3.4 in the same strain. Figure 4.7 depicts the 
resistance index values for the Fe-based compounds and also for 3.2 – 3.7.  
  















Figure 4.7: Resistance indices for compounds 3.2 – 3.7, 4.5 – 4.7, 
4.9 – 4.14, CQ and FQ 
 
Compound 4.9 was more active in the resistant strain compared to the sensitive strain and 
therefore an IC50 value could be obtained at the tested concentration. Contrary to this, the 
activity of 4.10 decreased in the resistant strain compared to the sensitive strain, this was also 
observed for the salicylaldimine derivatives 3.2 – 3.4 mentioned in chapter 3. As can be 
observed in Figure 4.7, compounds possessing the tris(2-aminoethyl)amine scaffold, 3.5 – 3.7 
and 4.11 exhibited resistance indices lower than values obtained for 3.2 – 3.4 and CQ. As 
mentioned in chapter 3, intramolecular hydrogen bonding may occur in these systems, similar 
to FQ. This may aid in these compounds overcoming the cross-resistance experienced by the 
monomeric analogues. Compound 4.11 was more active than its corresponding 
salicylaldimine derivatives 3.5 – 3.7 (IC50 = 2.3, 1.8 and 4.5 µM, respectively) in the resistant 
strain. This was also observed in the sensitive strain. All ferrocenyl azines, with the exception 
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RI values were less than 1 in these cases. In this strain the unsubstituted compounds were less 
active compared to the 5-Cl and 3-OMe derivatives. The activity of 4.7 decreased 4.5 times in 
the K1 strain compared to the NF54 strain. The activity of 4.14 also declined slightly. The  
5-Cl complex (4.12) exhibited the best activity in this series. Despite the observation that most 
of these compounds exhibited enhanced activity in this strain, none of the compounds 
displayed activity close to FQ, CQ or even compounds 3.2 – 3.4, further emphasising the 
importance of the quinoline moiety for antiplasmodial activity.   
 
4.3.2. β-Haematin inhibition studies 
 
The compounds described in this chapter were also screened for potential β-haematin 
inhibition activity using the NP-40 detergent mediated assay in order to rationalise their 
antiplasmodial activity. Figure 4.8 depicts the β-haematin inhibition activity for compounds 

















Figure 4.8: IC50 values obtained for the salicylaldimine ferrocenyl ligands (4.5 – 4.7)  
and complexes (4.12 – 4.14), quinoline ferrocenes (4.9 – 4.11), CQ  














Compounds 4.5 – 4.7 weakly inhibited β-haematin formation, displaying IC50 values greater 
than 90 µM. This was expected because these compounds did not possess quinoline moieties, 
which is usually required for strong β-haematin inhibition activity. The activity of the ligands 
decreased upon complexation for 4.12 and 4.13. The activity of 4.7 however, improved 
slightly when complexed. The ligand and complex possessing the 5-Cl group showed the best 
activity in each series. This is consistent with data obtained for the β-haematin inhibition 
activity of the monomeric salicylaldimine ligands (3.2 – 3.4) and complexes (3.9 – 3.11) 
discussed in chapter 3. Compound 4.9 exhibited similar activity to chloroquine in this study, 
while ferroquine displayed the highest β-haematin inhibition activity. Compound 4.10 showed 
slightly improved activity compared to 4.9, while compound 4.11 exhibited high activity. 
 
The β-haematin inhibition activity of the ferrocenyl azines 4.5 – 4.7 and 4.12 – 4.14 were 
compared to that of similar ferrocenyl derivatives depicted in Table 4.4. The β-haematin 
inhibition activities of these compounds were taken from literature.
7,8
 Compounds 4.15 and 
4.17 – 4.19 exhibited enhanced β-haematin inhibition activity compared to 4.5 – 4.7 and 4.12 
– 4.14. Compounds 4.5 – 4.7 and 4.12 – 4.14 did however exhibit enhanced activity compared 
to similar water-soluble derivatives 4.16, 4.20 and 4.21. It is apparent from this information 
that lipophilicity plays a role in inhibition of haem aggregation. From information acquired in 
earlier chapters, it was expected that compounds that were more water-soluble would exhibit 
lower β-haematin inhibition activity. Since compounds 4.5 – 4.7 and 4.12 – 4.14 exhibited 
low β-haematin inhibition activity, their antiplasmodial activity may be a consequence of their 
ability to generate free radicals. This has been shown to be the case in some ferrocene-based 
compounds that exhibited antiplasmodial activity.
6
 Ferroquine is also believed to be able to 
generate hydroxyl radicals from H2O2 in the parasitic digestive vacuole by means of a Fenton-
like reaction. This causes severe damage to the membranes of the parasite.
21
 The quinoline 
compounds (4.9 – 4.11) were able to inhibit β-haematin formation to a larger extent compared 
to the non-quinoline derivatives. No simple correlation can be made between the β-haematin 
inhibition and antiplasmodial activity, intracellular factors such as compound uptake and 
accumulation probably also greatly affects the antiplasmodial activity of these compounds 
confounding simple correlation.    








4.3.3. In vitro cytotoxicity studies 
 
Metallocenes have been known to possess various biological activities.
22,23
 Many ferrocenyl 
compounds specifically, have exhibited antitumour and cytotoxic activities.
24-27
 One of a few 
promising ferrocenyl-based drug candidates discovered was hydroxyferrocifen (Figure 4.9).
25
 
This was discovered when the organic drug hydroxytamoxifen was altered by substituting its 
phenyl ring with a ferrocene unit and screened for activity.
25
  







Figure 4.9. Hydroxyferrocifen, a potential ferrocene-based anticancer agent 
 
 
Based on this, all the ferrocenyl compounds described in this chapter were screened for 
cytotoxicity against WHCO1 oesophageal cancer cells. This was also carried out in order to 
gain insight about the selectivity of these compounds towards malarial parasites. All of the 
ferrocenyl quinoline derivatives exhibited activity against this particular cell-line. Compound 
4.12 was the only non-quinoline compound that exhibited cytotoxic activity. The rest of the 
non-quinoline derivatives (4.5 – 4.7, 4.13 and 4.14) were not active at the tested 
concentration. CQ and FQ were also tested for their activity in this cell-line. The data are 
presented in Table 4.5.     
 
 





IC50 values obtained for 4.9 - 4.12, CQ and FQ against WHCO1 cancer cells
a
 









4.9 10.0 8.4 – 11.8 nd 12 
4.10 5.8 5.1 – 6.6 70 10 
4.11 8.0 7.2 – 9.0 11 12 
4.12 9.7 9.0 – 10.4 0.54 2 
CQ 6.3 5.7 – 6.9 252 21 
FQ 17.3 13.1 – 22.8 523 1234 
cisplatin 13.0
d
 - - - 
a
 Values were determined from a dose response curve (assayed with MTT), IC50 represents the micromolar   










Compound 4.10 was the most cytotoxic, exhibiting an IC50 value of 5.8 µM. Compound 4.9 
and 4.12 displayed similar cytotoxicity to each other, with 4.11 showing slightly higher 
activity to 4.9. CQ and 4.10 exhibited comparable activity, while FQ was the least cytotoxic 
against this cell-line (IC50 = 17.3 µM). All the compounds, with the exception of FQ, 
exhibited higher cytotoxicity than cisplatin. The activity of 4.10 was compared to that of 
monomeric salicylaldimines 3.2 – 3.4 and 3.9 – 3.11. Compound 4.10 showed increased 
cytotoxicity compared to these salicylaldimine derivatives. The activity of 4.9 was compared 
to that of 3.2 – 3.4 and showed slightly lower cytotoxicity compared to the salicylaldimine 
derivatives. Compound 4.11 displayed similar activity to the monomeric salicylaldimines 3.2 
– 3.4. The enhanced activity of the quinolines against this cell-line compared to the non-
quinoline compounds may be due to their ability to target DNA. Many quinoline-based 
compounds have been shown to interact with DNA by means of intercalation.
29
     
 
Selectivity indices (SI) were calculated for these compounds for both the chloroquine-
sensitive strain (NF54) and the chloroquine-resistant strain (K1) of P. falciparum. Figure 4.10 
compares the selectivity indices for the tested compounds (numerical values are shown in 
Table 4.5).    
 


















Figure 4.10: Selectivity indices obtained for 4.9 – 4.12, CQ and FQ. 
 
CQ and FQ exhibited large SI values ( > 200) when comparing this cell-line and the CQS 
strain of P. falciparum. These compounds displayed potent activity against the NF54 strain 
and therefore exhibited large SI values. These SI values are greater than those observed for 
ligands 3.2 – 3.4 (116 – 163) for the same strain. Compound 4.10 exhibited lower selectivity 
than CQ and FQ towards the CQS strain, but this is due to the compound being less active 
than CQ and FQ against the NF54 strain and in addition to this, it exhibited the highest 
cytotoxicity. Compounds 4.11 exhibited slightly lower selectivity than 4.10 towards the NF54 
strain, but this was a consequence of its lower antiplasmodial activity compared to 4.10. 
Compound 4.12 did not exhibit any selectivity towards the CQS strain. In all cases, with the 
exception of FQ, low selectivity was observed towards the CQR strain of P. falciparum. This 
is mainly a consequence of low antiplasmodial activity of these compounds in the  
CQ-resistant strain. This was also observed for the monomeric salicylaldimines 3.2 – 3.4 and 
3.9 – 3.11. In the cases where low selectivity was observed, the cytotoxicity of the compounds 
may explain the antiplasmodial data obtained. In addition to intracellular factors, the 
cytotoxicity of these compounds may explain why no simple correlation could be discerned 
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4.3.4. Antiparasitic activity against T. vaginalis 
 
Since most of the non-quinoline based compounds prepared in this study did not exhibit any 
appreciable antiplasmodial activity, these compounds, in addition to the quinoline-containing 
compounds, were screened against the G3 strain of T.vaginalis at a concentration of 50 µM in 
order to evaluate activity against this parasite. The data obtained from this study is presented 
in Figure 4.11. Chloroquine and ferroquine were also evaluated for potential activity. The 
















Figure 4.11: Percentage parasite inhibition of salicylaldimine ferrocenyl ligands (4.5 – 4.7)  
and complexes (4.12 – 4.14), quinoline ferrocenes (4.9 – 4.11), CQ, FQ and M.  
(same coloured pairs represent ligand and corresponding Rh(I) complex) 
 
With the exception of metronidazole and compound 4.9, the tested compounds caused less 
than 50% parasite growth inhibition. Chloroquine exhibited the lowest activity, causing 
approximately 25% parasite growth inhibition. On the other hand, compound 4.9 displayed 
the highest activity by inducing about 79% parasite growth inhibition. The second most active 
compound was 4.10. This compound inhibited parasite growth by about 49%. The ferrocenyl 
salicylaldimine ligands 4.5 – 4.7, inhibited parasite growth modestly. The corresponding 
metal complexes 4.12 – 4.14, exhibited lower activity compared to their respective ligands. 
R = 5-Cl 
R = 3-OMe 
























Compound 4.5 and 4.12, the 5-Cl substituted derivatives, exhibited slightly higher parasite 
growth inhibition compared to the unsubtituted and 3-OMe derivatives. Ferroquine displayed 
similar activity to ferrocenyl ligands 4.5 and 4.6. None of the tested compounds exhibited 
activity comparable to metronidazole at the tested concentration. 
 
The low activity of some of these compounds may be a result of their lipophilicity. Ligands 
4.5 – 4.7 exhibited lipophilicities in the range of 3.12 – 4.04, which is low compared to the 
logP of compound 4.9, the most active compound. The latter has a logP equal to 6.97. Based 
on this, it was expected that compound 4.11 would exhibit enhanced activity due to its high 
lipophilicity (logP = 7.36), but this was not the case. It seemed that the activity of compound 
4.9 may be attributed to the various moieties present in the molecule. This compound contains 
a quinoline, ferrocene as well as a salicylaldimine moiety. Amalgamation of these moieties 
appeared to significantly increase the activity of the compound against this parasite. Evidence 
for this was seen for 4.10 and FQ. These compounds do not contain salicylaldimine moieties 
but do possess quinoline and ferrocene functionalities. These compounds exhibited lower 
activities than compound 4.9. Quinoline salicylaldimines 3.2 – 3.4 (discussed in chapter 3) not 
possessing the ferrocenyl moiety were also less active than compound 4.9, but exhibited 
comparable activity to compound 4.10. The ferrocenyl azines 4.5 – 4.7 and 4.12 – 4.14 also 




New ferrocenyl azines (4.5 – 4.7) containing a (dimethylamino)methyl moiety and their 
respective Rh(I) complexes (4.12 – 4.14) as well as ferrocenyl quinolines (4.9 – 4.11) were 
synthesised and characterised using various spectroscopic and spectrometric techniques. 




C NMR spectroscopy, IR spectroscopy and ESI-mass 
spectrometry. The data suggested formation of the desired compounds. The ferrocenyl azine 
ligands were afforded in moderate to good yields (67 – 88 %), while the complexes were 
afforded in excellent yields (94 – 98%). These ferrocenyl derivatives were prepared in order 
to compare their activity to the non-ferrocenyl salicylaldimines mentioned in chapter 3. 
Compound 4.9 was prepared in order to investigate the effect on activity by combining the 
salicylaldimine, quinoline and ferrocenyl moieties as part of the same system.   
 




A preliminary antiplasmodial screen was conducted against the NF54 CQS and K1 CQR 
strains of P. falciparum. The ferrocenyl azine ligands 4.5 – 4.7 exhibited weak to moderate 
activity across both parasite strains. Upon complexation the activity increased in all cases but 
not sufficiently to compare to CQ and FQ. Quinoline 4.10 displayed good activity in the NF54 
strain but decreased when examined in the resistant strain. Compound 4.9 did not exhibit 
activity at the tested concentration in the sensitive strain, but further tests should be conducted 
in order to quantify its activity. This compound did exhibit increased activity in the resistant 
strain. Compound 4.11 exhibited good activity in the sensitive strain but lower than 4.10, 
possibly a consequence of its lipophilicity. Compounds 4.9 – 4.11 exhibited good activity in 
the resistant strain, giving IC50 values less than 1 µM. Compound 4.10 exhibited similar 
activity to the monomeric salicylaldimines 3.2 – 3.4 in the sensitive strain. Compounds  
4.9 – 4.11 exhibited similar activities to 3.2 – 3.4 in the resistant strain.      
 
The compounds were also screened for their ability to inhibit β-haematin formation using the  
NP-40 detergent mediated assay. The quinoline-based derivatives exhibited the highest  
β-haematin inhibition activity. Specifically, compound 4.11 displayed the highest activity. 
Compound 4.9 exhibited similar activity to CQ, while 4.10 was slightly more active. The 
ferrocenyl azines 4.5 – 4.7 and 4.12 – 4.14 showed weak β-haematin inhibition activity (IC50 
values > 90 µM) but compounds possessing the 5-Cl substituent exhibited slightly higher 
activity to those that did not have this group. There did not appear to be a simple correlation 
between β-haematin inhibition activity and antiplasmodial activity, but the most potent 
antiplasmodials (quinoline-based) exhibited higher β-haematin inhibition activity than the 
non-quinolines, which were less active in the parasite.     
 
The compounds were tested against the WHCO1 cancer cell-line. All of the quinoline-based 
compounds exhibited activity against this cell-line, including CQ and FQ. Only one of the 
ferrocenyl azines (4.12) displayed activity at the tested concentration. Compound 4.10 
exhibited the highest cytotoxicity. CQ and FQ showed high selectivity towards the NF54 CQS 
strain compared to the WHCO1 cell-line. Compounds 4.10 and 4.11 exhibited moderate 
selectivity towards the NF54 strain, while 4.12 did not exhibit selectivity towards malarial 
parasites. Based on this data, it appears that the antiplasmodial activity may be a result of the 
cytotoxicity of some of these compounds. 
 




Lastly, the compounds were screened against the G3 strain of T. vaginalis. All of the 
compounds, with the exception of 4.9, exhibited less than 50% parasite growth inhibition. 
Comparing the activity of the ferrocenyl azine ligands (4.5 – 4.7) and complexes, the 
complexes (4.12 – 4.14) exhibited slightly lower activity than their respective ligands. The 
ferrocenyl azines exhibited lower lipophilicity, which may have been the reason for their low 
activity. The 5-Cl substituent appeared to slightly enhance the activity of the ferrocenyl 
azines. Compound 4.9 displayed the highest activity and also a calculated logP of 6.97. The 
combination of the quinoline, ferrocene and salicylaldimine moieties, in addition to its higher 
lipophilicity, appeared to have a favourable effect on parasite growth inhibition compared to 
the rest of the compounds. The activity of this compound was also greater than the activity 
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Conclusions and future outlook 
5.1. Conclusions  
 
The aim of this project was to prepare various quinoline and non-quinoline based monomeric 
and multimeric compounds as potential antiplasmodial agents. Specifically, various amines 
and polyamines were incorporated as part of these systems. Mono- and multimeric quinoline 
and ferrocenyl-based thioureas were synthesised by template procedures. Mono- and dimeric 
salicylaldimine ligands containing a quinoline moiety and corresponding Rh(I) complexes 
were also prepared by straightforward synthetic procedures. In addition to this, ferrocenyl 
quinolines as well as ferrocenyl-containing salicylaldimines were synthesised. Selected Rh(I) 







H} NMR spectroscopy, infrared spectroscopy and mass spectrometry.    
 
All compounds were screened for antiplasmodial activity against the NF54 CQS strain of P. 
falciparum. In addition to this, the compounds were either screened against the Dd2 or K1 
CQR strains of P. falciparum. P. falciparum is the most deadly causative parasite of malaria. 
In most cases, compounds possessing the quinoline moiety showed moderate to good activity 
against the CQS strain of P. falciparum. In many cases, however, the compounds exhibited 
lower activity in the CQR strain. This was observed for the monomeric salicylaldimine 
ligands and complexes. This phenomenon was less severe for the quinoline-based thioureas. 
In the case where the compound possessed the quinoline, ferrocene and salicylaldimine 
motifs, enhanced activity was observed in the CQR strain compared to the sensitive strain. 
With regards to the dimeric salicylaldimine ligands and complexes, it was found that 
incorporating the second salicylaldimine moiety did not favourably affect the antiplasmodial 
activity. Incorporation of the metal also did not appear to have a large influence on activity. 
The lower activity of the dimeric compounds may have been a consequence of their increased 
lipophilicity. Molecules that are too lipophilic may not accumulate sufficiently inside of the 
digestive vacuole due to strong interactions with cell membranes. These compounds did 
however show similar activity in both the CQS and CQR strains of P. falciparum, indicating 
that these compounds may be able to circumvent CQ resistance. Generally, compounds that




did not possess the quinoline motif, specifically the ferrocenyl azines, exhibited weak 
antiplasmodial activity compared to those that did.  
 
Some of the prepared compounds were potent β-haematin inhibitors. The most potent 
compounds were those containing more than one quinoline moiety. The most potent being the 
tetrameric quinoline thiourea. Increasing size and lipophilicity appeared to enhance  
β-haematin inhibition activity. Surprisingly, two non-quinoline based ferrocenyl thioureas 
showed moderate β-haematin inhibition activity, this may be attributed to the increased 
lipophilicity of these compounds. In the case of the salicylaldimine compounds, the dimeric 
salicylaldimines exhibited higher activity than the monomeric derivatives. Also the 
mononuclear Rh(I) complexes exhibited greater activity than their corresponding monomeric 
salicylaldimine ligands. This suggests that incorporation of the lipophilic COD moiety 
enhances activity. This could also be attributed to the planar nature of the Rh(I) metal ion. 
The non-quinoline salicylaldimine ferrocenes weakly inhibited β-haematin formation, but the 
quinoline-containing ferrocenyl compounds exhibited higher activity. Generally, compounds 
possessing the 5-Cl substituent exhibited slightly better activity than the unsubstituted 
derivatives and the derivatives containing the 3-OMe group. No correlation between 
antiplasmodial activity and β-haematin inhibition activity could be established but the most 
active compounds in the parasite displayed higher β-haematin inhibition activity. This was 
mainly attributed to the different conditions used for the two assays (since the β-haematin 
inhibition assay is conducted in a cell-free medium).  
 
The compounds were also screened against the WHCO1 oesophageal cancer cell-line. This 
was conducted in order to elucidate information about the toxicity of the compounds. Two of 
the quinoline-based thioureas were cytotoxic, showing IC50 values < 10 µM, the tetrameric 
derivative was the most cytotoxic. The ferrocenyl thioureas did not exhibit high cytotoxicity. 
The salicylaldimine quinolines also displayed cytotoxicity in the low micromolar range. The 
monomeric salicylaldimine quinolines appeared to be more selective towards the NF54 strain 
of the P. falciparum compared to cancer cells. The antimalarial activity of the dimeric 
compounds may be a consequence of their cytotoxicity since these compounds exhibited 
similar antiplasmodial and anticancer activity. The most cytotoxic thiourea and 
salicylaldimine compound were tested against KMST-6 human fibroblast. This was to gauge 
the toxicity of these compounds in normal cells. Both compounds were weakly cytotoxic in 




this particular cell-line. This suggested selectivity of the afore-mentioned towards cancer 
cells. The ferrocenyl quinoline-based compounds all exhibited cytotoxicity against the 
WHCO1 cell-line, while the ferrocenyl azines were inactive against this cell-line. The activity 
of the quinoline compounds may be a consequence of their ability to interact with DNA by 
intercalation or their ability to generate free radicals. It appears that the antiplasmodial 
activity of some of these compounds may also be a consequence of their cytotoxicity.  
 
The compounds were also evaluated for antiparasitic activity against T. vaginalis. In the case 
of the thioureas, the ferrocenyl compounds exhibited slightly enhanced activity compared to 
the quinoline-based thioureas. The most effective compound that inhibited parasite growth 
was the tetrameric ferrocenyl thiourea. The dimeric derivative was slightly less effective. 
Only one of the quinoline-based ferrocenyl compounds exhibited good activity against this 
parasite. The combination of the salicylaldimine, ferrocene and quinoline motifs resulted in 
enhanced activity compared to compounds not possessing all three of these moieties. 
Compounds possessing the 5-Cl moiety in the quinoline-based and non-quinoline 
salicylaldimines exhibited enhanced parasite growth inhibition. This further confirmed the 
importance of this electron withdrawing group on antiparasitic activity, specifically against 
this parasite. In addition to this, increased lipophilicity appeared to be another factor that 
contributes favourably towards activity against this parasite. Cytotoxicity may also play a role 
in the activity of these compounds against this strain. For example, the most cytotoxic 
binuclear Rh(I) salicylaldimine complex exhibited high parasite growth inhibition activity as 
well. This has also been observed for other compounds.  
 
5.2. Future outlook                 
 
Based on the data provided, some suggestions regarding future work can be made.  
 
Firstly, it is clear that the quinoline motif remains essential for potent antiplasmodial activity 
and should still be considered when designing alternative antimalarial therapies due to its 
ability to strongly inhibit β-haematin formation.  
 
Secondly, incorporation of polyamines as part of quinoline-containing systems may be 
advantageous in diminishing cross-resistance. Careful attention must be paid to the number of 




quinoline moieties incorporated. Too many, may result in an unwanted increase in the toxicity 
of the compounds, making them less suitable antiplasmodial agents.     
 
The lipophilicity of the compounds is also important to consider. Incorporating ferrocene 
alters the lipohilicity of compounds and in the case of ferroquine (and some of the compounds 
prepared in this study), results in consistent activity across sensitive and resistant strains. 
Incorporation of polyamines may result in increased lipophilicity of the compounds and this 
may lower accumulation of the compound inside of the digestive vacuole but to remedy this, 
water-soluble groups can be incorporated as part of these systems, which may counteract this 
effect and result in enhanced activity of the compound. The compound depicted in Figure 5.1 

















Figure 5.1: Rationale that can be used in the design of potential antimalarials 
 
Some of the compounds prepared in this study exhibited high cytotoxicity especially in the 
case of the multimeric thioureas. In the case of the tetrameric thiourea, activity decreased 
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when screened against normal cells. This suggests selectivity toward the oesophageal cancer 
cell-line. The next step would be to screen this compound against various other normal and 
cancer cell-lines to establish a cytotoxicity profile. The mode of action of this complex can be 
ascertained by performing DNA-binding studies (i.e. viscosity experiments, DNA denaturing 
studies, UV absorption studies), since quinoline compounds have been known to intercalate 
with this biomolecule.   
 
Further work regarding the antiparasitic activity of the 5-Cl salicylaldimine Rh(I) complex 
against T. vaginalis should be carried out in order establish its possible target in the parasite. 
A more detailed structure-activity study should also be performed using various derivatives of 
the ferrocenyl compound containing the salicylaldimine and quinoline groups in order to gain 







All reagents and solvents were obtained from commercial sources (Sigma-Aldrich, Merck, 





 were prepared according to literature procedures.
 
Nuclear 
magnetic resonance (NMR) spectra were recorded using a Varian Mercury 300 spectrometer 
(
1











H} at 100.577 MHz) or a Bruker 400 FT spectrometer (
1





H} at 100.600 MHz) at 30.0°C. Coupling constants are reported in Hz. Infrared 
(IR) spectra were determined using a Perkin Elmer Spectrum 100 FT-IR spectrometer and was 
carried out in the solid state using KBr pellets or using Attenuated Total Reflectance (ATR). 
In some cases, samples were analysed as neat oils using NaCl cells. Low resolution and high 
resolution (HR) ESI-mass spectrometry was used to further characterise new compounds and 
determinations were carried out using a Waters API Quattro instrument in the positive mode. 
EI mass spectrometry was used to confirm the molecular weights of new compounds and 
samples were analysed using a JEOL GCmateII apparatus. Melting points were recorded 
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6.2. Experimental details for Chapter 2 
 





















4,7-Dichloroquinoline (0.978 g, 4.94 mmol) and 1,3-propanediamine (2.1 ml) were heated to 
80 °C in a flask with gentle stirring. This was continued for 1 hour and the temperature was 
then increased to 139 °C and stirring continued for 4 hours. The product was cooled to room 
temperature and 1 N NaOH (10 ml) was added. The mixture was then extracted with DCM  
(5 x 50 ml). The organic layer was then washed with H2O (2 x 50 ml) and dried over MgSO4. 
Evaporation of the solvent results in a beige powder as the desired product 2.1 (1.00 g, 86%). 
1
H NMR (300.066 MHz, CD3OD-d4): (δ, ppm) 1.88 (2H, m, H-3’); 2.78 (2H, t, 
3
JH-H = 6.96, 
H-4’); 3.40 (2H, t, 
3
JH-H = 6.70, H-2’); 6.49 (1H, d, 
3





JH-H = 2.19, H-6); 7.75 (1H, d, 
4
JH-H = 2.15, H-8); 8.04 (1H, d, 
3
JH-H = 9.03, H-5); 8.32 
(1H, d, 
3
JH-H = 5.65, H-2). IR (KBr): (vmax/cm
−1
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To a cooled solution of KOH (0.317 g, 5.64 mmol) in H2O (15 ml), isopropanol (10 ml) and 
DMSO (5 ml), compound 2.1 (1.11 g, 4.70 mmol) was added. Ice-cooled CS2 (0.34 ml) was 
added dropwise over a 1 hour period (< 10 °C) whilst stirring. The mixture was stirred for an 
additional 2 hour period at room temperature. Ice-cooled iodomethane (0.35 ml) was added 
dropwise over 1.5 hour period and stirred for a further 1.5 hours at room temperature. The 
cream precipitate was then collected by filtration, washed with water and dried in vacuo, 
giving rise to a pale yellow powder as the desired compound (2.2) (0.891 g, 58%). 
1
H NMR 
(400.220 MHz, DMSO-d6): (δ, ppm) 2.01 (2H, m, H-3’); 2.46 (3H, s, H-8’); 3.36 (2H, m,  
H-4’); 3.75 (2H, m, H-2’); 6.44 (1H, d, 
3
JH-H = 5.60, H-3); 7.31 (1H, br s, NH); 7.39 (1H, dd, 
3
JH-H = 8.98, 
4
JH-H  = 2.20, H-6); 7.74 (1H, d, 
4
JH-H = 2.19, H-8); 8.17 (1H, d, 
3
JH-H = 9.04, 
H-5); 8.33 (1H, d, 
3
JH-H = 5.52, H-2), 9.95 (1H, s, NH). IR (KBr): (vmax/cm
−1
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Mono-quinoline thiourea  (2.3) 
 


























Compound 2.2 (0.354 g, 1.09 mmol) was dissolved in MeOH (20 ml), to this n-propylamine 
(0.15 ml) was added dropwise with stirring. The solution was refluxed for 24 hours and 
cooled to room temperature. The solvent was removed in vacuo and diethyl ether added to the 
residue. The residue was washed with diethyl ether and the supernatant decanted. This was 
repeated until the supernatant remained clear. The oily residue was dried under vacuum giving 
rise to the desired product (2.3) as a cream solid (0.220 g, 60%). 
1
H NMR (300.066 MHz, 
DMSO-d6): (δ, ppm) 0.86 (3H, t, 
3
JH-H = 7.36, H-10’); 1.49 (2H, m, H-9’); 1.90 (2H, m,  
H-3’); 3.30 (4H, m, H-4’ and H-8’); 3.52 (2H, m, H-2’); 6.47 (1H, d, 
3
JH-H = 5.45, H-3); 7.19 
(1H, br s, NH); 7.35 (2H, m, NH); 7.42 (1H, dd, 
3
JH-H = 8.99, 
4
JH-H = 2.24, H-6); 7.80 (1H, d, 
4
JH-H = 2.20, H-8); 8.24 (1H, d, 
3
JH-H = 9.03, H-5); 8.40 (1H, d, 
3





NMR (75.454 MHz, DMSO- d6): (δ, ppm) 11.10 (C-10’); 21.85 (C-9’); 27.59 (C-3’); 40.34 
(C-4’); 41.13 (C-2’); 45.10 (C-8’); 98.51 (C-3); 117.37; 123.82 (C-5, C-6); 127.36 (C-8); 
133.19; 148.98; 149.87; 151.72 (C-2); 181.99 (C-6’). IR (KBr): (vmax/cm
−1
) 3435 (N-H); 
1613 (C=N); 1136 (C=S). ESI-MS: m/z 337.1248 (100%, [M+H]
+
). Elemental Analysis 
C16H21ClN4S
.
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Compound 2.2 (1.49 g, 4.56 mmol) was dissolved in MeOH (20 ml), to this  
1,3-propanediamine (0.13 ml) was added dropwise with stirring. The solution was refluxed 
for 24 hours and cooled to room temperature. The solvent was removed in vacuo and acetone 
added to the residue. The mixture was washed with acetone and the supernatant decanted. 
This was repeated until the supernatant remained clear. The gummy matter was then washed 
with diethyl ether to remove the acetone. The diethyl ether was then decanted and the residue 
dried under vacuum giving rise to the product (2.4) as a beige powder (0.818 g, 85%). M.p. 
109 - 111°C.
 1
H NMR (300.066 MHz,  DMSO-d6): (δ, ppm) 1.73 (2H, m, H-9’); 1.90 (4H, 
m, H-3’); 3.30 (4H, m, H-8’); 3.40 (4H, m, H-4’); 3.51 (4H, m, H-2’); 6.46 (2H, d, 
3
JH-H = 
5.44, H-3); 7.19 (2H, m, NH); 7.37-7.47 (6H, m, NH, 6’); 7.77 (2H, d, 
4
JH-H = 2.14, H-8); 
8.24 (2H, d, 
3
JH-H = 9.03, H-5); 8.40 (2H, d, 
3




H} NMR (75.454 MHz, 
DMSO-d6): (δ, ppm)  27.41 (C-3’); 28.51 (C-9’); 40.79-40.93 (C-2’, C-4’, C-8’); 98.45 (C-3); 
117.18; 123.67 (C-5); 123.88 (C-6); 127.03 (C-8); 133.31; 148.66; 149.87; 151.60 (C-2); 
181.68 (C-6’). IR (KBr): (vmax/cm
−1







). Elemental Analysis 
C29H34Cl2N8S2
.
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Compound 2.2 (0.415 g, 1.27 mmol) was dissolved in MeOH (20 ml), to this  
tris(2-aminoethyl)amine (0.06 ml) was added dropwise with stirring. The solution was 
refluxed for 24 hours and cooled to room temperature. The solvent was removed in vacuo 
giving rise to a pale orange solid. The solid was washed with acetone and the supernatant 
decanted. This was repeated until the supernatant remained clear.  The residue was washed 
with diethyl ether, the ether was then decanted and the product dried under vacuum. The 
product (2.5) was isolated as a cream-yellow solid (0.242 g, 58%). M.p. 134 - 136°C. 
1
H 
NMR (300.066 MHz,  CD3OD-d4): (δ, ppm) 1.96 (6H, m, H-3’); 2.66 (12H, m, H-4’, H-9’); 
3.44-3.74 (12H, m, H-2’, H-8’); 6.44 (3H, m, H-6); 7.31 (3H, m, H-6); 7.71 (3H, m, H-8); 




H} NMR (75.454 MHz, DMSO-d6): (δ, ppm) 
27.49 (C-3’); 41.13 (C-4’); 41.58 (C-2’); 52.92 (C-8’); 54.41 (C-9’); 98.46 (C-3); 117.33; 
123.75 (C-5, C-6); 127.29 (C-8); 133.12; 148.92; 149.81; 151.64 (C-2); 182.23 (C-6’). IR 
(KBr): (vmax/cm
−1





). Elemental Analysis C45H54Cl3N13S3
.
3H2O calculated: C 52.29, H 
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Tetra-quinoline thiourea  (2.6) 














































Compound 2.2 (0.888 g, 2.72 mmol) and G1 DAB dendrimer (0.164 g, 0.518 mmol) were 
combined in MeOH (20 ml). The solution was refluxed for 24 hours and cooled to room 
temperature. The supernatant was decanted giving a yellow oily residue which was dried in 
vacuo. The residue was washed with acetone, followed by diethyl ether. The supernatant was 
decanted and the oil dried under vacuum giving rise to the product (2.6) as a cream powder 
(92.0 mg, 12%). M.p. 115 - 117°C. 
1
H NMR (300.066 MHz, DMSO-d6): (δ, ppm) 1.32 (4H, 
m, H-12’); 1.59 (8H, m, H-9’); 1.89 (8H, m, H-3’); 2.35 (12H, m, H-10’, H-11’); 3.21-3.45 
(16H, m, H-4’ and H-8’); 3.50 (8H, m, H-2’); 6.44 (4H, br d, 
3
JH-H = 5.45, H-3); 7.19 (4H, br 
s, NH); 7.41 (12H, m, NH, H-6); 7.77 (4H, d, 
4
JH-H = 2.15, H-8); 8.25 (4H, m, H-5); 8.38 (4H, 
d, 
3




H} NMR (100.600 MHz, d6-DMSO): (δ, ppm) 24.73 (C-12’); 
26.78 (C-9’); 28.07 (C-3’); 41.42-42.87 (C-2’, C-4’, C-8’); 51.57 (C-10’); 53.75 (C-11’); 
99.10 (C-3); 117.96; 124.47 (C-5, C-6); 127.95 (C-8); 133.82; 149.55; 150.45; 152.33 (C-2); 
182.28 (C-6’). IR (KBr): (vmax/cm
−1
) 3272 (N-H); 1611 (C=N); 1138 (C=S). ESI-MS: m/z 
1429 (70%, [M+H]
+
). Elemental Analysis C68H88Cl4N18S4
.
5H2O calculated: C 53.81, H 6.51, 
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To a cooled solution of KOH (5.98 g, 0.107 mmol) in H2O (25 ml), isopropanol (25 ml), 
NH2NH2
.
H2O (3.32 ml) was added. Ice-cooled CS2 (6.44 ml) was added dropwise whilst 
stirring giving rise to a yellow solution. The mixture was stirred for an additional 2.5 hour 
period at room temperature. Ice-cooled iodomethane (6.64 ml) was added dropwise over a 1 
hour period and stirred for a further 1.5 hours at room temperature. The precipitate was then 
collected by filtration, washed with water and dried in vacuo, giving rise to a cream powder as 
the product 2.7 (4.17 g, 32%).
 1
H NMR (300.066 MHz, DMSO-d6): (δ, ppm) 2.36 (3H, s,  
H-1); 5.02 (2H, s, NH2); 10.73 (1H, br s, NH). IR (KBr): (vmax/cm
−1






















1,2-Diaminopropane (1.68 mL, 25.0 mmol) was added to NaOH (2.16 g, 49.0 mmol) in water 
(40 ml). To this solution, CS2 (4.50 ml, 75.0 mmol) was added and the mixture stirred for 4 
hours, after which the organic layer disappeared. The solution was treated with sodium 
chloroacetate (5.77 g, 49.5 mmol) and the mixture was stirred for a further 16 hours at room 
temperature. The yellow solution was then acidified with 2 M HCl (5 ml) and an excess of 





H2O (11 ml) was added. The mixture was heated at 90 °C for 2 hours. The 
precipitate that was formed was collected by filtration, washed with water and dried in vacuo. 
The product (2.8) was isolated as a white powder (2.07 g, 40%). 
1
H NMR (399.953 MHz, 
DMSO-d6): (, ppm) 3.63 (4H, s, H-1); 4.41 (4H, s, NH2); 7.97 (2H, s, NH); 8.50 (2H, s, 
NH). 
 
















Methyl hydrazinecarbodithioate 2.7 (0.156 g, 1.28 mmol) was suspended in iPrOH (15 ml) 
and treated with ferrocenecarboxaldehyde (0.274 g, 1.29 mmol) at room temperature. The 
resulting solution was stirred for 24 hours at room temperature. The resulting precipitate was 
filtered and washed with cold iPrOH. The product (2.9) was isolated as a red powder (0.356 g, 
87%). 
1
H NMR (399.935 MHz, DMSO-d6): (δ, ppm) 2.50 (3H, m, H-1); 4.24 (5H, s, 
Cpunsub); 4.51 (2H, m, Cpsub H-6); 4.67 (2H, m, Cpsub H-5); 8.12 (1H, s, H-3); 12.98 (1H, br s, 
NH). IR (KBr): (vmax/cm
−1
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Compound 2.9 (0.197 g, 0.618 mmol) was suspended in EtOH (20 ml). n-Propylamine (0.06 
ml) was added to the suspension and the resulting solution was refluxed under Argon for 12 
hours. The solvent was removed in vacuo and the residue dissolved in DCM (15 ml). The 
organic layer was washed with water until the water layer remained clear. The solvent was 
removed in vacuo and the residue was dissolved in a minimum amount of diethyl ether. To 
this, petroleum ether was added and the product was allowed to precipitate at -20°C. The 
product (2.10) was isolated as a red-brown powder (62.0 mg, 30%). M.p. 98 - 101°C. 
1
H 
NMR (399.953, DMSO-d6): (δ, ppm) 0.86 (3H, t, 
3
JH-H = 7.50, H-1); 1.59 (2H, m, H-2); 3.49 
(2H, m, H-3); 4.21 (5H, s, Cpunsub); 4.42 (2H, m Cpsub H-8); 4.72 (2H, m, Cpsub H-7); 7.89 




H} NMR (100.635 MHz,  
DMSO-d6): (δ, ppm) 11.69 (C-1); 22.68 (C-2); 45.54 (C-3); 68.02 (C-8); 69.40 (Cpunsub); 
70.43 (C-7); 79.59 (C-6); 143.45 (C-5); 176.75 (C-4). IR (KBr): (vmax/cm
−1
) 3371 (N-H); 
3129 (N-H); 1604 (C=N); 816 (C=S); 1090 (ferrocene). ESI-MS: m/z 330.0724 (100%, 
[M+H]
+
). Elemental Analysis C15H19FeN3S calculated: C 54.72, H 5.82, N 12.76%; found: C 



































Ethane-1,2-dithiosemicarbazide 2.8 (0.160 g, 0.767 mmol) was suspended in H2O (25 ml). To 
this, a few drops of 10.1 M HCl was added. Ferrocenecarboxaldehyde (0.331 g, 1.55 mmol) 
was added to the suspension and the reaction mixture stirred for 24 hours at room 
temperature. The precipitate was filtered, washed with water and dried in vacuo. The product 





H NMR (300.066 MHz, DMSO-d6): (δ, ppm) 3.78 (4H, s, H-1); 4.17 (10H, s, 
Cpunsub); 4.39 (4H, t, 
3
JH-H = 1.83, Cpsub H-6); 4.74 (4H, t, 
3
JH-H = 1.84, Cpsub H-5); 7.90 (2H, 




H} NMR (100.635 MHz, DMSO-d6): 
(δ, ppm) 44.01 (C-1); 68.19 (C-6); 69.43 (Cpunsub); 70.49 (C-5); 79.43 (C-4); 143.96 (C-3); 
177.23 (C-2). IR (KBr): (vmax/cm
−1
) 3437 (N-H); 3267 (N-H); 1611 (C=N); 816 (C=S).  
ESI-MS: m/z 601.0582 (100%, [M+H]
+
). Elemental Analysis C26H28Fe2N6S2
.
H2O 
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Tris-ferrocene thiourea (2.12) 
























Compound 2.9 (0.506 g, 1.59 mmol) was suspended in absolute EtOH (20 ml) under argon. 
To this mixture, tris(2-aminoethyl)amine (0.08 ml) was added dropwise and the resulting 
solution refluxed for 24 hours. The solution was cooled to room temperature, and the solvent 
removed under reduced pressure. The residue was dissolved in DCM (15 ml) and extracted 
with water until the aqueous layer was clear. The organic extract was evaporated to dryness 
giving rise to the product (2.12) as a red powder (0.226 g, 46%). M.p. 124 - 127 °C. 
1
H NMR 
(300.066 MHz, DMSO-d6): (δ, ppm) 2.83 (6H, m, H-1); 3.71 (6H, m, H-2); 4.18 (15H, s, 
Cpunsub); 4.41 (6H, m, Cpsub H-7); 4.69 (6H, m, Cpsub H-6); 7.90 (3H, s, H-4); 8.15 (3H, br s, 




H} NMR (100.635 MHz, DMSO-d6): (δ, ppm) 43.37 (C-2); 
53.27 (C-1); 68.03 (C-7); 69.44 (Cpunsub); 70.51 (C-6); 79.42 (C-5); 143.70 (C-4); 176.73  
(C-3). IR (KBr): (vmax/cm
−1
) 3431 (N-H); 3366 (N-H); 1606 (C=N); 818 (C=S); 1103 
(ferrocene). ESI-MS: m/z 957.1362 (70%, [M+H]
+
). Elemental Analysis C42H48Fe3N10S3 
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6.3. Experimental details for Chapter 3 
6.3.1. Synthetic methods and characterisation of 4-amino-7-chloroquinoline mono-
imines 3.2 – 3.4 
6.3.1.1. General method to prepare ligands 3.2 – 3.4 
(N’-(7-Chloroquinolin-4-yl)-propane-1,3-diamine) (2.1) was suspended in diethyl ether (10 
ml). To this, a slight excess of the desired salicylaldehyde in diethyl ether (10 ml) was added 
dropwise and the resulting mixture stirred at room temperature for 16 hours. The resulting 
precipitate was filtered using a Büchner funnel and washed with diethyl ether to remove 
excess aldehyde. The product was then dried in vacuo. 
Mono-5-chlorosalicylaldimine quinoline (3.2)  





















8 1  
N’-(7-Chloroquinolin-4-yl)-propane-1,3-diamine (2.1) (0.329 g, 1.40 mmol) was reacted with 
5-chlorosalicylaldehyde (0.263 g, 1.68 mmol). The product (3.2) was obtained as a pale 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 
2.18 (2H, m, H-2’); 3.46 (2H, m, H-1’); 3.78 (2H, t, 
3
JH-H = 6.44, H-3’); 5.07 (1H, br s, NH); 
6.40 (1H, d, 
3
JH-H = 5.38, H-3); 6.91 (1H, d, 
3
JH-H = 8.80, H-9’) ; 7.17 (1H, d, 
4
JH-H = 2.58,  
H-6’); 7.24-7.33 (2H, m, H-6, H-8’); 7.61 (1H, d,  
3
JH-H = 8.94, H-5); 7.94 (1H, d, 
4
JH-H = 
2.13, H-8); 8.30 (1H, s, H-4’); 8.52 (1H, d, 
3





NMR (100.635  MHz, CDCl3): (δ, ppm) 29.92 (C-2’); 41.28 (C-1’); 57.35 (C-3’); 99.13  
(C-3); 117.12; 118.59 (C-9’); 119.33; 120.71 (C-5); 123.48; 125.45 (C-6); 128.88 (C-8); 
130.45 (C-6’); 132.38 (C-8’); 134.97; 149.13; 149.46; 151.98 (C-2); 159.53; 164.65 (C-4’). 
IR (KBr): (vmax/cm
−1
) 3238 (N-H); 1637 (C=N); 1615 (C=N) quinoline. ESI-MS: m/z 
374.0824 (100%, [M+H]
+
). Elemental Analysis C19H17Cl2N3O calculated: C 60.97; H 4.58; 
N 11.23%, found: C 61.11; H 4.88; N 11.33%.  
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Mono-3-methoxysalicylaldimine quinoline (3.3)  

























N’-(7-Chloroquinolin-4-yl)-propane-1,3-diamine (2.1) (0.231 g, 0.979 mmol) was reacted 
with o-vanillin (0.165 g, 1.08 mmol). The product (3.3) was obtained as a yellow powder 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 2.16 (2H, m, 
H-2’); 3.47 (2H, m, H-1’); 3.76 (2H, t, 
3
JH-H = 6.76, H-3’); 3.91 (3H, s, H-11’); 5.12 (1H, br s, 
NH); 6.40 (1H, d, 
3
JH-H = 5.39, H-3); 6.81 (2H, m, H-8’, H-7’); 6.94 (1H, m, H-6’); 7.28 (1H, 
dd,  
4
JH-H = 2.17, 
3
JH-H  = 8.94, H-6); 7.63 (1H, d, 
3
JH-H  = 8.99, H-5); 7.92 (1H, d, 
4
JH-H  = 2.14, 
H-8); 8.35 (1H, s, H-4’); 8.50 (1H, d, 
3





(100.635 MHz, CDCl3): (δ, ppm) 29.96 (C-2’); 41.25 (C-1’); 56.16 (C-11’); 56.97 (C-3’); 
99.12 (C-3); 114.33 (C-8’); 117.18; 118.29 (C-7’); 118.50; 120.89 (C-5); 122.93 (C-6’); 
125.33 (C-6); 128.82 (C-8); 134.86; 148.48; 149.18; 149.52; 151.50; 152.04 (C-2); 165.86  
(C-4’). IR (KBr): (vmax/cm
−1
) 3424 (N-H); 1631 (C=N); 1611 (C=N) quinoline. ESI-MS: m/z 
370.1319 (100%, [M+H]
+
). Elemental Analysis C20H20ClN3O2
.
2H2O calculated: C 59.19; H 
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Mono-salicylaldimine quinoline (3.4)  




















8 1  
N’-(7-Chloroquinolin-4-yl)-propane-1,3-diamine (2.1) (0.644 g, 2.73 mmol) was reacted with 
salicyladehyde (0.337 g, 2.76 mmol). The product (3.4) was obtained as a pale yellow powder 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 2.18 (2H, m, 
H-2’); 3.47 (2H, m, H-1’); 3.77 (2H, t, 
3
JH-H  = 6.71, H-3’); 5.10 (1H, br s, NH); 6.40 (1H, d, 
3
JH-H  = 5.37, H-3); 6.88 (1H, td, 
4
JH-H  = 1.09, 
3
JH-H  = 7.53, H-7’); 6.98 (1H, d, 
3
JH-H  = 8.30, 
H-9’); 7.21 (1H, dd,  
4
JH-H  = 1.69, 
3
JH-H  = 7.65, H-6’); 7.28 (1H, dd, 
4
JH-H  = 2.19, 
3
JH-H  = 
8.93, H-6); 7.33 (1H, m, H-8’); 7.61 (1H, d, 
3
JH-H  = 8.96, H-5); 7.94 (1H, d, 
4
JH-H  = 2.16, H-
8); 8.38 (1H, s, H-4’); 8.52 (1H, d, 
3





(100.635 MHz, CDCl3): (δ, ppm) 30.11 (C-2’); 41.48 (C-1’); 57.40 (C-3’); 99.15 (C-3); 
117.06 (C-9’); 117.24; 118.71; 118.81 (C-7’); 120.67 (C-5); 125.36 (C-6); 129.01 (C-8); 
131.31 (C-6’); 132.52 (C-8’); 134.90; 149.35; 149.49; 152.03 (C-2); 161.03; 165.83 (C-4’). 
IR (KBr): (vmax/cm
−1
) 3260 (N-H); 1634 (C=N); 1613 (C=N) quinoline. EI-MS: m/z 
339.0903 (87%, [M]
+
). Elemental Analysis C19H18ClN3O calculated: C 67.15; H 5.33; N 
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6.3.2. Synthetic methods and characterisation of 4-amino-7-chloroquinoline bis-imines 
3.1 and 3.5 – 3.7  
N-(7-Chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1)
9 





















A mixture of 4,7-dichloroquinoline (0.588 g, 2.97 mmol) and tris(2-aminoethyl)amine (5 ml) 
was heated to 90 °C for 7 hours with stirring. The reaction was quenched with 1N NaOH (20 
ml) and extracted with DCM (3 x 50 ml), followed by brine. The combined organic layers 
were dried using anhydrous MgSO4. The drying agent was filtered off and the solvent 
removed in vacuo to give an orange semi-solid (3.1) (0.576 g, 63%). 
1
H NMR (399.951, 
CDCl3): (δ, ppm) 1.48 (4H, br s, NH2); 2.47-2.60 (4H, m, H-1”); 2.65-2.83 (6H, m, H-2”,  
H-2’); 3.26 (2H, m, H-1’); 6.30 (1H, d, 
3
JH-H  = 5.40, H-3); 6.64 (1H, br s, NH); 7.25 (1H, dd, 
4
JH-H  = 2.73, 
3
JH-H  = 8.91, H-6); 7.82-7.94 (2H, m, H-5, H-8); 8.45 (1H, d, 
3
JH-H  = 5.37, H-2).  
 
6.3.2.1 General method to prepare ligands 3.5 – 3.7 
N-(7-Chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) was dissolved in EtOH (5 ml). To 
this, the appropriate aldehyde in EtOH (10 ml) was added and the resulting solution stirred at 
room temperature for 16 hours. The solvent was removed under reduced pressure and the 
residue washed continuously with diethyl ether. The resulting solid was then dried in vacuo. 
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Bis-5-chlorosalicylaldimine quinoline (3.5)  





























N-(7-Chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) (0.105 g, 0.339 mmol) was reacted 
with 5-chlorosalicylaldehyde (0.117 g, 0.747 mmol). The product (3.5) was isolated as a 




H NMR (399.951, CDCl3): (δ, ppm) 2.83 
(2H, m, H-2’); 2.88 (4H, m H-1”); 3.31 (2H, m, H-1’); 3.57 (4H, m, H-2”); 5.96 (1H, br s, 
NH);  6.26 (1H, d, 
3
JH-H  = 5.53, H-3); 6.61 (2H, d, 
3
JH-H  = 8.81, H-8”); 6.67 (1H, dd, 
4
JH-H  = 
2.04, 
3
JH-H  = 8.86, H-6); 6.72 (2H, d, 
4
JH-H  = 2.61, H-5”); 7.09-7.12 (3H, m, H-5, H-7”); 7.84 
(1H, d, 
4
JH-H  = 2.11, H-8); 7.99 (2H, s, H-3”); 8.37 (1H, d, 
3





(100.635 MHz, DMSO-d6): (δ, ppm) 41.28 (C-1’); 52.62 (C-2’); 54.88 (C-1”); 56.36 (C-2”); 
99.22 (C-3); 117.50; 119.37 (C-8”); 119.51; 121.68; 124.05 (C-5); 124.74 (C-6); 127.15  
(C-8); 130.78 (C-5”); 132.53 (C-7”); 134.26; 148.37; 150.76; 151.39 (C-2); 161.27; 165.58 
(C-3”). IR (KBr): (vmax/cm
−1
) 3312 (N-H); 1648 (C=N); 1609 (C=N) quinoline. ESI-MS: m/z 
584.1404 (30%, [M+H]
+
); 292.5737 (100%, [M+2H]
2+
). Elemental Analysis 
C29H28Cl3N5O2
.
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Bis-3-methoxysalicylaldimine quinoline (3.6)  































N-(7-Chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) (0.199 g, 0.647 mmol) was reacted 
with o-vanillin (0.197 g, 1.293 mmol). The product (3.6) was filtered and isolated as a yellow 




H NMR (399.951, CDCl3): (δ, ppm) 2.89-2.99 
(6H, m, H-2’, H-1”); 3.42 (2H, m, H-1’); 3.64 (4H, m, H-2”); 3.84 (6H, s, H-10”); 6.34 (1H, 
d, 
3
JH-H  = 6.25, H-3); 6.49-6.58 (4H, m, H-6”, H-7”); 6.72 (1H, dd, 
4
JH-H  = 1.79, 
3
JH-H  = 8.89, 
H-6); 6.76 (2H, dd, 
4
JH-H  = 1.79, 
3
JH-H  = 7.62, H-5”); 7.67 (1H, d, 
3
JH-H  = 8.95, H-5); 8.06 
(1H, m, H-8); 8.16 (2H, s, H-3”); 8.30 (1H, d, 
3




H} NMR (100.635 
MHz, DMSO-d6): (δ, ppm) 41.91 (C-1’); 52.90 (C-2’); 55.21 (C-1’’); 55.90 (C-2”); 56.42  
(C-10”); 99.16 (C-3); 115.58 (C-7”); 116.84; 117.24 (C-6”); 118.49; 123.56 (C-5); 123.83  
(C-5”); 125.15 (C-6); 125.79 (C-8); 136.09; 147.44; 147.84; 149.01; 153.16; 154.26 (C-2); 
166.71 (C-3”). IR (KBr): (vmax/cm
−1
) 3414 (N-H); 1635 (C=N); 1613 (C=N) quinoline.  
EI-MS: m/z 574.9313 (5%, [M]
+
). Elemental Analysis C31H34ClN5O4
.
3H2O calculated: C 
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Bis-salicylaldimine quinoline (3.7)  



























N-(7-Chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) (0.151 g, 0.491 mmol) was reacted 
with salicylaldehyde (0.126 g, 1.04 mmol). The product (3.7) was filtered and isolated as a 




H NMR (399.951, CDCl3): (δ, ppm)  
2.94-3.01 (6H, m, H-2’, H-1”); 3.43 (2H, m, H-1’); 3.66-3.72 (4H, m, H-2”); 6.29 (1H, d,  
3
JH-H  = 6.63, H-3); 6.49 (1H, dd, 
4
JH-H  = 2.08, 
3
JH-H  = 8.96, H-6); 6.67-6.71 (4H, m, H-8”, 
H6”); 6.92 (2H, dd, 
4
JH-H  = 1.53, 
3
JH-H  = 7.63, H-5”); 7.19 (2H, m, H-7”); 7.33 (1H, br s, 
NH); 7.36 (1H, d, 
3
JH-H  = 9.04, H-5); 8.04 (1H, d, 
4
JH-H  = 2.07, H-8); 8.09 (1H, d, 
3
JH-H  = 




H} NMR (100.635 MHz, DMSO-d6): (δ, ppm) 41.87  
(C-1’); 52.45 (C-2’); 54.96 (C-1’’); 56.62 (C-2”); 99.00 (C-3); 117.04 (C-8”); 118.53 (6”); 
118.82; 121.05; 125.67 (C-5); 126.52 (C-6); 129.58 (C-8); 131.88 (C-5”); 132.68 (C-7”); 
136.79; 137.37; 146.64; 154.73 (C-2); 161.61; 166.78 (C-3”). IR (KBr): (vmax/cm
−1
) 3414 





2.5H2O calculated: C 62.08; H 6.29; N 12.48%, found: C 62.00; H 
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6.3.3. Synthetic methods and characterisation of 4-amino-7-chloroquinoline mono-
imine Rh(I) complexes 3.9 – 3.11 
6.3.3.1. General method to prepare complexes 3.9 – 3.11 
The appropriate ligand was dissolved in dry DCM (30 ml) and to this NaH was added in 
excess. The mixture was stirred at room temperature for 1.5 hours under argon. A solution of 
[RhCl(COD)]2 in DCM (5 ml) was then added dropwise to the mixture and stirred for 3 hours 
at room temperature. After this time, water (20 ml) was added to the reaction mixture and the 
organic extract washed with water (3 x 20 ml). The organic layer was dried over anhydrous 
MgSO4. The drying agent was removed by filtration and the solvent of the resulting filtrate 
reduced under vacuum. The product was precipitated with n-hexane and filtered using a 
Büchner funnel. 
 
Mono-5-chlorosalicylaldimine quinoline Rh(I)complex (3.9)  
























Compound 3.2 (81.4 mg, 0.217 mmol), NaH (6.24 mg, 0.258 mmol) and [RhCl(COD)]2 (53.4 
mg, 0.108 mmol) were reacted. The product (3.9) was isolated as a bright yellow powder 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 1.84 (4H, m, 
CH2 (COD)exo); 2.17 (2H, m, H-2’); 2.34 (4H, m, CH2 (COD)endo); 3.33 (2H, t, 
3
JH-H  = 7.28, 
H-1’); 3.41 (2H, m, H-3’); 3.66 (2H, m, CH=CH (COD)); 4.54 (2H, m, CH=CH (COD)); 5.08 
(1H, br s, NH); 6.41 (1H, d, 
3
JH-H  = 5.25, H-3); 6.78 (1H, d, 
3
JH-H  = 9.04, H-9’); 7.05 (1H, d, 
4
JH-H  = 2.72, H-6’); 7.21 (1H, dd, 
4
JH-H  = 2.83, 
3
JH-H  = 9.36, H-8’); 7.34 (1H, dd, 
4
JH-H  = 2.13, 
3
JH-H  = 8.98, H-6); 7.64 (1H, d, 
3
JH-H  = 8.90, H-5); 7.87 (1H, s, H-4’); 7.97 (1H, d, 
4
JH-H  = 
2.03, H-8); 8.56 (1H, d, 
3




H} NMR (100.635  MHz, CDCl3): (δ, ppm) 
28.81 (COD); 31.63 (COD); 32.66 (C-2’); 40.87 (C-1’); 57.19 (C-3’); 71.66 (d, 
1
JRh-C = 14.09, 
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COD); 86.04 (d, 
1
JRh-C = 11.86, COD); 99.17 (C-3); 117.25; 118.45; 119.53; 121.01 (C-5); 
123.25 (C-9’); 125.50 (C-6); 128.92 (C-8); 132.87 (C-6’); 134.85 (C-8’); 135.04; 149.23; 
149.28; 152.05 (C-2); 158.15; 164.96 (C-4’). IR (KBr): (vmax/cm
−1
) 3435 (N-H); 1609 (C=N). 
EI-MS: m/z 582.7133 (30%, [M]
+
). Elemental Analysis C27H28Cl2N3ORh calculated: C 
55.50; H 4.83; N 7.19%, found: C 55.15; H 5.34; N 6.64%.  
Mono-3-methoxysalicylaldimine quinoline Rh(I)complex (3.10)  

























Compound 3.3 (91.3 mg, 0.247 mmol), NaH (7.08 mg, 0.295 mmol) and [RhCl(COD)]2 (61.3 
mg, 0.124 mmol) were reacted. The product (3.10) was isolated as a bright yellow powder 
(93.2 mg, 65%). 
1
H NMR (399.951 MHz, CDCl3): (δ, ppm) 1.85 (4H, m, CH2 (COD)exo); 
2.16 (2H, m, H-2’); 2.35 (4H, m, CH2 (COD)endo); 3.33 (2H, t, 
3
JH-H  = 6.89, H-1’); 3.39 (4H, 
m, H-3’); 3.68 (2H, m, CH=CH (COD)); 3.81 (3H, s, H-11’) 4.66 (2H, m, CH=CH (COD)); 
5.14 (1H, br s, NH); 6.38 (1H, d, 
3
JH-H  = 5.33, H-3); 6.46 (1H, t, 
3
JH-H  = 7.80, H-7’); 6.73 
(1H, dd, 
4
JH-H  = 1.55, 
3
JH-H  = 8.14, H-8’) ; 6.85 (1H, dd, 
2
JH-H  = 1.58, 
3
JH-H  = 7.52, H-6’); 
7.34 (1H, dd, 
4
JH-H  = 2.05, 
3
JH-H  = 8.87, H-6); 7.66 (1H, d, 
3
JH-H  = 8.95, H-5); 7.95 (2H, m, 
H-4’, H-8); 8.53 (1H, d, 
3




H} NMR (100.635 MHz, CDCl3): (δ, ppm) 
28.81 (COD); 31.68 (COD); 32.66 (C-2’); 40.89 (C-3’); 56.74 (C-1’); 57.01 (C-11’); 71.21  
(d, 
1
JRh-C = 14.12, COD); 85.49 (d, 
1
JRh-C = 11.78, COD); 99.09 (C-3); 113.65 (C-7’); 115.82 
(C-6’); 117.26; 119.11; 121.15 (C-5); 125.46; (C-6); 126.84 (C-8’); 128.82 (C-8); 132.22; 
134.97; 149.21; 149.34; 151.24; 152.04 (C-2); 165.78 (C-4’). IR (KBr): (vmax/cm
−1
) 3439  
(N-H); 1613 (C=N). EI-MS: m/z 578.7728 (2%, [M]
+
). Elemental Analysis C28H31ClN3O2Rh 
calculated: C 57.99; H 5.39; N 7.25%, found: C 57.19; H 6.11; N 5.36%.  
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Mono-salicylaldimine quinoline Rh(I)complex (3.11)  























Compound 3.4 (0.108 g, 0.318 mmol), NaH (15.0 mg, 0.620 mmol) and [RhCl(COD)]2 (0.078 
mg, 0.159 mmol) were reacted. The product (3.11) was isolated as a bright yellow powder 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 1.84 (4H, m, 
CH2 (COD)exo); 2.17 (2H, m, H-2’); 2.34 (4H, m, CH2 (COD)endo); 3.35 (2H, t, 
3
JH-H  = 6.83, 
H-1’); 3.41 (4H, m, H-3’); 3.66 (2H, m, CH=CH (COD)); 4.54 (2H, m, CH=CH (COD)); 5.12 
(1H, br s, NH); 6.39 (1H, d, 
3
JH-H  = 5.36, H-3); 6.53 (1H, t, 
3
JH-H  = 7.88, H-7’); 6.85 (1H, d, 
3
JH-H  = 8.51, H-9’) ; 7.09 (1H, dd, 
4
JH-H  = 1.76, 
3
JH-H  = 7.93, H-6’); 7.27-7.34 (2H, m, H-6, 
H-8’); 7.65 (1H, d, 
3
JH-H  = 8.98, H-5); 7.94 (2H, m, H-4’, H-8); 8.54 (1H, d, 
3





H} NMR (100.635 MHz, CDCl3): (δ, ppm) 28.83 (COD); 31.67 (COD); 32.66  
(C-2’); 40.98 (C-3’); 57.02 (C-1’); 71.29 (d, 
1
JRh-C = 14.08, COD); 85.70 (d, 
1
JRh-C = 11.96, 
COD); 99.13 (C-3); 114.62 (C-7’); 117.26; 119.02; 121.10 (C-5); 121.63 (C-9’); 125.47;  
(C-6); 128.89 (C-8); 134.90 (C-6’); 135.01 (C-8’); 149.24; 149.34; 152.06 (C-2); 166.02  
(C-4); 166.37. IR (KBr): (vmax/cm
−1
) 3431 (N-H); 1607 (C=N). EI-MS: m/z 548.6803 (15%, 
[M]
+
). Elemental Analysis C27H29ClN3ORh calculated: C 58.97; H 5.32; N 7.64%, found: C 
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6.3.4. Synthetic methods and characterisation of 4-amino-7-chloroquinoline bis-imine 
Rh(I) complexes 3.12 – 3.14 
6.3.4.1. General method to prepare complexes 3.12 – 3.14 
The appropriate ligand was dissolved in dry DCM (30 ml) and to this NaH was added in 
excess. The mixture was stirred at room temperature for 1.5 hours under argon. A solution of 
[RhCl(COD)]2 in DCM (5 ml) was then added dropwise to the mixture and stirred for 5-6 
hours at room temperature. After this time, water (20 ml) was added to the reaction mixture 
and the organic extract washed with water (3 x 20 ml). The organic layer was dried over 
anhydrous MgSO4. The drying agent was removed by filtration and the solvent of the 
resulting filtrate reduced under vacuum. The product was precipitated with n-hexane and 
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Bis-5-chlorosalicylaldimine quinoline Rh(I)complex (3.12)  































Compound 3.5 (107 mg, 0.184 mmol), NaH (16.6 mg, 0.692 mmol) and [RhCl(COD)]2 (90.2 
mg, 0.183 mmol) were reacted. The product (3.12) was isolated as a bright yellow powder 




H NMR (399.935, CDCl3): (δ, ppm) 1.84 (8H, m, CH2 
(COD)exo); 2.37 (8H, m, CH2 (COD)endo); 2.88 (6H, m, H-1”, 2’); 3.17 (4H, m, H-2”); 3.46 
(2H, m, H-1’); 3.51 (4H, m, CH=CH (COD)); 4.52 (4H, m, CH=CH (COD)); 5.23 (1H, br s, 
NH); 6.37 (1H, d, 
3
JH-H  = 5.52, H-3); 6.72 (2H, d, 
3
JH-H  = 9.02, H-8”); 7.03 (2H, d, 
4
JH-H  = 
2.61, H-5”); 7.18 (2H, dd, 
4
JH-H  = 2.64, 
3
JH-H  = 9.05, H-7”) 7.26-7.31 (2H, m, H-5, H-6); 7.71 
(2H, s, H-3”); 7.93 (1H, m, H-8); 8.53 (1H, d, 
3




H} NMR (100.635  
MHz, CDCl3): (δ, ppm) 28.93 (COD); 31.67 (COD); 40.88 (C-1’); 53.96 (C-2’); 57.89  
(C-2”); 58.21 (C-1”); 71.48 (d, 
1
JRh-C = 14.03, COD); 86.08 (d, 
1
JRh-C = 11.53, COD); 99.31 
(C-3); 118.61; 119.54; 120.66 (C-5); 120.90; 123.30 (C-8”); 125.73 (C-6); 128.94 (C-8); 
132.75 (C-5”); 134.88 (C-7”); 135.04; 149.25; 149.32; 151.99 (C-2); 159.20; 164.81 (C-4’). 
IR (KBr): (vmax/cm
−1
) 3427 (N-H); 1607 (C=N). ESI-MS (HR) m/z 1004.1231 (55%, 
[M+H]
+
 requires 1004.1218). Elemental Analysis C45H50Cl3N5O2Rh2 calculated: C 53.88; H 
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Bis-3-methoxysalicylaldimine quinoline Rh(I)complex (3.13)  

































Compound 3.6 (90.2 mg, 0.156 mmol), NaH (13.1 mg, 0.546 mmol) and [RhCl(COD)]2 (77.5 
mg, 0.157 mmol) were reacted. The product (3.13) was isolated as a bright yellow powder 




H NMR (399.935, CDCl3): (δ, ppm) 1.83 (8H, m, CH2 
(COD)exo); 2.36 (8H, m, CH2 (COD)endo); 2.87 (6H, m, H-1”, H-2’); 3.18 (4H, m, H-2”); 3.43 
(2H, m, H-1’); 3.51 (4H, m, CH=CH (COD)); 3.77 (6H, s, H-10”); 4.64 (4H, m, CH=CH 
(COD)); 5.19 (1H, br s, NH); 6.32 (1H, d, 
3
JH-H  = 5.46, H-3); 6.46 (2H, t, 
3
JH-H  = 7.75, H-6”); 
6.64 (2H, dd, 
4
JH-H  = 1.42, 
3
JH-H  = 8.07, H-7”); 6.84 (2H, dd, 
4
JH-H  = 1.54, 
3
JH-H  = 7.58,  
H-5”); 7.06-7.20 (2H, m, H-5, H-6); 7.75 (2H, s, H-3”); 7.90 (1H, m, H-8); 8.48 (1H, d, 
3
JH-H  




H} NMR (100.635  MHz, CDCl3): (δ, ppm) 28.90 (COD); 31.68 (COD); 
41.12 (C-1’); 53.64 (C-2’); 56.65 (C-2”); 58.08 (C-1”, C-10’); 71.04 (d, 
1
JRh-C = 14.18, COD); 
85.47 (d, 
1
JRh-C = 11.68, COD); 99.11 (C-3); 113.74 (C-6”); 115.65 (C-5”); 117.28; 119.08; 
121.23 (C-5); 125.34 (C-6); 126.77 (C-7”); 128.70 (C-8); 134.78; 149.21; 149.35; 151.30 
151.99 (C-2); 158.01; 165.58 (C-3”). IR (KBr): (vmax/cm
−1
) 3362 (N-H); 1604 (C=N).  
ESI-MS (HR) m/z 996.2199 (20%, [M+H]
+
, requires 996.2209). Elemental Analysis 
C47H56ClN5O4Rh2
.
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Bis-salicylaldimine quinoline Rh(I)complex (3.14)  





























Compound 3.7 (0.065 g, 0.126 mmol), NaH (9.00 mg, 0.412 mmol) and [RhCl(COD)]2 (61.0 
mg, 0.125 mmol) were reacted. The product (3.14) was isolated as a bright yellow powder 
(76.0 mg, 65%). 
1
H NMR (399.935, CDCl3): (δ, ppm) 1.82 (8H, m, CH2 (COD)exo); 2.36 
(8H, m, CH2 (COD)endo); 2.88 (6H, m, H-1”, H-2’); 3.19 (4H, m, H-2”); 3.47 (2H, m, H-1’); 
3.51 (4H, m, CH=CH (COD)); 4.53 (4H, m, CH=CH (COD)); 5.28 (1H, br s, NH); 6.34 (1H, 
d, 
3
JH-H  = 5.05, H-3); 6.53 (2H, t, 
3
JH-H  = 7.47, H-6”); 6.80 (2H, d, 
3
JH-H  = 8.53, H-8”); 7.01 
(2H, d, 
3
JH-H  = 7.64, H-5”); 7.19-7.34 (4H, m, H-6”, H-5, H-6); 7.76 (2H, s, H-3”); 7.92 (1H, 
m, H-8); 8.51 (1H, d, 
3




H} NMR (100.635  MHz, CDCl3): (δ, ppm) 
28.95 (COD); 31.69 (COD); 40.94 (C-1’); 53.63 (C-2’); 57.95 (C-2”); 58.06 (C-1”); 71.13 (d, 
1
JRh-C =13.69, COD); 85.67 (d, 
1
JRh-C = 11.67, COD); 99.22 (C-3); 114.70 (C-6”); 117.29; 
119.04; 121.09 (C-5); 121.66 (C-8”); 125.45 (C-6); 128.78 (C-8); 134.88 (C-7”; C-5”); 
149.20; 149.35; 152.01 (C-2); 165.78 (C-3”); 166.35. IR (KBr): (vmax/cm
−1
) 3418 (N-H); 
1606 (C=N). ESI-MS (HR) m/z 936.2004 (28%, [M+H]
+
, requires 936.1998).  Elemental 
Analysis C45H52ClN5O2Rh2
.
2H2O calculated: C 55.59; H 5.81; N 7.20%, found: C 55.81; H 
5.80; N 6.49%. 
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6.4. Experimental details for Chapter 4 
 
 
6.4.1. Synthetic methods and characterisation of ferrocenyl ligands and  














To a solution of (dimethylamino)methyl ferrocene (2.00 g, 8.23 mmol) in anhydrous diethyl 
ether (20 ml), n-butyllithium (6 ml, 12.0 mmol) was added slowly at -78
◦
C under an argon 
atmosphere. The solution was allowed to warm to room temperature and stirred for a further 
18 hours. After this time, an orange precipitate was observed. Anhydrous DMF (0.8 ml, 10.3 
mmol) was added dropwise to the mixture. The resulting mixture was stirred at room 
temperature for an additional 4 hours. The reaction was quenched with water (20 ml). The 
aqueous layer was washed with diethyl ether (3 x 15 ml) and the combined organic extracts 
dried using sodium sulphate. The solution was filtered by gravity and the solvent removed 
under vacuum. The product was purified by means of column chromatography. Diethyl ether: 
petroleum ether: triethylamine (70:20:10) was used to elute the product. Compound 4.1 was 
obtained as a dark red oil (1.50 g, 67%). 
1
H NMR (399.951 MHz, CDCl3): (δ, ppm) 2.15 
(6H, s, H-3); 3.28 (1H, d, 
2
JH-H = 13.18, H-2a); 3.76 (1H, d, 
2
JH-H = 13.18, H-2b); 4.16 (5H, s, 




H} NMR (100.635 MHz, CDCl3): (δ, ppm) 44.67 (C-3); 56.46 (C-2); 70.08 (Cp); 70.28 
(Cp); 71.72 (Cp); 75.74 (Cp); 77.73; 86.48; 193.10 (C-1). IR (NaCl cells): (vmax/cm
−1
) 1675 

























To a stirred solution of hydrazine hydrate (2 ml) in absolute EtOH (70 ml), a solution of 5-
chlorosalicylaldehyde (1.24 g, 7.95 mmol) in absolute EtOH (30 ml) was added dropwise over 
a 2 hour period. After this time, the solvent was reduced and the solution kept at -20
◦
C for 16 
hours. After this time, a precipitate formed and was filtered. The product was dried in vacuo. 
Compound 4.2 was obtained as a white powder (0.434 g, 32%). 
1
H NMR (399.951 MHz, 
CDCl3): (δ, ppm) 5.51 (2H, br s, NH2); 6.87 (1H, d, 
3
JH-H = 8.79, H-6); 7.05 (1H, d, 
4
JH-H = 
2.56, H-3); 7.14 (1H, dd, 
4
JH-H = 2.56, 
3
JH-H = 8.79, H-5); 7.77 (1H, s, H-1); 10.98 (1H, s, 
OH). IR (ATR): (vmax/cm
−1


















To a stirred solution of hydrazine hydrate (1.56 ml) in absolute EtOH (70 ml), a solution of 5-
chlorosalicylaldehyde (1.03 g, 6.80 mmol) in absolute EtOH (30 ml) was added dropwise over 
a 2 hour period. After this time, the solvent was reduced to about 2 ml and the solution kept at 
-20
◦
C for 16 hours. After this time, the precipitate was filtered and washed with water to 
remove excess hydrazine hydrate. The compound was dried in vacuo. Compound 4.3 was 
obtained as a pale yellow powder (0.326 g, 29%). 
1
H NMR (399.951 MHz, CDCl3): (δ, ppm) 
3.90 (3H, s, H-8); 5.45 (2H, br s, NH2); 6.73 (1H, dd, 
4
JH-H = 1.83, 
3
JH-H = 7.69, H-5); 6.81 
(1H, t, 
3
JH-H = 7.69, H-4); 6.85 (1H, dd, 
4
JH-H = 1.83, 
3
JH-H = 7.69, H-3); 7.86 (1H, s, H-1); 
11.15 (1H, s, OH). IR (ATR): (vmax/cm
−1
) 3418 (N-H); 1623 (C=N); 1574 (C=C). 


















To a stirred solution of hydrazine hydrate (2 ml) in absolute EtOH (70 ml), a solution of 
salicylaldehyde (0.990 g, 8.11 mmol) in absolute EtOH (15 ml) was added dropwise over a 1 
hour period. The solution was stirred for an additional 10 minutes. After this time, the solvent 
was reduced and the solution kept at -20
◦
C for 16 hours. After this time, a precipitate formed 
and was filtered. Compound 4.4 was obtained as a white crystalline solid (0.496 g, 45%). 
1
H 
NMR (399.951 MHz, CDCl3): (δ, ppm) 5.43 (2H, br s, NH2); 6.85 (1H, t, 
3
JH-H = 7.69, H-4); 
6.93 (1H, d, 
3
JH-H = 8.06, H-6); 7.09 (1H, d, 
3
JH-H = 7.69, H-3); 7.20 (1H, t, 
3
JH-H = 8.79, H-5); 
7.86 (1H, s, H-1); 11.02 (1H, s, OH). IR (ATR): (vmax/cm
−1
) 3380 (N-H); 1613 (C=N); 1570 
(C=C). 
 
6.4.1.1. General method to prepare ferrocenyl azines 4.5 – 4.7 
 
To a stirred solution of the (dimethylamino)methyl ferrocenecarboxaldehyde 4.1 in diethyl 
ether (20 ml) under argon, the appropriate salicylaldehyde hydrazone was added and the 
resulting solution stirred for 16 hours at room temperature. As time continued, the solution 
became dark red in colour. After the 16 hour period, the solvent was removed and the residue 
purified by silica gel column chromatography. The starting reagents were eluted using 100% 
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5-Chlorosalicylaldimine ferrocene (4.5) 
 



















(Dimethylamino)methyl ferrocenecarboxaldehyde 4.1 (0.136 g, 0.499 mmol) and  
5-chlorosalicylaldehyde hydrazone 4.2 (0.0849 g, 0.498 mmol) was reacted. The product (4.5) 
was obtained as a red oil (0.186 g, 88%).
1
H NMR (399.951 MHz, CDCl3): (δ, ppm) 2.21 
(6H, s, H-1); 3.29 (1H, d, 
2
JH-H  = 13.01, H-2a); 3.73 (1H, d, 
2
JH-H = 12.92; H-2b); 4.18 (5H, s, 
Cpunsub); 4.51 (1H, t, 
3
JH-H = 2.57, Cpsub); 4.54 (1H, m, Cpsub); 4.86 (1H, m, Cpsub); 6.96 (1H, 
d, 
3
JH-H = 9.48, H-9); 7.27 – 7.30 (1H, m, H-6, H-8); 8.59 (1H, s, H-4); 8.66 (1H, s, H-3); 




H} NMR (100.635 MHz, CDCl3): (δ, ppm) 44.96 (C-1); 57.18  
(C-2); 68.42 (Cpsub); 70.12 (Cpunsub); 70.74 (Cpsub); 71.56; 74.33 (Cpsub); 76.21; 118.42 (C-9); 
119.07; 124.10; 130.91 (C-6); 132.04 (C-8); 158.14; 161.23 (C-3); 163.91 (C-4). IR (ATR): 
(vmax/cm
−1
) 1618 (C=N); 1582 (C=C). ESI-MS (HR): m/z 424.0874 (100%, [M+H]
+
, requires 
424.0879). Elemental Analysis C21H22ClFeN3O calculated: C 59.53; H 5.23; N 9.92%, 
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(Dimethylamino)methyl ferrocenecarboxaldehyde 4.1 (0.167 g, 0.616 mmol) and 3-
methoxysalicylaldehyde hydrazone 4.3 (0.103 g, 0.620 mmol) was reacted. Compound 4.6 
was obtained as a red oil (0.171, 66%). 
1
H NMR (399.951 MHz, CDCl3): (δ, ppm) 2.22 (6H, 
s, H-1); 3.32 (1H, d, 
2
JH-H = 12.61, H-2a); 3.74 (1H, d, 
2
JH-H = 13.01; H-2b);  3.95 (3H, s,  
H-11); 4.19 (5H, s, Cpunsub); 4.50 (1H, t, 
3
JH-H = 2.58, Cpsub); 4.54 (1H, m, Cpsub); 4.87 (1H, 
m, Cpsub); 6.89 (1H, m, H-7); 6.98 (2H, m, H-6, H-8); 8.66 (1H, s, H-3); 8.67 (1H, s, H-4); 




H} NMR (100.635 MHz, CDCl3): (δ, ppm) 44.87 (C-1); 56.33  
(C-11); 57.11 (C-2); 68.40 (Cpsub); 70.09 (Cpunsub); 70.58 (Cpsub); 74.16 (Cpsub); 76.43; 85.71; 
114.60 (C-7); 118.18; 119.07 (C-6); 123.73 (C-8); 148.41; 149.64; 162.54 (C-3); 163.22  
(C-4). IR (ATR): (vmax/cm
−1
) 1616 (C=N); 1587 (C=C). ESI-MS (HR): m/z 420.1369 (100%, 
[M+H]
+
, requires 420.1374). Elemental Analysis C22H25FeN3O2
.
H2O calculated: C 60.42; H 
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Salicylaldimine ferrocene (4.7) 


















(Dimethylamino)methyl ferrocenecarboxaldehyde 4.1 (0.250 g, 0.923 mmol) and 
salicylaldehyde hydrazone 4.4 (0.126 g, 0.925 mmol) was reacted. Compound 4.7 was 
obtained as a red oil (0.241, 67%). 
1
H NMR (399.951 MHz, CDCl3): (δ, ppm) 2.21 (6H, s, 
H-1); 3.30 (1H, d, 
2
JH-H = 12.97, H-2a); 3.72 (1H, d, 
2
JH-H = 12.96; H-2b); 4.18 (5H, s, 
Cpunsub); 4.49 (1H, t, 
3
JH-H = 2.44, Cpsub); 4.52 (1H, m, Cpsub); 4.86 (1H, m, Cpsub); 6.93 (1H, t, 
3
JH-H = 7.27,  H-7); 7.02 (1H, d, 
3
JH-H = 8.60, H-9); 7.31 - 7.37 (2H, m, H-8, H-6); 8.66 (1H, s, 




H} NMR (100.635 MHz, CDCl3): (δ, ppm) 
45.01 (C-1); 57.18 (C-2); 68.18 (Cpsub); 70.06 (Cpunsub); 70.51 (Cpsub); 74.07 (Cpsub); 76.51; 
86.02; 116.91 (C-7); 118.07; 119.44 (C-9); 132.03 (C-6); 132.34 (C-8); 159.61; 162.60 (C-3); 
162.99 (C-4). IR (ATR): (vmax/cm
−1
) 1618 (C=N); 1585 (C=C). ESI-MS (HR): m/z 390.1258 
(100%, [M+H]
+
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6.4.2. Synthetic methods and characterisation of ferrocenyl quinolines 4.9 – 4.11 
 
Salicylaldimine ferrocenyl quinoline (4.9) 
  





























To a solution of ferrocene salicylaldehyde (4.8) (30.0 mg g, 0.0903 mmol) in 20 ml of 
DCM/MeOH (1:1), N’-(7-Chloroquinolin-4-yl)-propane-1,3-diamine (2.1) (20.4 mg, 0.0865 
mmol) was added and the resulting solution stirred for 16 hours at room temperature under 
argon. The solvent was removed in vacuo and the resulting residue washed with cold diethyl 
ether (2 ml) to remove any unreacted aldehyde. The supernatant was decanted and the 
resulting red solid dried in vacuo. The product (4.9) was obtained as a red powder (36.8 mg, 




H NMR (300.077 MHz, CDCl3): (δ, ppm) 2.21 (2H, m, H-2’); 3.50 
(m, 2H, H-1’); 3.78 (2H, t, 
3
JH-H = 6.35, H-3’); 4.16 (5H, s, Cpunsub); 4.33 (2H, t, 
3
JH-H = 1.95, 
Cpsub); 4.50 (2H, t, 
3
JH-H = 1.95, Cpsub); 5.10 (1H, m, NH); 6.43 (1H, d, 
3
JH-H = 5.37, H-3); 
6.65 (1H, d, 
3
JH-H = 16.13, H-11’); 6.94 – 7.06 (3H, m, H-7’, H-9’, H-12’); 7.16 (1H, d, 
3
JH-H 
= 7.81, H-6’); 7.31 (1H, dd, 
4
JH-H = 1.95, 
3
JH-H = 8.79, H-6); 7.63 (1H, d, 
3
JH-H = 8.79, H-5); 
7.93 (1H, d, 
4
JH-H = 1.95, H-8); 8.35 (1H, s, H-4’); 8.54 (1H, d, 
3





NMR (100.635 MHz, CDCl3): 30.01 (C-2’); 41.48 (C-1’); 57.40 (C-3’); 67.22 (Cpsub); 69.32 
(Cpunsub); 69.48 (Cpsub); 82.61; 99.11 (C-3); 113.59 (C-9’); 116.79 (C-7’); 117.14; 117.31; 
120.82 (C-5); 125.12 (C-6); 125.43 (C-11’); 128.81 (C-8); 130.07 (C-12’); 131.60 (C-6’); 
134.97; 142.38; 149.09; 149.56; 151.97 (C-2); 161.38; 165.37 (C-4’). IR (ATR): (vmax/cm
−1
) 
1611 (C=N); 1578 (C=C). ESI-MS (HR): m/z 550.1339 (15%, [M+H]
+
, requires 550.1348); 
275.5708 (100%, [M+2H]
2+
). Elemental Analysis C31H28ClFeN3O
.
3H2O calculated: C 61.65; 
H 5.67; N 6.96%, found: C 62.05; H 5.26; N 5.71%. 
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Mono-ferrocenyl quinoline (4.10) 
 



















To a suspension of N’-(7-Chloroquinolin-4-yl)-propane-1,3-diamine 2.1 (0.203 g, 0.862 
mmol) in diethyl ether (30 ml), a solution of ferrocenecarboxaldehyde (0.204 g, 0.952 mmol) 
in diethyl ether (5 ml) was added and the mixture stirred for 16 hours at room temperature. 
After this time, an orange precipitate formed and was filtered, washed with diethyl ether to 
remove excess aldehyde and the solid dried in vacuo. Compound 4.10 was obtained as an 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 
2.10 (2H, m, H-2’); 3.47 (2H, m, H-1’); 3.70 (2H, t, 
3
JH-H = 5.49, H-3’); 4.18 (5H, s, Cpunsub); 
4.46 (2H, t, 
3
JH-H = 1.83, Cpsub); 4.69 (2H, t, 
3
JH-H = 1.83, Cpsub); 6.36 (1H, d, 
3
JH-H = 5.49,  
H-3); 6.76 (1H, m, NH); 7.26 (1H, dd, 
4
JH-H = 1.83, 
3
JH-H = 8.79, H-6); 7.80 (1H, d, 
3
JH-H = 
8.79, H-5); 7.93 (1H, d, 
4
JH-H = 2.19, H-8); 8.18 (1H, s, H-4’); 8.50 (1H, d, 
3




H} NMR (100.635 MHz, CDCl3): (δ, ppm) 29.68 (C-2’); 43.57 (C-1’); 61.32 (C-3’); 
68.50 (Cpsub); 69.16 (Cpunsub); 70.78 (Cpsub); 80.31; 98.57 (C-3); 117.49; 122.07 (C-5); 124.83 
(C-6); 128.63 (C-8); 134.66; 149.20; 150.27; 152.17 (C-2); 162.00 (C-4). IR (KBr): 
(vmax/cm
−1
) 3274 (N-H); 1638 (C=N); 1613 (C=N) quinoline. ESI-MS: m/z 432.0937 (50%, 
[M+H]
+
). Elemental Analysis C23H22ClFeN3
.
2H2O calculated: C 59.06; H 5.60; N 8.98%, 
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N-(7-Chloroquinolin-4-yl)-tris(2-aminoethyl)amine (3.1) (0.144 g, 0.469 mmol) was 
dissolved in EtOH (25 ml). To this, ferrocenecarboxaldehyde (0.200 g, 0.935 mmol) in EtOH 
(5 ml) was added and the resulting solution stirred at room temperature for 16 hours. The 
solvent was removed in vacuo and the residue washed continuously with pentane. The product 





(399.951 MHz, CDCl3): (δ, ppm) 2.91 (4H, t, 
3
JH-H = 5.49, H-1”); 2.99 (2H, t, 
3
JH-H = 5.13,  
H-2’); 3.31 (2H, m, H-1’); 3.59 (4H, t, 
3
JH-H = 5.86, H-2”); 4.31 (10H, s, Cpunsub); 4.29 (4H, 
m, Cpsub); 4.50 (4H, m, Cpsub); 6.33 (1H, d, 
3
JH-H = 5.13, H-3); 6.66 (1H, m, NH); 7.07 (1H, d, 
3
JH-H = 8.42, H-6); 7.70 (1H, d, 
3
JH-H = 8.79, H-5); 7.89 (1H, s, H-8); 8.10 (2H, s, H-3”); 8.48 
(1H, d, 
3




H} NMR (100.635 MHz, CDCl3): (δ, ppm).  41.11 (C-2’); 
53.19 (C-1’); 55.95 (C-1”); 60.89 (C-2”); 68.48 (Cpsub); 69.05 (Cpunsub); 70.47 (Cpsub) 80.31; 
99.01 (C-3); 117.78; 122.35 (C-5); 125.18 (C-6); 128.31 (C-8); 134.54; 149.22; 150.37; 
151.95 (C-2); 162.04 (C-3”). IR (KBr): (vmax/cm
−1
) 3267 (N-H); 1639 (C=N); 1611 (C=N) 
quinoline. ESI-MS (HR): m/z 700.1611 (100%, [M+H]
+
, requires 700.1593). Elemental 
Analysis C37H38ClFe2N5
.
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6.4.3. Synthetic methods and characterisation of ferrocenyl salicylaldimine Rh(I) 
complexes 4.12 – 4.14 
 
6.4.3.1. General method to prepare complexes 4.12 – 4.14 
 
To a solution of the appropriate ligand in DCM (30 ml), NaH was added. The mixture was 
stirred at room temperature under argon for 1.5 hours. After this time, a solution of 
[RhCl(COD)]2 was added and the mixture stirred for a further 3 hours at room temperature. 
The resulting mixture was washed with water (2 x 20 ml) and the organic layer collected. The 
organic layer was dried over Na2SO4 and the drying agent removed by filtration. The filtrate 
was collected, the solvent removed in vacuo and the resulting solid dried. 
 
5-Chlorosalicylaldimine ferrocene Rh(I) complex (4.12) 
 



















Compound 4.5 (59.1 mg, 0.139 mmol), NaH (13.4 mg, 0.558 mmol) and [RhCl(COD)]2 (34.7 
mg, 0.0704 mmol) were reacted. Compound 4.12 was obtained as an orange solid (86.2 mg, 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 1.95 (4H, m, (COD)exo); 
2.19 (6H, s, H-1); 2.46 (4H, m, (COD)endo); 3.24 (1H, d, 
2
JH-H = 12.99, H-2a); 3.59 (1H, d, 
2
JH-H = 13.03, H-2b); 3.98 (2H, m, CH=CH (COD));  4.20 (5H, s, Cpunsub); 4.45 (1H, t, 
3
JH-H = 
2.54, Cpsub); 4.50 (1H, m, Cpsub); 4.60 (2H, m, CH=CH (COD)); 4.70 (1H, m, Cpsub); 6.84 
(1H, d, 
3
JH-H = 9.08, H-9); 7.12 (1H, d, 
4
JH-H = 2.75, H-6); 7.22 (1H, dd,  
4
JH-H = 2.77, 
3
JH-H = 




H} NMR (100.635 MHz, CDCl3): (δ, 
ppm) 29.17 (d, 
2
JRh-C = 6.73, COD); 31.48 (d, 
2
JRh-C = 6.73, COD); 45.04 (C-1); 57.22 (C-2); 
67.92 (Cpsub); 70.03 (Cpunsub); 70.27 (Cpsub); 73.38 (d, 
1
JRh-C = 13.36, COD); 73.77 (Cpsub); 
76.05; 85.43 (d, 
1
JRh-C = 12.12, COD); 85.95; 118.03; 118.42; 123.36 (C-9); 132.21 (C-6); 
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133.95 (C-8); 152.06 (C-4); 157.65 (C-3); 164.94. IR (ATR): (vmax/cm
−1
) 1600 (C=N); 1574 
(C=C). ESI-MS (HR): m/z 634.0776 (20%, [M+H]
+
, requires 634.0795). Elemental Analysis 
C29H33ClFeN3ORh calculated: C 54.96; H 5.25; N 6.63%, found: C 55.85; H 5.91; N 5.44%. 
 
3-Methoxysalicylaldimine ferrocene Rh(I) complex (4.13) 
 




















Compound 4.6 (56.9 mg, 0.136 mmol), NaH (13.0 mg, 0.543 mmol) and [RhCl(COD)]2 (33.6 
mg, 0.0681 mmol) were reacted. Compound 4.13 was obtained as a red solid (83.3 mg, 98%). 




H NMR (300.077 MHz, CDCl3): (δ, ppm) 1.95 (4H, m, (COD)exo); 2.20 
(6H, s, H-1); 2.47 (4H, m, (COD)endo); 3.28 (1H, d, 
2
JH-H = 13.67, H-2a); 3.60 (1H, d, 
2
JH-H = 
12.69, H-2b); 3.84 (3H, s, H-11); 3.98 (2H, m, CH=CH (COD));  4.20 (5H, s, Cpunsub); 4.44 
(1H, t, 
3
JH-H = 2.44, Cpsub); 4.50 (1H, m, Cpsub); 4.70 (3H, m, Cpsub, CH=CH (COD)); 6.51 
(1H, t, 
3
JH-H = 8.30, H-7); 6.82 (1H, d, 
3
JH-H = 8.30, H-8); 6.88 (1H, d, 
3
JH-H = 7.32, H-6); 7.68 




H} NMR (100.635 MHz, CDCl3): (δ, ppm) 29.16 (d, 
2
JRh-C = 9.42, COD); 31.52 (d, 
2
JRh-C = 10.77, COD); 44.98 (C-1); 56.96 (C-11); 57.22 (C-2); 
67.93 (Cpsub); 70.00 (Cpunsub); 70.15 (Cpsub); 72.77 - 73.35 (m, COD); 73.62 (Cpsub); 76.29; 
84.86 (d, 
1
JRh-C = 10.71, COD); 85.78; 113.65 (C-7); 115.79 (C-6); 117.51; 126.50 (C-8); 
151.34; 152.99 (C-4); 157.55 (C-3); 158.11. IR (ATR): (vmax/cm
−1
) 1600 (C=N); 1576 (C=C). 
ESI-MS (HR): m/z 630.1291 (35%, [M+H]
+
, requires 630.1290). Elemental Analysis 





Experimental                                                                                           Chapter 6 
183 
 
Salicylaldimine ferrocene Rh(I) complex (4.14) 
 


















Compound 4.7 (92.5 mg, 0.238 mmol), NaH (23 mg, 0.950 mmol) and [RhCl(COD)]2 (58.3 
mg, 0.118 mmol) were reacted. Compound 4.14 was obtained as a red solid (0.133 g, 94%). 




H NMR (399.951 MHz, CDCl3): (δ, ppm) 1.95 (4H, m, (COD)exo); 2.20 
(6H, s, H-1); 2.48 (4H, m, (COD)endo); 3.27 (1H, d, 
2
JH-H = 13.08, H-2a); 3.59 (1H, d, 
2
JH-H = 
13.32, H-2b); 3.98 (2H, m, CH=CH (COD));  4.21 (5H, s, Cpunsub); 4.44 (1H, t, 
3
JH-H = 2.29, 
Cpsub); 4.49 (1H, m, Cpsub); 4.62 (2H, m, CH=CH (COD)); 4.71 (1H, m, Cpsub); 6.58 (1H, t, 
3
JH-H = 6.79, H-7); 6.90 (1H, d, 
3
JH-H = 8.11, H-9); 7.17 (1H, d, 
3
JH-H = 7.82, H-6); 7.31 (1H, 




H} NMR (100.635 MHz, CDCl3): (δ, 
ppm) 29.20 (d, 
2
JRh-C = 7.40, COD); 31.51 (d, 
2
JRh-C = 8.08, COD); 45.02 (C-1); 57.20 (C-2); 
67.88 (Cpsub); 69.99 (Cpunsub); 70.13 (Cpsub); 72.86 (d, 
1
JRh-C = 13.46, COD); 73.61 (Cpsub); 
76.29; 85.02 (d, 
1
JRh-C = 12.12, COD); 85.91; 114.58 (C-7); 117.39; 121.80 (C-9); 134.12  
(C-6); 134.22 (C-8); 153.12 (C-4); 157.57 (C-3); 166.38. IR (ATR): (vmax/cm
−1
) 1601 (C=N); 
1574 (C=C). ESI-MS (HR): m/z 600.1182 (20%, [M+H]
+
, requires 600.1184). Elemental 
Analysis C29H34FeN3ORh
.
0.5H2O calculated: C 57.25; H 5.80; N 6.91%, found: C 57.40; H 
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6.5. In vitro antiplasmodial assay 
The test samples were tested in triplicate on one occasion against the chloroquine-sensitive 
NF54 strain and chloroquine-resistant Dd2 or K1 strains of Plasmodium falciparum. 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method of Trager and Jensen.
13
 Quantitative assessment of antiplasmodial 
activity in vitro was determined via the parasite lactate dehydrogenase assay using a modified 
method described by Makler et al.
14
 The test samples were prepared as a 20 mg/ml stock 
solution using DMSO and sonicated to enhance solubility. Samples were tested as a 
suspension if not completely dissolved. Stock solutions were stored at -20°C. Further dilutions 
were prepared on the day of the experiment. Chloroquine was used as the reference drug in all 
experiments. A full dose-response measurement was performed for all compounds to 
determine the concentration inhibiting 50% of parasite growth (IC50 value). Test samples were 
tested at a starting concentration of 1000 ng/ml, which was then serially diluted 2-fold in 
complete medium to give 10 concentrations; with the lowest concentration being 2 ng/ml. The 
same dilution technique was used for all samples. The highest concentration of solvent to 
which the parasites were exposed to had no measurable effect on the parasite viability. The 
IC50 values were obtained using a non-linear dose-response curve fitting analysis via Graph 
Pad Prism v.4.0 software. Evaluation is based on means from three independent experiments. 
 
6.6. β-Haematin inhibition assay 
 
The β-haematin formation assay was adapted from the method described by Wright and co-
workers.
15
 Test compounds were prepared as a 10mM stock solution in 100% DMSO. Test 
samples were tested at a starting concentration of 500μM and the lowest drug concentration 
being 5 μM. The stock solution was serially diluted to give 12 concentrations in a 96 well  
flat-bottom assay plate. NP-40 detergent was then added to mediate the formation of  
β-haematin (30.55 μM, final concentration).  A 25 mM stock solution of haematin was 
prepared by dissolving haemin (16.3 mg) in dimethyl sulfoxide (1 ml). A 177.76 μl aliquot of 
haematin stock was suspended in 20 ml of a 2 M acetate buffer, pH 4.7. The haematin 
suspension was then added to the plate to give a final haematin concentration of 100 μM. The 
plate was then incubated for 16 hours at 37°C. The assay was analysed using the pyridine-
ferrochrome method developed by Ncokazi and Egan.
16
 32 μl of a solution of 50% pyridine, 
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20% acetone, 20% water, and 10% 2M HEPES buffer (pH 7.4) was added to each well. To 
this, 60 μl acetone was then added to each well and mixed. The absorbance of the resulting 
complex was measured at 405 nm on a SpectraMax 340PC plate reader. The IC50 values were 
obtained using a non-linear dose-response curve fitting analysis via Graph Pad Prism v.5.0 
software. 
 
6.7. In vitro cytotoxicity (MTT) assay 
 
The oesophageal cancer cell line WHCO1, derived from a primary oesophageal squamous cell 
carcinoma, was provided by Professor Rob Veale (University of the Witwatersrand, 
Johannesburg, South Africa). IC50 determinations were carried out using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.
17
 3000 cells were seeded per 
well in 96-well plates. Cells were incubated at 37 °C under 5% CO2 (24 hours), after which 
aqueous DMSO solutions of each compound (10 μL, with a constant final concentration of 
DMSO of 0.2%) were plated at various concentrations. After 48 hours incubation, 
observations were made, and MTT (10 μL) solution added to each well. After 4 hours of 
incubation, solubilisation solution (100 μL) was added to each well, and incubated overnight. 
Plates were read at 595 nm on a BioTek microplate reader, and IC50 values calculated using 
GraphPad Prism 4.00 Package of GraphPad Software, San Diego, USA. 
 
6.8. In vitro cytotoxicity (WST1) assay 
 
KMST-6 cell lines were obtained from Sigma Aldrich. Cell proliferation was determined 
using the WST1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate) assay in which cells were trypsinized and cell counts of 5.010
4
 (for all cell lines) 
were prepared in 15 ml cell culture tubes. 100 µl of this was withdrawn and seeded into wells 
of 96 well plates and were allowed to grow. The culture medium was then removed and 
replaced with 100 µl of fresh medium with or without various concentrations of the test 
compounds. Triplicate wells were carried out for each concentration and the cells were 
incubated for 24 hours at 37
°
C in a humidified CO2 incubator. WST1 reagent (10 µl solution) 
was added to each well and the plates were incubated for 4 hours at 37
°
C in a humidified CO2 
incubator. At the end of the incubation period the plate was shaken on a rotating shaker for 10 
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minutes before taking readings at 450 nm and 600 nm using a microplate reader. Assays were 
done in triplicate to ensure reproducibility. 
 
6.9. In vitro T. vaginalis assay 
  
Cultures of T. vaginalis G3 strain were grown in 5 ml complete TYM Diamond’s media in a 
37ºC incubator for 24 hours. 10 mM stocks of the compounds were made by dissolving in 
DMSO and were screened against G3 stain of T. vaginalis. Cells untreated and inoculated 
with 5 µl DMSO are used as controls.  5 μl of 10 mM stocks of compound library were 
inoculated for a final concentration of 10 µM. Results were calculated based on counts 
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